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Emerging and re-emerging infectious diseases are increasing throughout the world and highly 
pathogenic influenza is among those that pose a significant threat to mankind.  Pandemic 
outbreaks of influenza are caused by the emergence of a highly pathogenic and transmissible 
virus to which the human population is immunologically naïve.  Ongoing outbreaks of highly 
pathogenic avian influenza of the H5N1 subtype are of particular concern because of the high 
mortality rate (>60%) and novel subtype.  Vaccines are considered the most effective way to 
prevent the morbidity and mortality associated with pandemic influenza and therefore 
developing an H5N1 vaccine is a public health priority.  One of the hurdles facing H5N1 vaccine 
development is the antigenic diversity of the subtype as evidenced by the identification of ten 
phylogenetic clades.  To overcome the challenge of antigenic diversity, a centralized 
hemagglutinin was developed and termed computationally optimized broadly reactive antigen 
(COBRA).  The COBRA HA sequence was based upon HA amino acid sequences from clade 2 
H5N1 human infections and the expressed protein retained the ability to bind the receptor, as 
well as mediate particle fusion.  COBRA virus-like particle (VLP) vaccines elicited broadly 
reactive receptor blocking antibodies in multiple animal species: mice, ferrets and non-human 
primates.  The reactivity profile was broader than that elicited by primary isolate-based vaccines 
given in either monovalent or polyvalent formulations.   Although all vaccinated animals were 
protected from severe disease and death from experimental infection with highly pathogenic 
H5N1 virus, animals receiving the COBRA vaccine had reduced peak virus replication and 
cleared the infection more rapidly.  COBRA vaccines were shown to be superior to primary 
isolate-based vaccines with both a broader antibody profile and more efficient protective 
efficacy.  The development of COBRA resulted in a novel antigen generation methodology that 
is applicable to both pandemic and seasonal influenza. 
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1.0 INTRODUCTION 
 
 
 
1.1 GENERAL BACKGROUND 
 
Influenza viruses are members of the family Orthomyxoviridae, which is comprised of 6 genera: 
Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus and Quarjavirus [1].  
Influenza viruses are pleomorphic, enveloped viruses with negative-stranded, segmented RNA 
genomes [2].  There are three types of influenza: A, B and C of which only A and B cause 
significant human disease.  Furthermore, only influenza A viruses (IAV) are a significant threat 
to cause pandemic outbreaks.  The distinction among the three types is based upon the 
antigenic differences in their nucleoprotein (NP) and matrix (M1) proteins that is determined via 
monoclonal antibody enzymatic immunoassay [3].  Additionally, polymerase chain reaction 
(PCR) based assays have been developed for more rapid typing of clinical samples [4].  
Influenza A and B both have similar virion structures while influenza C is more divergent.  
Influenza A and B are composed of eight individual gene segments that all encode at least one 
protein (Table 1).  Influenza virions contain three main subviral components: the viral envelope, 
core and ribonucleoparticle (vRNP) (Figure 1).  The viral envelope is derived from the host 
plasma membrane and contains the viral glycoproteins hemagglutinin (HA) and neuraminidase 
(NA), as well as the ion channel (M2).  The core of the virus is composed of the matrix protein 
(M1) that packages the vRNP and interacts with cytoplasmic regions of HA and NA at the apical 
surface of the host cell.  The vRNP complex consists of the nucleoprotein (NP), the polymerase 
 2 
 
complex (PB1, PB2 and PA), viral RNA and small amounts of nuclear export protein (NEP or 
NS2).  Viral egress usually occurs from the apical membrane of polarized epithelial cells.  All 
viral components (viral envelope, core and vRNP) must be brought together at the assembly 
site at the apical membrane where viral buds are formed and particles released via the closure 
of the buds [5]. 
 
 
 
 
Figure 1: Representation of Influenza A virus.  The two viral glycoproteins, HA and NA, and 
the ion channel, M2, are embedded in the lipid envelope.  The M1 protein makes up the core of 
the particle and interacts with surface proteins and vRNPs.  vRNPs consist of the eight gene 
segments, NP, and the polymerase complex (PA, PB1, PB2).  The nuclear export protein (NS2) 
is also found in the virion. 
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Table 1: Influenza gene segments. 
 
*Listed in decreasing order of size 
** Encodes two messenger RNAs 
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1.2 INFLUENZA VIRUS GENOME AND PROTEINS 
 
1.2.1 Hemagglutinin 
 
HA is a glycosylated type I integral membrane protein and functions to both bind the cellular 
virus receptor and also mediate cell fusion (Figure 2A).  The HA protein binds to terminal sialic 
acids (N-acetyl neuraminic acid) located on sugars found on host glycoproteins.  The orientation 
of the glycosidic bond isomerization between sialic acid and the terminal sugar (galactose or N-
Acetylgalactosamine) is a critical factor in HA receptor affinity.  The various bond orientations 
lead to either a “bent” ( 2-6) or “flat” ( 2-3) conformation that impact how the receptor interacts 
with the receptor binding domain (RBD) of HA (Figure 2B).   Interestingly, HA from IAVs 
adapted to humans have higher specificity for 2-6 sialic acid while IAVs adapted to avian 
species have HA proteins that are specific for 2-3 sialic acid [6].  In humans, the upper 
respiratory tract contains primarily 2-6 sialic acid while the lower respiratory tract has 2-3 
sialic acid.  The difference in receptor availability restricts replication of human IAVs to the upper 
respiratory tract and is hypothesized to be one factor involved in limiting human susceptibility to 
avian IAVs, which will be discussed below (See Section 1.6.2).  Once HA has bound its cognate 
receptor, the virus is internalized into the target cell via receptor mediated endocytosis.  The low 
pH of the endosomal compartment leads to an irreversible conformational change in the HA 
exposing the fusion peptide that then mediates fusion of the viral envelope and cell membrane.  
After membrane fusion, the vRNPs are released into the cell and traffic to the nucleus, which 
will be discussed in detail below (See Section 1.3).  Both receptor binding and cell fusion 
functions of HA require oligomerization and post-translational modifications.  The HA protein 
forms a trimer and each monomer must be proteolytically cleaved to form disulfide-bonded 
subunits HA1 (containing the receptor binding site) and HA2 (containing the fusion peptide) prior 
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to activation (Figure 2A).  Most IAV require host-derived serine proteases (trypsin-like) for 
activation.  These proteases recognize a conserved Q/E-X-R motif located at the cleavage site 
between HA1 and HA2.  In mammals, the protease is likely the tryptase Clara that is produced 
by bronchiolar epithelial cells [7].  Addition of insertional mutations into the cleavage site of HA 
can broaden protease reactivity and lead to systemic spread via intracellular activation.  Indeed, 
presence of this polybasic cleavage site (R-X-R/K-R) is a critical virulence factor in highly 
pathogenic avian influenza.  Although no anti-influenza drugs are currently licensed that target 
HA, a peptide has been described that specifically binds to HA and prevents sialic acid binding 
[8].  Furthermore, anti-HA antibodies that prevent receptor binding or cell fusion are neutralizing 
and are therefore the most important component of anti-influenza immunity because they are 
able to prevent infection. 
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Figure 2: Schematics of HA and sialic acid.  HA is translated as a monomer (HA0) and 
requires protease cleavage to generate the subunits HA1 and HA2.  HA1 contains the receptor 
binding domain and HA2 contains the fusion peptide (A).  Sialic acid glycosidic bond 
isomerization with the terminal sugar impacts conformation leading to either “bent” 2-6 (B) or 
“flat” 2-3 (C). 
 
1.2.2 Neuraminidase 
 
The NA protein is a type II integral membrane glycoprotein, functions as a tetramer and acts as 
a sialidase.  NA hydrolyzes the glycosidic bond that links the terminal sialic acid to the terminal 
saccharide (Figure 2).  While HA is required for infecting the cell, its presence in the viral buds 
inhibits particle release by binding to sialic acids on membrane proteins.  The enzymatic activity 
of NA is critical to cleave sialic acid on both host cells to allow particle release during viral 
egress and also nascent virions to prevent aggregation. The complementary functions of HA 
binding to sialic acid and NA cleaving sialic acid indicate that these proteins likely require 
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coadaptation during the course of IAV evolution.  The enzymatic activity of NA activates host 
transforming growth factor beta (TGF- ), which decreases disease severity [9].  Additionally, NA 
is the target of the anti-influenza drugs oseltamivir and zanamivir which are both sialic acid 
analogs that bind to the enzymatic pocket of NA and act to inhibit the enzymatic activity.  Drug-
mediated intervention reduces duration of disease and decreases rates of lower-respiratory tract 
complications [10].  Despite the effectiveness of the NA-inhibitors, resistance to oseltamivir is 
present in multiple subtypes of IAV [11-13].  NA is also a target of the humoral immune 
response and anti-NA antibodies can limit the cell to cell spread of infecting virus, thereby 
decreasing the severity of illness.  
 
1.2.3 Matrix and Ion Channel 
 
The M1 and M2 proteins are alternative splice products generated from the same gene 
segment.  M1 underlies the viral envelope, interacts with both surface glycoproteins and vRNPs, 
and promotes assembly and budding [14].  The M2 protein is a small type III integral membrane 
and functions as a tetramer.  M2 is a proton channel and is activated upon exposure to the low 
pH of the endosome [15].  The influx of protons due to M2 function is crucial during the early 
phase of the infection cycle to dissociate the association between M1 and vRNPs during viral 
uncoating [14].  M2 is the target for the adamantane class of influenza antiviral drugs which 
prevent the low pH activation and therefore inhibit viral uncoating.  Additionally, anti-M2 
antibodies that prevent activation can limit viral growth by inhibiting M1-vRNP dissociation and 
have been proposed as a strategy to generate a “universal” influenza vaccine due to the cross-
subtype conservation of M2 [16-18]. 
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1.2.4 Nucleoprotein and Polymerase Complex 
 
NP encapsidates all of the RNA gene segments and primarily serves as the structural protein of 
vRNPs.  Additionally, NP is involved in transcription by stabilizing template-polymerase 
interactions and in intracellular trafficking of vRNPs.  NP interacts with several cellular 
polypeptides:  importin nuclear import receptors, filamentous actin, the nuclear export receptor 
CRMI and a DEAD-box helicase [19].  The interaction between NP and host proteins is required 
for proper subcellular localization of viral RNA.  In virions, viral RNA is wrapped around NP 
monomers and, together with the polymerase proteins, are packaged into vRNPs.  The 
polymerase proteins comprise the largest gene products of influenza: polymerase basic proteins 
1 and 2 (PB1 and PB2) and polymerase acidic protein (PA).  PB1 functions as the RNA-
dependent RNA polymerase and PB2 is required for mRNA synthesis by binding and cleaving 
host 5’ mRNA methyl caps [14].  Although PA is essential for all stages of viral replication, 
including synthesis of both genomic and messenger RNA, its biological roles remain poorly 
understood.  The polymerase complex functions as a heterotrimer and binds to a short hairpin 
structure derived from a conserved and partially complementary sequence at the terminal 3’ and 
5’ untranslated regions of each gene segment.  The roles of the different polymerase proteins 
during the virus replication cycle will be discussed in detail below (See Section 1.3). 
 
1.2.5 Nonstructural Proteins 
 
The nonstructural proteins (NS1 and NS2) are alternative splice products from the same gene 
segment.  The NS1 protein has multiple functional domains: N-terminal RNA binding domain, a 
central effector domain, and a C-terminal PDZ binding domain [20].  The RNA binding domain 
functions via multiple mechanisms: binding and sequestering dsRNA intermediates that are 
produced during the replication cycle to prevent activation of both 2’-5’ oligoadenylate sythetase 
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(OAS) and retinoic acid inducible gene I (RIG-I) to antagonize the interferon response [21-23] 
and sequestering small interfering RNA to inhibit induction of RNA interference [24, 25].  The 
central effector domain interacts directly with distinct cellular proteins: binds and prevents 
activation of protein kinase R (PKR) to maintain cellular protein synthesis [26], interacts with 
cleavage and polyadenylation specificity factor (CPSF) and poly (A) binding protein II (PABII) to 
block cellular mRNA processing and export from the nucleus [27, 28] and functions via a 
trimeric interaction with eukaryotic translation initiation factor 4 gamma (eIF4GI) and poly (A) 
binding protein I (PABI) to promote translational initiation of viral mRNAs [29].  The PDZ binding 
domain interacts with PDZ-containing proteins, many of which are involved in cellular signal 
transduction pathways [30].  Together, these effects prevent induction of the interferon response 
by sequestering dsRNA and suppressing cellular gene expression by blocking nuclear mRNA 
processing.  The NS2 protein is also referred to as nuclear export protein (NEP) and is found in 
small amounts in virions.  NS2 facilitates the nuclear export of vRNP complexes and transport to 
the assembly site at the apical cell membrane.  Deletion of the NS1 coding region from the gene 
segment that encodes for both NS1 and NS2 increases virus susceptibility to the interferon 
response and results in reduced viral protein production and replication [31].  The NS1 deletion 
severely attenuates the virus and has been proposed as a mechanism for the generation of new 
vaccines [32-34].  
 
1.2.6 PB1-F2 
 
An additional small protein that is produced during influenza infection is PB1-F2, which is 
encoded on the PB1 gene segment in an alternative reading frame.  PB1-F2 was initially 
discovered to be pro-apoptotic and contributes to virulence in animal models by delaying viral 
clearance [35, 36].  In addition to the pro-apoptotic functions, PB1-F2  down regulates interferon 
induction by interacting with mitochondrial anti-viral signaling protein (MAVS) and preventing the 
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activation of interferon regulatory factor 3 (IRF3) [37].  The interferon antagonism acts in a 
synergistic manner to that of NS1 and together with pro-apoptotic functions make PB1-F2 an 
important virulence factor and a possible key component in the pathogenicity of pandemic 
influenza. 
 
 
 
1.3 REPLICATION CYCLE 
 
Influenza virus replication cycle (Figure 3) begins with the HA-mediated attachment to cellular 
surface receptors via engagement of sialic acid.  After the attachment step, the virus is 
internalized via receptor-mediated endocytosis and enters the endosomal pathway in a clathrin 
dependent manner.  Acidification of the endosome to a pH of ~5.0 results in two structural 
changes in the virion: 1) the M2 ion channel allows protons to enter the virus particle resulting in 
disruption of M1-vRNP interactions and 2) a conformational change in HA exposes the fusion 
peptide that inserts into the endosomal membrane and results in envelope fusion.  After the 
fusion event, vRNPs are released into the cytoplasm and imported to the nucleus under the 
control of nuclear localization signals found on the NP protein. 
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Figure 3: Schematic of influenza virus replication cycle.  Infection begins with HA-mediated 
attachment to cellular receptors.  This is followed by endocytosis and transporting through the 
endosomal pathway.  Low pH conditions of the endosome induce membrane fusion and particle 
uncoating.  vRNPs are trafficked to the nucleus where all transcription and replication takes 
place.  Internal proteins are trafficked back into the nucleus where they interact with vRNA to 
form vRNPs and are eventually trafficked to the apical membrane where they are packaged into 
nascent virions.  Surface proteins enter the endoplasmic reticulum, are trafficked through the 
golgi apparatus to the cell surface and are incorporated into viral buds. 
 
 Once in the nucleus, influenza synthesizes three types of viral RNA: viral messenger 
RNAs of positive polarity (vmRNA), viral genomic RNAs of negative polarity (vRNA) and viral 
complementary RNA (cRNA) of positive polarity.  Genome replication requires the synthesis of 
both vRNA for generation of new virus particles and also cRNA as template strands.  Synthesis 
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of vRNA and cRNA is primed by NP, which also binds to elongating strands and blocks the 
generation of vmRNA (Figure 4A).  The vRNA is used in the production of both of the positive 
polarity RNAs, vmRNA and cRNA.  In turn, cRNA is the template from which additional vRNA is 
synthesized.  Transcription of vmRNA utilizes host-derived 5’ methyl cap structures to efficiently 
bind cellular proteins involved in RNA processing, nuclear export and protein production.  This 
process is described as “cap-snatching” and involves PB2 binding to the host mRNA and PB1 
endonucleolytically cleaving the host RNA that then serves to prime vmRNA synthesis (Figure 
4B).  All gene segments are subsequently transcribed into 5’ capped, 3’ polyadenylated vmRNA 
for individual proteins.  Splicing of vmRNA to generate the coding regions for M2 and NS2 also 
occurs in the nucleus and is dependent on cellular enzymes.  Newly synthesized vmRNA is 
exported out of the nucleus to the cytoplasm for viral protein production. 
 After vmRNA is exported into the cytoplasm, viral proteins are translated by cellular 
protein production machinery.  PB1, PB2, PA, NP, NS1, NS2 and M1 are all produced in the 
cytoplasm by ribosomes that are organized into polysome complexes. Newly synthesized 
proteins are transported back into the nucleus where they are involved in transcription, genome 
replication and formation of vRNPs for packaging into nascent viral particles.  HA, NA and M2 
are synthesized by ribosomes bound to the membrane of the endoplasmic reticulum (ER).  The 
envelope proteins are inserted into the ER and glycosylated prior to transport to the Golgi 
apparatus.  They are then transported to the cell surface via the secretory pathway and are 
assembled with the vRNP complexes. 
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Figure 4: Different priming mechanisms of influenza polymerase complex.  The influenza 
polymerase complex uses NP to prime synthesis of cRNA and vRNA (A).  NP also binds to the 
elongating strand of RNA to promote stability of the polymerase-template interaction.  Influenza 
mRNA is generated using host mRNA to prime synthesis (B).  mRNA production is initiated 
when the 5’ untranslated region of the vRNA binds PB1 and activates the cap-binding function 
of PB2 and endonuclease activity of PB1.  After a host mRNA is bound, it is cleaved and 
vmRNA synthesis is initiated with incorporation of the 5’ methyl cap into the vmRNAs.  
 
 Formation of vRNP complexes occurs in the nucleus and involves the binding of the viral 
polymerase complex, NP and NS2 proteins to vRNA.  M1 interacts with nuclear vRNPs and, 
together with NS2, directs the export of M1-vRNP complexes.  After nuclear export, M1 inhibits 
the import of vRNPs back into the nucleus and directs localization to the cell surface.  M1-vRNP 
complexes interact with cytoplasmic regions of HA and NA proteins at the cell membrane and 
lead to the formation of viral buds.  The packaging of vRNPs is a specific event with no more 
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than 8 gene segments being included in each particle.  The exact mechanism by which specific 
packaging occurs likely involves RNA signals from each gene segment and leads to the vast 
majority of particles being infectious [38].  Cellular membrane proteins are largely excluded from 
viral envelopes due to the NA protein.  Nascent virions are first released ~8 hours after initial 
infection [5]. 
 
 
 
1.4 INFLUENZA DIVERSITY 
 
1.4.1 Antigenic Drift 
 
There is great diversity among type A viruses with 16 HA (H1 to H16) and 9 NA (N1 to N9) 
subtypes currently identified [39, 40].  Subdivisions of IAV are determined via antigenic 
characteristics of the HA and NA proteins as measured by double immunodiffusion assays.  The 
different subtypes show up to 30% diversity at the amino acid level, and therefore subtyping IAV 
is also possible via sequence analysis [41].  Due to the low fidelity RNA-dependent RNA 
polymerase, IAVs have a high mutation rate ranging from 1x10 -3 to 8x10-3 substitutions per site 
per year [42].  Mutations that alter amino acids found in antigenic regions of HA and NA likely 
confer selective advantages via evasion of pre-existing immunity.  Viral diversity generated by 
the mechanism of mutation accumulation is termed antigenic drift (Figure 5A).  Drift variants are 
critical for IAVs adapted to infect humans because of strong immunological pressures in the 
host population from both vaccination and prior infection.  Antigenic drift mediated diversity 
results in seasonal epidemics, but is not a cause of pandemic virus emergence. 
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1.4.2 Antigenic Shift 
 
The segmented nature of the influenza virus genome can lead to another mechanism of 
diversity in which an entire gene segment(s) is exchanged: a process termed reassortment.  Co-
infection of one host cell with two different IAVs (e.g. H3N2 and H5N1) can lead to the 
production of progeny virus with genes from both parental strains (e.g. H5N2 and H3N1).  
Reassortment events involving the surface proteins HA and/or NA result in antigenic shift 
(Figure 5B).  From any two parental viruses, there are a possible 256 different combinations of 
the eight gene segments in nascent virions.  Even in the event of co-infection with two viruses of 
the same subtype, exchange of internal genes such as polymerase proteins or NS can alter the 
pathogenic phenotypes of viruses that are produced without altering the antigenic classification 
of the progeny.  Indeed, reassortment is an important event that is relatively common in the 
evolution of IAV [43, 44].  Similarly, drifted viruses of the same subtype can reassort with each 
other resulting in the selection and spread of the drifted virus.  The emergence of a pandemic 
virus is almost always associated with reassortment events and typically involves both surface 
and internal proteins [45-49]. 
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Figure 5: Diversity mechanisms of influenza viruses.  Mutations occur over time due to the 
low fidelity polymerase.  When these mutations accumulate in the antigenic regions of the 
surface proteins and the virus can escape pre-existing immunity the process is termed antigenic 
drift (A).  The segmented nature of the genome allows for rearrangement of gene segments 
from different viruses when a cell is simultaneously infected.  When the gene segment 
reassortment results in production of progeny virions with novel surface protein(s), the process 
is termed antigenic shift (B).  
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1.5 INFLUENZA ANIMAL RESERVOIRS 
 
Wild avian species are reservoir hosts to genetically diverse IAVs across the globe.  Most 
documented infections are asymptomatic and are found in aquatic birds of which over 100 
species have been identified as harboring virus [50].  IAVs are usually transmitted via the fecal-
oral route where the infection is located in the epithelial cells of the lower intestinal tract.  
Distribution of HA and NA subtypes is not uniform, with some being more prevalent than others.   
An example of this disparity is that more than half of the avian isolates in the Influenza Virus 
Resource database (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) belong to the H5 or 
H9 subtypes [51].  It is unknown whether the prevalence of circulating IAV subtypes matches 
the available data from isolates harvested during routine surveillance.  Additionally, the majority 
of surveillance efforts have focused on aquatic waterfowl and shorebirds and there is not 
enough data to determine if particular subtypes or strains within a given subtype have evolved 
to a replicate in a particular species [52].  However, factors such as geographic location, 
migration patterns and feeding behavior likely are involved in viral adaptation and fitness [53]. 
 Although aquatic birds are the reservoir of IAVs [54], viruses from wild birds are 
associated with emergence of novel viral lineages that are transmissible in the new host.  The 
most common host switch is to domestic poultry including chicken, turkeys and quails [40].  In 
addition to avian species, IAVs have also been isolated from multiple mammalian species 
including humans, pigs, horses, cats, dogs, and even sea mammals [40].  Although IAV strains 
are isolated consistently from swine and horses, other wild and domestic mammalian species 
have only sporadic virus isolation which could be due to occasional zoonotic infectious 
outbreaks that fail to persist.  Equine IAV has been recognized for hundreds of years and is 
often associated with human epidemics and/or pandemics [55].  Both H7N7 and H3N8 IAV 
subtypes have been isolated from horses, although only the H3N8 subtype persists today.  
Phylogenetic analysis indicates that equine IAV strains are likely derived directly from avian IAV 
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and not human or swine influenza virus strains [54].  IAV in swine was first detected in 1918 and 
persists through today as a stable lineage [56].  Multiple subtypes of IAV have been isolated 
from swine including H1N1, H2N2 and H3N2 [57].  Swine are susceptible to both avian and 
human adapted IAV strains and as such are proposed as a “mixing vessel” in which reassortant 
viruses with pandemic potential can be generated [58].  The susceptibility to diverse strains of 
IAV could be due to the presence of both 2-3 and 2-6 linked sialic acids, although little 2-3 
is found in the upper respiratory tract [59].  Notably, the combination of two unrelated swine 
H1N1 viruses resulted in the novel H1N1 pandemic of 2009 indicating that swine IAV may be 
the reservoir from which human pandemics emerge [48, 60]. 
 
 
 
1.6 HUMAN INFLUENZA INFECTIONS 
 
1.6.1 Seasonal Influenza 
 
Influenza viruses of types A (H1N1 and H3N2) and B are a significant cause of morbidity and 
mortality in humans and are able to cause repeated disease due to antigenic drift.  Human 
influenza is maintained as a permanent lineage by person to person spread during acute 
infection.  Additionally, there is no evidence of persistent or chronic infection of influenza in 
humans [40].  Although influenza infection is generally associated with seasonal epidemics, the 
virus can be detected in a large city throughout the year and influenza is detected year round in 
various parts of the world [61].  In North America, influenza epidemics generally occur from 
January through April with occasional outbreaks in December or May [62].  IAV transmits more 
efficiently in the cold and dry atmospheric conditions that exist in the winter months and this 
could be one explanation for the pattern of seasonal epidemics [63].  Seasonal influenza 
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epidemics in the United States result in up to 200,000 hospitalizations and 36,000 excess 
deaths annually [40, 64].   
 Infection with influenza occurs in the columnar epithelial cells of the respiratory tract.  
The virus then spreads from person to person by small-particle respiratory droplets or by direct 
contact.  After infection with influenza virus, the disease presents clinically with fever, headache, 
sore throat, muscle pain and a dry cough.  The illness usually lasts for 3 days with full recovery 
in 7-10 days.  Complications of influenza infection include secondary bacterial infections, 
myositis, and Reye’s syndrome [65].  Secondary bacterial pneumonia usually involves 
Streptococcus pneumoniae, Haemophilus influenza or Staphylococcus aureus [66].  Although 
rare, primary viral pneumonia can also occur and is associated with a high mortality rate [66].  
High-risk groups include the young, the elderly, pregnant women, and those with chronic 
underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), 
diabetes, or human immunodeficiency virus (HIV) [67].  The most important factor to limiting 
morbidity post-infection is the presence of pre-existing immunity to influenza, from either 
vaccination or prior infection with an antigenically similar virus.  Indeed, influenza vaccination 
has been in use for over 50 years and influenza is unique among variable viruses in that it can 
be prevented by current vaccines but remains a significant cause of morbidity and mortality [68, 
69].  An important consideration is that the relative severity of influenza infection is dependent 
upon the interplay between pre-existing immunity and the pathogenicity of the infecting virus.  
Furthermore, the relationship of influenza antigenic diversity, pathogenicity, and population 
immunity is reflected in the size and impact of both seasonal epidemics and also occasional 
pandemics.  
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1.6.2 Pandemic Influenza 
 
Pandemic outbreaks of influenza occur sporadically in the human population and appear to 
have occurred for over 500 years [55, 70].  Up to 50% of the population can be infected during a 
single pandemic year and this increase can be associated with a dramatic rise in influenza-
related mortality [60].  More recently, IAVs have caused four different pandemics in the last 100 
years: the 1918 “Spanish” influenza (H1N1), the 1957 “Asian” influenza (H2N2), the 1968 “Hong 
Kong” influenza (H3N2) and the 2009 novel H1N1 “Swine Flu” (Figure 6) [71, 72].  The three 
20th century influenza pandemics are all suspected to have involved antigenic shift resulting 
from the reassortment of HA and other gene segments from an avian virus with a currently 
circulating human virus [73].  Although the 2009 pandemic virus included some gene segments 
from avian IAVs, the novel virus was derived from a reassortment of two swine H1N1 viruses 
[74].  The “Spanish” influenza of 1918 was the worst pandemic in recorded history and resulted 
in an estimated 675,000 deaths in the U.S.A. and up to 50 million deaths across the globe [75].  
Although the pandemics of 1957, 1968 and 2009 have all been less severe than that of 1918, 
they have all caused significantly more disease than is observed during seasonal epidemic 
years.  Interestingly, all of the pandemic viruses since 1918 have contained genes derived from 
the 1918 virus which may indicate the presence of a larger “pandemic era” [76]. 
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Figure 6: Pandemic viruses from the last 100 years.  Pandemic outbreaks of influenza occur 
sporadically.  The 1918 pandemic was caused by the emergence of an avian virus into the 
human population.  The pandemics of 1957 and 1968 were caused by the reassortment of an 
avian virus with a circulating human virus.  In 1977, the human H1N1 virus re-emerged and 
enough immunity in the population prevented another pandemic.  The 2009 pandemic was a 
reassortant virus combing swine, avian and human viruses.  All pandemic viruses have included 
gene segments from the 1918 virus (red bars). 
 
 Emergence of pandemic viruses into the human population from animal reservoirs has 
indicated that the host switch events are polygenic and involve adaptation of replication and 
transmission properties [55, 77].  Indeed, recent pandemic viruses have all emerged in different 
ways, which complicates the understanding of zoonotic IAV adaptation to humans [60].  Direct 
infection of humans with avian IAVs has occurred in the past 15 years and is predominately 
associated with the epizootics of H5N1 in Southeast Asia, the Middle East and Africa and 
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smaller outbreaks of H7N7 in the Netherlands and H7N3 in Canada [78-80].  Prior to these 
relatively recent zoonotic infections, there was little serological evidence of direct avian to 
human IAV infection [81].  Genetic mutation signatures of human IAV adaptation have been 
proposed using comparative analyses to relate contemporary viruses to the host-switching 1918 
strain [45, 82].  However, when avian to mammalian switch events are evaluated independently, 
no parallel evolution has been observed indicating that switch events are polygenic and ongoing 
evolution of IAV in various hosts is likely changing the requirements for host-switch [49].  Viral 
properties including virulence, replication competency and transmission may be related, but 
independent, properties that are associated with different mutations in different gene segments.  
Indeed, the emergence of the genetically diverse 2009 H1N1 pandemic virus supports the 
finding that independent and polygenic changes can lead to IAV adaptation in humans [83-85]. 
 Even though identification of specific molecular markers indicating IAV human 
adaptation has been elusive, several features of host switch events have been identified.  IAVs 
from an avian origin generally have a higher GC content than those viruses adapted to humans 
[86, 87].  Although the biological significance of the altered nucleotide composition is unclear, 
possible reasons include higher core temperatures in avian species, host-specific mutations in 
the cellular components required for RNA replication and avoiding immune detection via host 
mRNA composition mimicry [86, 87].  Another feature of IAV human adaptation is HA receptor 
binding specificity.  The HA receptor binding domain is conserved in avian IAV, but is mutated in 
human IAVs.  These mutations have been mapped to several key residues and alter the binding 
preference from 2-3 sialic acid to 2-6 sialic acid [40].  Although receptor usage is clearly 
important for IAV ability to infect cells, its relative role in the overall phenomenon of host switch 
is more complicated.  Avian IAV of H7N7, H7N3 and H9N2 subtypes have enhanced specificity 
for 2-6 sialic acid, but have only caused sporadic infections in humans indicating that receptor 
binding alone is not sufficient for sustained infection in the human population [88-90].  
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Furthermore, the H5N1 subtype generally has 2-3 receptor preference and introduction of 
mutations resulting in 2-6 usage did not result in enhanced replication or transmission in a 
ferret model [91].  Additionally, H5N1 has infected hundreds of humans and fixation of mutations 
that mediate 2-6 binding has yet to occur [92].  The role of polymerase proteins is also 
important to host switch as emergence of pandemic strains usually involves the polymerase 
complex in addition to HA and NA evading prior immunity.  The PB1 genes from the 1918, 1957 
and 1958 pandemics have all been avian-like indicating that this gene segment retains function 
without much adaptation to a new host [40, 45, 60].  Additionally, specific residues in the PB2 
protein are linked to IAV adaptation to mammalian hosts [93, 94].  Mutations at these residues 
are linked to pathogenicity, transmission and replication fitness [95-97].  The molecular 
mechanisms of host switch in IAV are undoubtedly complex and involve the interplay between 
multiple gene segments.  It is clear that no single mutation is associated with replication in 
mammals, but rather a collection of changes involving HA receptor specificity, polymerase 
activity and even global nucleic acid composition all are involved in IAV adapting to a new host. 
 
 
 
1.7 INFLUENZA IMMUNOLOGY 
 
Neutralizing and receptor-blocking antibodies against HA are the primary means of protection 
from influenza infection [66].  Antibodies directed against NA play an important, but secondary, 
role.  Although immunity against multiple influenza proteins can mitigate disease, only anti-HA 
antibodies are able to prevent infection [98].  Five antibody binding regions, A-E, have been 
determined based upon the H3 subtype and the corresponding structural regions have been 
mapped onto other subtypes, although the exact position and number of antibody binding 
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regions remains uncertain for avian subtypes (Figure 7) [99].  The majority of the anti-HA 
antibody response is focused on the variable epitopes on the surface of the molecule where the 
virus escapes via antigenic drift.  Receptor-blocking antibodies recognize the variable head 
region of the HA molecule and are subtype or even strain specific [100].  Antibodies that are 
specific for a more conserved epitope located in the stem region of the HA molecule do not 
prevent receptor engagement, but neutralize the infectivity of the virus by blocking the low pH 
conformational change required for fusion [101-103].  These broadly-neutralizing, stem-reactive 
antibodies are less prevalent than antibodies against the globular head, but are elicited by both 
infection and vaccination [104, 105].  Several hypotheses have been proposed to explain the 
sub-dominance of the broadly neutralizing antibody repertoire: the epitope may be inherently 
poorly immunogenic, the epitope may be not be readily accessible on the intact virion, or the 
globular head epitopes may be overwhelmingly immunodominant [106].  Antibodies that block 
the function of HA, via either blocking receptor binding or preventing fusion, are the most 
important factor in mitigating human disease caused by influenza virus infection. 
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Figure 7: Antigenic regions of HA.  The crystal structure of H5 HA is displayed as a trimeric 
molecule with each subunit (HA1 or HA2) colored per monomer.  The antigenic regions for a 
single monomer that are predicted from H3 residues are circled.  The receptor biding site (RBS) 
is shaded yellow.  The image was generated using the 2FKO structure deposited into the 
Protein Data Bank (www.pdb.org) and visualized with Jmol software [107]. 
 
 Immune responses to other influenza proteins have also been shown to limit disease, 
but are not able to prevent infection.  NA-inhibiting antibody responses can block the enzymatic 
activity that is required for particle release.  Therefore, anti-NA antibody responses reduce viral 
spread within the host after initial infection.  Preventing NA activity does not prevent infection 
and appears to play a secondary role in protection, but it can limit disease severity when anti-
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HA mediated immunity is not effective [108, 109].  In the context of pandemic influenza, anti-NA 
antibodies from H2N2 viruses reduced disease severity during the H3N2 pandemic of 1968 but 
were unable to completely prevent the pandemic [110].  Additionally, anti-NA immunity is 
increased by vaccination and is believed to contribute to reduced disease in elderly populations 
during the 2009 H1N1 pandemic [111].  The conserved proteins M2 and NP have also been 
proposed as antigens against which a universal influenza immune response may be generated 
[112-115].  Although the efficacy of these antigens has been demonstrated in mice, the findings 
were not confirmed in a more rigorous ferret challenge [116].  In humans, robust universal 
protection by conserved antigens is not supported by epidemiological evidence.  Repeated 
infection would not be possible if conserved antigens elicited effective cross-reactive immunity 
and influenza would resemble one-time childhood illnesses such as measles, mumps or chicken 
pox.  Instead, viruses differing only in their HA and NA are able to spread across the world and 
re-infect individuals who have previously experienced influenza either through vaccination or 
primary infection [69]. 
 Even though immunity directed against conserved antigens does not prevent infection 
and spread of influenza, cell-mediated immunity against these targets does play a role in 
reducing disease severity.  Influenza virus infected cells are eliminated in the absence of 
antibody responses and animals primed for a cell mediated immune response clear virus more 
rapidly than naïve animals [117-120].  CD4+ T cells do not efficiently function directly in viral 
control, but rather are required to promote high quality antibody responses [121].  Additionally, 
analysis of IFN-  production has suggested that influenza specific CD4+ T cell populations are 
smaller, but more diverse than the CD8+ T cell populations [122, 123].   CD8+ effector T cells 
function to eliminate influenza infected cells via either the Fas-Fas ligand pathway or perforin 
and granzyme mediated cytotoxicity [124].  Memory CD8+ T cells are generated in large 
quantities after primary influenza infection, but re-infection even in the presence of large 
numbers of effector memory CD8+ T cells still results in high viral titers for 48 hours after 
 27 
 
infection [120].  Therefore, although cell-mediated immunity to conserved viral antigens is able 
to restrict viral replication and limit disease severity, influenza can still infect and transmit in the 
absence of neutralizing antibody regardless of the magnitude of the cell-mediated response. 
 In addition to adaptive immune responses, innate immunity also plays a role in influenza 
control and pathogenesis. Type 1 interferons induce a number of anti-viral responses in cells 
and therefore provide a protective function in the early stages of influenza infection.  One of the 
anti-viral responses that is stimulated is the induction of Mx genes that inhibit primary 
transcription of influenza gene segments [125, 126].  Complement and natural antibody mediate 
protection in the absence of prior adaptive immunity in mouse models of influenza infection 
[127, 128].  Additionally, natural killer (NK) cells control influenza infection and have activating 
receptors that directly recognize HA from multiple subtypes [129, 130].  NK cells kill influenza 
virus infected cells rather than directly destroying virions.  Neutrophils and alveolar 
macrophages can mediate protection against infection by low pathogenicity influenza viruses 
[131].  However, these same cell types are associated with excess lung damage during infection 
with high pathogenicity viruses, such as the reconstructed 1918 H1N1 strain or highly-
pathogenic H5N1 influenza isolates [132-134].  Aberrant cytokine and chemokines responses 
have also been correlated with increased pathogenicity [135].  This “cytokine storm” directly 
contributes to the pathogenicity of virulent influenza infection and is important factor in severe 
human infections [136].  Innate immune factors are often able to directly control influenza virus 
replication, but in the context of highly pathogenic infections, innate immunity can contribute to 
disease severity and therefore it is of utmost importance for vaccine strategies to utilize the 
efficient control mechanisms by the adaptive immune response, specifically neutralizing 
antibodies against HA. 
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1.8 INFLUENZA VACCINES 
 
Vaccines against influenza have been in use in the human population for over 50 years [68].  
Influenza vaccines elicit a strain specific anti-hemagglutinin antibody response and serum 
hemagglutination inhibition antibody titer is the most commonly measured correlate of 
protection.  Susceptibility to infection is inversely correlated to the reciprocal dilution titers of 
receptor blocking antibodies with levels of 1:40 preventing infection in about 50% of the 
population [137].  The majority of influenza-related mortality occurs in the elderly and those with 
underlying conditions, such as pregnancy, diabetes or HIV infection, and therefore the 
immunization strategies are focused on protecting these vulnerable populations [138, 139].  
Currently licensed vaccines are composed of a trivalent formulation containing a representative 
strain from each of the circulating strains: IAV (H1N1 and H3N2) and influenza B.  Each year, 
the World Health Organization proposes recommendations to vaccine manufacturers and 
governmental agencies about which influenza strains to include in the vaccine upcoming 
influenza season.  For the 2011-2012 season, the vaccine strains are A/California/7/2009 
(H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 (type B).  Despite global sequencing 
efforts, predictions of what will be the dominant circulating strain are not certainties and 
occasionally drift variants emerge as the most prevalent strain, resulting in vaccine escape 
[140].  Influenza viruses chosen for vaccine production are propagated in embryonated chicken 
eggs and although this requires large amounts of eggs and specialized production facilities, this 
strategy remains the most consistent production system for high titer influenza virus.  Cell-based 
production systems have also been evaluated, but they have not been approved for wide use in 
humans [141]. 
 Two types of influenza vaccines are approved for use in humans in the United States: 
inactivated virus (TIV), which includes split and subunit vaccines, and live-attenuated virus 
(LAIV) vaccines generated from cold-adapted influenza viruses.  TIV is approved for use in 
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individuals greater than 6 months of age, is administered via intramuscular injection and is 
generally well tolerated [66].  Additionally, TIV is immunogenic and efficacious in children and 
adults inducing immunity in 60-90% of recipients [67].  Immunogenicity in the elderly is generally 
reduced and this is due, at least in part, to immunosenescence in the older population [142, 
143].  LAIV is administered via an intranasal spray and is approved for use for those individuals 
between 2 to 49 years of age.  Use is not approved for young children due to wheezing 
concerns, although the relative risk is under debate [144-147].  An advantage of using LAIV is 
the ability to stimulate CD8+ T cell memory, however, the live-attenuated vaccine does not 
efficiently elicit serum hemagglutination inhibition antibodies that is the standard measure of 
immunogenicity.  Despite low levels of receptor blocking antibody, LAIV is effective at protecting 
recipients from infection and this is likely due to mucosal immune responses that are not 
detected with standard serum antibody assays [148].   
 New vaccine platforms and adjuvants are also being developed to address the problems 
of long lead times for traditional egg-based manufacturing and poor immunogenicity in high risk 
populations.  Novel technologies include virus-like particles, recombinant subunits and HA head 
or stalk specific region vaccines [105, 149-154].  These technologies offer several advantages 
over traditional egg-based manufacturing including recombinant technology, rapid scale-up and 
directed immune responses.  Adjuvants are vaccine components that enhance the immune 
response against co-administered antigens.  These compounds are used to enhance 
immunogenicity and/or lower the dose required to achieve protective immunity.  Aluminum salts 
have been used to enhance antibody titers for almost 100 years [155].  These adjuvants 
function to increase antigen uptake and processing by antigen presenting cells and also activate 
the NOD-like receptor protein 3 inflammasome pathway [156, 157].  MF59 is an oil-in water  
emulsion and is another example of an adjuvant licensed for use in humans [158].  This novel 
adjuvant functions to enhance immune responses via a TLR-independent pathway that involves 
injection-site activation of a diverse set of immuno-stimulatory genes [159].  Importantly, novel 
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technologies, such as virus-like particles, and novel adjuvants, such as MF59, have been 
proposed as methodologies to improve influenza vaccination in high risk populations.  The long 
history of influenza vaccine administration has demonstrated the safety and efficacy of both 
inactivated and live-attentuated vaccines when matched to the dominant strains in a given year.  
However, due to the diversity of influenza viruses, the protective capacity of traditional 
strategies remains limited to that of the individual components and is subject to regular escape 
by viral evolution.  By using new technologies, it may be possible to further improve influenza 
vaccines via elicitation of immune responses in high risk populations and also increasing the 
breadth of the antibody repertoire. 
 
 
 
1.9 STRATEGIES TO INCREASE VACCINE BREADTH 
 
Simultaneous circulation of diverse IAV (H1N1 and H3N2) and influenza B viruses has been a 
challenge for seasonal influenza vaccine production for over 30 years.  The current seasonal 
vaccine, both TIV and LAIV, uses a polyvalent formulation to address the issue of distinct 
viruses circulating simultaneously.  Polyvalent influenza vaccine formulations utilize mixtures of 
the same antigen from different strains.  Other polyvalent strategies have included mixing 
matched antigens from different strains or mixing different antigens.  The goal of polyvalency is 
to increase the breadth of vaccine coverage by combining diverse components into a single 
vaccination.  Polyvalent vaccine strategies increase reactivity for many pathogens including, but 
not limited to, influenza [160-162], monkey pox [163], HIV [164, 165], HPV [166, 167] and 
pneumococcal disease [168].  Although polyvalent vaccine formulations clearly expand the 
breadth of a single vaccine formulation, the reactivity is still limited to the individual components.   
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 An alternative to polyvalent vaccines is the use of centralized sequences to generate 
vaccine antigens (Figure 8).  These vaccines consist of synthetic sequences that represent a 
population of sequences and are generated by three different methods: center-of-the tree, 
ancestral, and consensus [169].  Center-of-the tree (COT) sequences are derived by 
constructing a phylogenetic tree and selecting the sequence that is equidistant from all points 
[170].  Ancestral sequences represent the most recent common ancestor for the population of 
sequences selected and are effective influenza vaccine candidates [171, 172].  Consensus 
sequences encode the most common amino acid found at each position for the selected 
population [173].  Ancestral and COT sequences are an estimate of an actual sequence that 
existed in the past, while consensus sequences are more relevant to the current epidemic [173].  
The population that is assembled for the generation of a centralized sequence should be an 
accurate representation of circulating sequences and every effort taken to avoid bias due to 
sampling or outbreak dominance.  Consensus based vaccine strategies elicit broadly reactive 
immune responses against multiple pathogens including HIV-1 [174-178] and influenza [179-
182].  Consensus HA, NA and M1 sequences have been developed for H5N1 DNA vaccination 
and elicited robust cellular immune responses to each vaccine component, as well as antibodies 
to the HA [180-182].  Using centralized antigens for influenza vaccines either alone or as 
components of polyvalent formulations has the potential to overcome the challenge imposed by 
antigenic diversity and improve the effectiveness of both seasonal and pandemic influenza 
vaccines. 
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Figure 8: Strategies to elicit broader immune responses. Schematic showing possible 
vaccine designs for diverse antigens.  Red, orange and green circles represent single isolates 
from different antigenic clusters that are selected for inclusion in a polyvalent mixture.  The blue 
circle represents the hypothetical relationship of a centralized antigen to the various clusters. 
 
 
 
1.10 HIGHLY PATHOGENIC H5N1 INFLUENZA 
 
1.10.1 Pandemic Risk 
 
The World Health Organization (WHO)  has identified three criteria for defining the start of a 
pandemic: 1) a virus to which the world’s population is mostly naïve must emerge, 2) the new 
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virus must be able to replicate in and cause severe disease to humans, and 3) the virus must be 
efficiently transmitted among humans as indicated by chains of human to human spread [183].  
Several avian subtypes have caused human infections including H5N1, H7N7, and H9N2.  All of 
these avian strains have a novel HA to which the human population is largely immunologically 
naïve.  In particular, the avian influenza subtype H5N1 has emerged as a highly pathogenic 
virus in domestic poultry and humans after making its first appearance in 1997.  The novel 
antigenicity of H5N1, as well as its high pathogenicity, fulfills two of the three requirements for 
pandemic virus set forth by WHO.  As revealed by ongoing surveillance, H5N1 is spreading 
geographically through avian species and represents a significant threat to human health as 
incidences of human cases involving direct transmission from birds have been reported 
consistently since 2003 [184].   Through June of 2011, there have been 562 confirmed cases of 
human infection from H5N1 viruses that have resulted in 329 deaths (Figure 9) [185].  Of 
obvious concern is the almost 60% case-fatality rate which demonstrates the need to develop 
effective vaccines to protect against this potentially devastating pandemic. 
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Figure 9: Human infections of H5N1 by year.  Human infections continue to occur at a similar 
frequency since the re-emergence of H5N1 in 2004.  The graph shows non-fatal (gray) and fatal 
(black) human cases of H5N1 infection per year.   
 
1.10.2 Challenges to H5N1 Vaccine Development 
 
Although a clear need exists to develop vaccines against H5N1 influenza, these viruses present 
unique practical challenges to vaccine development.  Many of the vaccine development 
strategies are being directly applied from the long history with seasonal influenza, but this 
method may not be directly applicable due to specific challenges presented by H5N1 influenza 
viruses.  Currently licensed influenza vaccines are derived by growing viral stocks in 
embryonated chicken eggs and the entire process, from strain selection to virus growth to 
quality assurance, normally takes 6 to 9 months to complete [186].  The high virulence of H5N1 
influenza in both poultry and humans makes growing viral stocks for traditional inactivation and 
generation of split vaccines both difficult and dangerous in the contemporary egg-based 
systems.  The manufacturing process must take place under more rigorous biosafety conditions 
and these influenza viruses are lethal to the eggs and prevent the harvesting of high titer virus 
 35 
 
from the allantoic fluid.  A major determinant of the increased virulence involves a multibasic 
cleavage site in the H5 that is cleaved by ubiquitous cellular proteases.  Reverse genetics is a 
method by which custom influenza viruses and mutations can be engineered by introducing viral 
DNA into cells with promoters in place to ensure protein production and negative sense RNA 
synthesis resulting in rescued engineered viruses.  These systems can be employed to mutate 
and eliminate the polybasic cleavage site, thus attenuating the highly pathogenic H5N1 virus 
and making it less virulent without affecting antigenicity [187]. Another challenge during a new 
avian influenza pandemic will be the lack of embryonated eggs due to virulence in domesticated 
poultry and therefore the classical production system would be rendered useless.  Cell culture 
based systems can overcome the practical hurdle of a dwindling egg supply and should be 
developed for use in a pandemic setting.  The HA of H5N1 is poorly immunogenic and requires 
higher doses of antigen [188] or the use of adjuvants to elicit an effective antibody response 
[189].  Stockpiling efforts are complicated by the need for higher doses and these dose 
calculations are insufficient because they are based on the seasonal influenza dose needed to 
protect a given population.  While novel adjuvants have greatly reduced the dose needed to 
elicit immunity, the long term effects of these new compounds is unknown.  Additional difficulties 
facing vaccine development are insufficient information regarding specific antigenic sites on 
H5N1 surface proteins and immune correlates of protection are inconclusive, which makes the 
evaluation of potential vaccine efficacy difficult [190].  Hemagglutination-inhibition (HAI) assays 
are traditionally the methods employed to determine influenza immunity.  These assays take 
advantage of the viral characteristic of agglutinating chicken or turkey erythrocytes and evaluate 
immunity via the ability of serum antibodies to inhibit this agglutination.  Because H5N1 viruses 
have different receptor specificity than seasonal influenza viruses, the avian erythrocytes used 
for seasonal influenza are not useful for the H5N1 hemagglutination inhibition assay.  Horse 
erythrocytes are agglutinated by the H5N1 viruses [191], but the correlation between inhibiting 
serum antibody titer and protection is unclear.  Another method for evaluating serum antibody 
 36 
 
efficacy for protection is the neutralization assay.  In this assay, serum antibody is evaluated for 
the ability to inhibit virus from infecting tissue culture cells.  Neutralization assays are more time 
consuming than hemagglutination inhibition assays, but provide more information about the 
quality of the antibodies and their ability to protect from infection.  Hemagglutination inhibition 
and virus neutralization assays both traditionally require live virus and H5N1 viruses must be 
handled under high containment conditions adding another problem to evaluating vaccines.  To 
circumvent the need for high containment, non-infectious virus particles expressing H5N1 
surface molecules and reporter genes are being developed for use in neutralization and 
hemagglutination assays [192-194]. 
 
1.10.3 H5N1 Diversity 
 
In addition to the practical challenges of H5N1 vaccine development, the antigenic diversity is 
substantial and poses further challenges.  H5N1 viruses are separated into 10 clades based 
upon phylogenetic relationships among the HA genes (Figure 10) [195].  The vast majority of 
the viral isolates used to establish these associations are from avian species and have not yet 
caused human disease.  Although limited, human infections have included isolates from clades 
0, 1, 2 and 7.  Clade 2 H5N1 viruses have caused more reported infections than isolates from 
the other clades.  Antigenic heterogeneity exists between clades and is even beginning to arise 
within a given clade as demonstrated by subclade and sub-subclade divisions within clade 2.    
Despite total sequence identity of HA between clades is high (>90%), there is little cross-
reactivity in receptor blocking antibodies across clades and even within subclades [196].  An 
antigenic profile was determined for H5N1 viruses from all clades resulting in the identification of 
20 residues that are critical to determining antigenicity [197].  Identity patterns across these 20 
amino acids are as low as 30% between clades indicating that total sequence identity likely 
obscures inter-clade diversity.  Each clade and subclade is geographically isolated and evolving 
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under unique pressures specific to the respective location. As would be expected by the 
subclade diversity, clade 2 is the most geographically diverse and spans over 60 countries 
[195].  Independent viral evolution and the subsequent antigenic heterogeneity complicate 
vaccine preparation and stockpiling efforts because predicting which clade or subclade of H5N1 
would be responsible for a pandemic is difficult.  The geographic diversity and isolation of H5N1 
influenza viruses has led to multiple independently evolving viral lineages posing enormous 
hurdles for vaccine manufacturers [198].     
 A goal of H5N1 vaccine development is the elicitation of cross-protective immunity.  It is 
currently impossible to predict which clade may cause a pandemic and therefore an ideal 
vaccine will elicit immunity to all or multiple clades.  Even within clade 2, it is clear that the 
antigenic difference between subclades is substantial and that a vaccine strain selected from 
one subclade may not protect against an infection from a virus of a different subclade.  The 
continuing independent evolution of H5N1 virus clades increases the antigenic distance among 
currently circulating virus strains, as well as the antigenic heterogeneity of strains that will 
actually be circulating during a potential pandemic.  Stockpiling vaccines that are targeted 
against past viral isolates is a worthwhile strategy only if the virus used to make the vaccine is 
antigenically similar to the circulating virus during a pandemic.  Developing a cross-reactive 
vaccine that elicits cross-protective immunity to multiple clades may provide more promise than 
a vaccine that is unable to elicit immunity across current clades.  Current vaccine strategies 
have met this goal with mixed success.  In the following sections, studies published before the 
outset of this work that describe vaccine designs and immunization strategies designed to elicit 
cross-protective immune responses to H5N1 influenza will be reviewed. 
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Figure 10: Relative distribution of H5N1 clades.  The relative frequency of various clades 
from both human and environmental infections is plotted.  Clade 2 is the most prevalent (olive 
green) in both human and environmental infections. 
 
1.10.4 Eliciting Immune Responses to H5 Hemagglutinin 
 
1.10.4.1 Inactivated Virus Vaccines.  Inactivating virus for use in vaccines is the most common 
method for generation of current seasonal influenza vaccines.  The process entails growing 
virus in either embryonated chicken eggs or cell culture and then purifying the virus and 
chemically inactivating it, usually with formalin.  Season influenza vaccines are then further 
processed by splitting the virus particles with detergent and this split vaccine is subsequently 
used for immunizations.  Generating H5N1 inactivated vaccines is challenging in multiple 
aspects.  These highly pathogenic viruses must be handled under greater biosafety conditions 
than seasonal viruses.  More recently, H5N1 viruses have been grown using cell-based 
methods, but these methods also require increased precautions and safety conditions.  One 
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method of avoiding the need for high containment is to generate reassortant viruses that contain 
the HA and NA of H5N1 viruses, but have the internal proteins of a high growth virus.  Using 
reverse genetics technology [187, 199], vaccine candidates are grown under less stringent 
safety conditions and reach a higher titer more easily in eggs.  An H5N1 clade 1 reassortant 
virus generated using the internal proteins from the mouse adapted strain A/Puerto Rico/8/34 
(PR8; H1N1) with the HA and NA from A/Hong Kong/213/03 (clade 1) was evaluated as a 
vaccine candidate [200].  The inactivated whole virion was delivered to ferrets intramuscularly 
with or without aluminum hydroxide (alum) as an adjuvant.  Regardless of adjuvant, the vaccine 
resulted in antibody responses to homologous virus, but no HAI and neutralization antibody 
titers were detected to the heterologous virus A/Vietnam/1203/04 (clade 1).  Despite the lack of 
specific antibody, the vaccine protected animals from lethal challenge of A/Vietnam/1203/04 
(clade 1), demonstrating heterologous protection despite a lack of immune correlate [200].   
 Additional reassortant viruses using the HA and NA from either A/Hong Kong/213/03  
(clade 1) or A/Vietnam/1203/04 (clade 1) and the internal genes from PR8 were generated and 
used as inactivated whole virion vaccines delivered subcutaneously with alum [201].  The 
A/Hong Kong/213/03 (clade 1) vaccine elicited cross-reactive antibodies measured by 
neutralization to both A/Indonesia/5/05 (clade 2.1) and A/Turkey/12/06 (clade 2.2), but 
A/Vietnam/1203/04 (clade 1) vaccine did not.  Despite relatively low neutralizing titers and no 
HAI titers, both vaccines were able to protect mice from A/Vietnam/1203/04 (clade 1) lethal 
challenge at multiple doses with and without adjuvant.  Interestingly, the adjuvanted A/Hong 
Kong/213/03 (clade 1) vaccine protected mice from A/Vietnam/1203/04 (clade 1) virus even 
better than the A/Vietnam/1203/04 (clade 1) vaccine at lower doses [201].  A proposed 
mechanism for this phenomenon is that the A/Vietnam/1203/04 (clade 1) virus has a serine at 
position 224 in HA that may reduce its immunogenicity [202].  Although the A/Hong 
Kong/213/03  (clade 1) vaccine is efficacious against more contemporary H5N1 viruses such as 
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A/Indonesia/5/05 (clade 2.1) [201], continued evolution of the virus pushes the antigenic 
diversity of potential pandemic viruses ever further away from the older isolates.   
 To meet the challenge of not having a homologous vaccine for contemporary viral 
isolates, wild type A/Vietnam/1203/04 (clade 1) and A/Indonesia/5/05 (clade 2.1) viruses were 
prepared by growth in Vero cells under high containment conditions [203].  The wild type viruses 
were then doubly inactivated with formalin and UV irradiation.  The A/Vietnam/1203/04 (clade 1) 
whole virion vaccine was adjuvanted with alum and elicited neutralizing antibody titers to 
homologous and heterologous viruses when administered to guinea pigs.  Mice immunized 
subcutaneously with A/Vietnam/1203/04 (clade 1) vaccine produced high titers of antibody and 
neutralizing antibodies to homologous virus without adjuvant and were subsequently protected 
from homologous (A/Vietnam/1203/04; clade 1) challenge as well as heterologous 
(A/Indonesia/5/05; clade 2.1 and A/Hong Kong/156/97; clade 0) challenge [203].  Mice that were 
vaccinated with A/Indonesia/5/05 (clade 2.1) vaccine were also protected from homologous and 
heterologous (A/Vietnam/1203/04; clade 1) challenge [203].  The inactivated whole wild-type 
virion nature of these vaccines is likely responsible for the immunogenicity and effectiveness 
without adjuvant.  Despite double inactivation and rigorous safety testing of the vaccines, the 
potential for infection with surviving virus is a regulatory hurdle that will be difficult to overcome.   
 To circumvent the need for whole virus preparations, novel adjuvant technology has 
been applied to lower the dose of vaccine required to elicit an effective immune response.  One 
adjuvant that has been particularly promising is the MF59 adjuvant from Novartis.  As discussed 
previously, (see Section 1.8) MF59 is an oil-in water emulsion that enhance immune responses 
via a TLR-independent pathway [158, 159].  A vaccine consisting of reverse genetics 
engineered A/Vietnam/1194/04 (rgVN1194; clade 1) that had the polybasic cleavage site 
removed was inactivated and split and then administered to human volunteers with and without 
the proprietary MF59 adjuvant [204].  Including the adjuvant in the vaccine formulation greatly 
increased the neutralizing antibody titers to both homologous virus (A/Vietnam/1194/04; clade 
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1) and heterologous virus (A/Indonesia/5/05; clade 2.1).  Importantly, the adjuvant also greatly 
reduced the amount of antigen administered and allowed for dose sparing.  This a critical factor 
in a pandemic setting as the supply of vaccine is likely to be limited and high dose requirements 
only exacerbate the problem.  Ethical issues obviously preclude the ability to challenge the 
volunteers who were given the vaccine, so the same vaccine and adjuvant system was 
analyzed in a ferret model [205].  Ferrets vaccinated with rgVN1194 (clade 1) inactivated split 
virus with the MF59 adjuvant developed neutralizing antibodies to both A/Vietnam/1194/04 
(clade 1) and A/Indonesia/5/05 viruses (clade 2.1) [205].  Upon challenge with both 
A/Vietnam/1194/04 (clade 1) and A/Indonesia/5/05 (clade 2.1), rgVN1194 (clade 1) with 
adjuvant vaccinated ferrets had greater survival, lower virus titer in the nose and lungs, and 
decreased viral shedding than unadjuvanted or mock vaccinated controls [205].  Evidence of 
safety in humans together with efficacy in ferrets provide promise that an effective pre-pandemic 
vaccine is possible.   
 The MF59 adjuvant has also been used in a monovalent HA vaccine from an H5N3 
virus, A/Duck/Singapore/97.  This vaccine has been tested for safety in human volunteers and 
elicits heterosubtypic neutralizing antibodies to an antigenically similar virus A/Hong 
Kong/156/97 (clade 0) and antigenically distinct viruses A/Hong Kong/213/03 (clade 1), 
A/Vietnam/1203/04 (clade 1), and A/Thailand/16/04 (clade 1) [189].  The A/Duck/Singapore/97 
virus was also used as an unadjuvanted, inactivated split vaccine delivered intramuscularly in 
ferrets to evaluate immunogenicity and effectiveness [206].  Vaccinated animals had low HAI 
titers to homologous virus and no HAI titers to heterologous viruses A/Hong Kong/156/97 (clade 
0) and A/Vietnam/1203/04 (clade 1).  Additionally, A/Duck/Singapore/97 elicited neutralizing 
titers to homologous virus and heterologous  A/Hong Kong/156/97 (clade 0) virus but not to 
heterologous A/Vietnam/1203/04 (clade 1) [206].  Despite the apparently low immunogenicity of 
the vaccine regimen, the ferrets were protected from severe disease and death upon challenge 
with A/Vietnam/1203/04 (clade 1) wild type virus [206].  Even without HAI or neutralizing 
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antibody, the vaccinated animals had lower levels of virus replication in the upper respiratory 
tract compared to mock vaccinated controls [206].  These data agree with previous studies 
showing that despite a low or complete lack of HAI or neutralizing antibodies, vaccines can 
protect animals from infection with heterologous virus [200, 206].    
 While the heterologous protection shown in response to vaccination with H5 viruses is 
encouraging and indicates that an effective pre-pandemic vaccine is possible, work with 
seasonal influenza vaccines has been intriguing.  Delivery of influenza vaccines is traditionally 
administered via intramuscular injection for inactivated vaccines and intranasally for live-
attenuated vaccines.  By directly targeting mucosal surfaces in the respiratory tract it is possible 
to elicit secretory antibody that may be more effective at neutralizing virus than serum antibody.  
Mice were immunized intranasally with inactivated whole virion H3N2 virus X-31 (A/Aichi/2/68 
HA and NA with A/Puerto Rico/8/34 internal genes) with mutant heat-labile enterotoxin (LT) from 
E. coli [207].  LT is a toxin produced by enterotoxinogenic strains of E. coli and induces chloride 
flux and fluid loss.  The toxin is a potent mucosal adjuvant, but the toxicity of the native toxin 
precludes its use as an adjuvant.  The mutant LT is less toxic than native LT and retains the 
adjuvant properties of the unaltered toxin.  This vaccine strategy elicited serum and mucosal 
antibodies to both whole H5N1 (A/Hong Kong/483/97; clade 0) virus particles and recombinant 
H5 HA but these antibodies were unable to neutralize H5N1 virus.  Despite a lack of neutralizing 
antibody, mice vaccinated with X-31 with LT intranasally were protected from lethal challenge 
with A/Hong Kong/483/97 (clade 0) virus.  Mice vaccinated subcutaneously with X-31 plus LT 
were not protected from lethal challenge and had much lower serum and lung antibody titers to 
H5N1 virus.  Interestingly, mice that were experimentally infected with X-31 prior to challenge 
with H5N1 were also completely protected from lethality and mice vaccinated intranasally with 
X-31 without adjuvant were partially protected.  Protection correlated with lower virus titers in 
the lungs and a lack of virus in the nose or brain.  This protection was also shown to be 
dependent on B cells as both CD8 depletion and CD8 deficiency resulted in vaccinated animals 
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surviving H5N1 challenge while B cell deficiency resulted in death regardless of vaccination.  
CD8+ cells may not be required for survival, but virus titers were higher in the absence of CD8+ 
cells indicating an important role in clearance.   
 The concept of seasonal viruses being used in intranasal vaccines with mucosal 
adjuvants and prior seasonal influenza infection providing protection to H5N1 infection indicates 
that an immunologically naïve population may be more protected to novel HA subtypes than 
suspected.  Further evidence of potential protective effects of seasonal influenza vaccines was 
provided when mice were vaccinated intranasally with trivalent inactivated split vaccine 
prepared for the 2005-2006 season (A/New Caledonia/20/99 (H1N1), A/New York/55/04 
(H3N2), and B/Shanghai/361/02) plus Ampligen, a proprietary TLR-3 agonist [208].  The 
intranasally delivered, adjuvanted seasonal vaccine did not elicit H5N1 HAI or neutralizing 
antibodies, but did yield serum and lung antibodies to A/Vietnam/1194/03.  Mice that were 
vaccinated intranasally with adjuvanted trivalent vaccine had increased survival when 
challenged with multiple H5N1 viruses (A/Vietnam/1194/04; clade 1, A/Indonesia/6/05; clade 2.1 
and A/Hong Kong/483/97; clade 0) and had lower virus titer in nasal washes compared to mock 
vaccinated controls.  Intranasal delivery of influenza vaccines has been shown to be an effective 
way of eliciting heterosubtypic immunity, but an H5N1 vaccine could be even more effective 
when administered by this route.  Inactivated whole virus rgVN1194 (described above, clade 1) 
was used with Ampligen as an adjuvant to vaccinate mice [209].  Regardless of delivery route or 
adjuvant, the vaccine elicited neutralizing antibody titers to homologous virus (A/Vietnam/1194; 
clade 1), but not to heterologous viruses (A/Hong Kong/483/97; clade 0 and A/Indonesia/6/05; 
clade 2.1).  When the vaccine was administered intranasally with the adjuvant, mice were 
protected from lethal challenge by not only the homologous virus, A/Vietnam/1194/04 (clade 1), 
but also heterologous viruses: A/Hong Kong/483/97 (clade 0) and A/Indonesia/6 2005 (clade 
2.1). 
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   Inactivated vaccines are the main strategy of current seasonal influenza vaccines, but 
generating inactivated vaccines for H5N1 viruses presents unique challenges because these 
viruses are highly pathogenic and must be handled under increased biosafety precautions.  
Furthermore, the viruses are difficult to grow in traditional egg-based systems due to their high 
pathogenicity and therefore require new methods of virus production such as cell culture.  Using 
whole inactivated virus also causes apprehension among licensing bodies due to the high 
pathogenicity of the virus and the extremely slight possibility of incomplete inactivation 
inadvertently infecting patients. Methods, such as reverse genetics, can generate viruses that 
are less pathogenic than the wild-type strain and that can be handled under lower safety 
conditions, but these take time and would extend the lead time needed to produce a vaccine 
after the start of a pandemic.  Low immunogenicity and higher dose requirements are additional 
challenges for inactivated vaccines that further hinder vaccine stockpiling efforts.  Novel 
adjuvants, such as MF59 and Ampligen, are safe not only at lower doses, but also help to elicit 
cross-protective immunity.  Non-traditional delivery methods, such as subcutaneous or 
intranasal, can also lower the dose that is required and broaden reactivity of the elicited 
immunity.  Inactivated virus vaccines are clearly important and have been progressing through 
clinical trials, but alternative vaccine strategies can also elicit cross-protective immunity to H5N1 
viruses. 
 
1.10.4.2 Live-Attenuated Virus Vaccines.  Live-attenuated viruses are potential vaccine 
candidates for H5N1 influenza.  A seasonal influenza live attenuated virus vaccine is currently 
licensed in the United States for non-pregnant and non-immunocompromised individuals ages 
2-49 years of age [210].  Additionally, live-attenuated vaccines have been available in Russia for 
years [211].  These vaccines are made by adapting an influenza virus to cold temperatures, 
such that it has limited growth at temperatures encountered in the human body.  Surface 
glycoproteins are then substituted to match the recommended strains for of seasonal influenza 
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vaccines or H5N1 candidates for pandemic influenza.  For H5N1 vaccines, the polybasic 
cleavage site in HA is removed to return the viruses to a state of trypsin dependence.  Live 
attenuated vaccine strategies have several advantages, including stimulation of an immune 
response in naïve individuals after a single vaccination, induction of cross-reactive immune 
responses and poor transmissibility [212, 213].  H5N1 live attenuated vaccines containing the 
surface glycoproteins of A/Hong Kong/213/03 (clade 1), A/Vietnam/1203/04 (clade 1), and 
A/Hong Kong/491,486/97 (clade 0; HA from A/Hong Kong/491/97 and NA from A/Hong 
Kong.486/97) have been generated and evaluated in mice and ferrets [214].  All HA genes were 
modified to remove the polybasic cleavage site and trypsin dependence was verified.  The 
vaccine strains were all shown to be attenuated by 1) detecting only low titers of virus in the 
respiratory tract of infected mice or ferrets and 2) the lack of detection of these attenuated 
strains in the brain.  A single vaccination in mice resulted in low neutralizing and HAI antibody 
responses to both homologous and heterologous viruses, although serum antibodies to 
recombinant HA were detected by ELISA.  Interestingly, a second dose of attenuated virus 
increased both the titer and cross-reactivity of neutralizing and HAI antibodies even though no 
replication in the respiratory tract could be detected after the boost.  All mice vaccinated with a 
single dose of attenuated virus survived challenge with both homologous and heterologous 
virus, including the more recent A/Indonesia/5/05 (clade 2.1) strain despite undetectable 
neutralizing and HAI antibody responses.  Control mice that were immunized with only the 
attenuated virus without H5N1 surface glycoproteins were partially protected from lethality (40-
80% survival) after H5N1 challenge and this protection waned as the challenge dose was 
escalated.  Although complete protection from lethality was achieved in H5N1 vaccinated mice, 
a single dose of vaccine did not protect from viral replication in the respiratory tract.  Viral titers 
in the lungs were lower in vaccinated mice as compared to controls and virus did not 
disseminate to the brain, data consistent with low neutralizing antibody titers.  Protection that 
prevented viral replication in the lungs of infected mice was more effective in mice that received 
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two doses of the vaccines, regardless if the challenge virus was homologous or heterologous to 
the vaccine strain.  Ferrets that received two doses of the vaccine strains were also protected 
from homologous and heterologous challenge and had lower viral titer in nasal washes.  Live 
attenuated vaccines based upon H5N1 strains that emerged in 1997 (clade 0) are effective at 
protecting animals from challenge with phylogenetically distinct virus from 2004 (clade 1).   
 A live attenuated virus has been constructed using the HA from a nonpathogenic, but 
antigenically related H5N2 avian influenza virus A/Duck/Pottsdam/1042-6/86, with all other gene 
segments (including NA) from a Russian cold-adapted strain.  This vaccine was evaluated for 
use as both a live attenuated vaccine and as an inactivated vaccine [215].  Mice that were 
vaccinated intranasally with the live attenuated vaccine did not have cross-reactive neutralizing 
antibodies while intramuscular administration of the same vaccine inactivated and adjuvanted 
with alum did yield cross-reactive neutralizing antibodies to an antigenically similar virus, 
A/Hong Kong/156/97 (clade 0) and an antigenically distinct virus, A/Hong Kong/213/03 (clade 1) 
but not to a second antigenically distinct virus, A/Vietnam/1203/04 (clade 1).  Despite the lack of 
neutralizing antibodies, antibodies that cross-reacted in an ELISA with HA from 
A/Vietnam/1203/04 (clade 1) were present in sera from both the live attenuated vaccine and the 
inactivated vaccine.  Mice vaccinated with either the live attenuated virus or the inactivated virus 
were protected from lethal challenge with A/Vietnam/1203/04 (clade 1) virus despite a lack of 
neutralizing antibodies.  Survival correlated with lower virus titers in vaccinated mice as 
compared to control animals.   
 In general, these live attenuated virus vaccines are a safe and effective way to vaccinate 
for seasonal influenza and are currently licensed for that purpose.  Live attenuated viruses have 
the advantage of replicating to low levels in the host and therefore elicit cellular immunity and 
are able to generate potent immune responses without the need of a booster vaccination.  
Applying attenuated virus strategies to H5N1 viruses has been successful in animal models, 
although multiple doses are needed to increase immunity to the H5N1 antigens.  A major hurdle 
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in order to approve live attenuated viruses as vaccines is, despite the attenuated phenotype, 
these viruses are still able to transmit from person to person in the case of seasonal vaccines, 
which is a concern for the development of live-attenuated H5N1 vaccines.  Another problem 
with live attenuated virus vaccines is that if a person is infected with a seasonal strain of 
influenza at the same time the live attenuated vaccine is administered, a reassortment event 
could occur that may generate a virus with seasonal influenza internal proteins and H5N1 
glycoproteins.  Although the HA is mutated to be less pathogenic prior to attenuated vaccine 
formulation the chance of directly causing reassortment with seasonal influenza is not a 
favorable possibility.  Despite the drawbacks of using a live attenuated vaccine for pre-
pandemic immunizations, the live attenuated vaccine’s ability to elicit broadly protective 
immunity with relatively low doses would be a valuable tool at the beginning of a pandemic to 
limit spread and mortality. 
 
1.10.4.3 Viral Vector Vaccines.  Using virus vectors for delivery of H5N1 vaccines is another 
strategy that is being developed.  Viral vectors are low pathogenic viruses that are modified to 
produce influenza proteins.  The vector can also be constructed such that it cannot produce 
progeny virions and is therefore rendered replication incompetent.  Since the vector actually 
infects cells, viral vector antigen delivery systems have the advantage of producing influenza 
proteins within the host in a manner similar to live attenuated viruses.  This leads to the 
generation of a more complete immune response that includes cytotoxic T cells in addition to 
antibody.  Several viruses are effective vectors to elicit cross-protection among H5N1 viruses.  
Adenovirus vectors elicit a potent immune response which is protective against antigenically 
distinct H5N1 strains [216, 217].    A replication-defective adenovirus vector carrying the full 
length HA gene of A/Hong Kong/156/97 (clade 0) was used to vaccinate mice both intranasally 
and intramuscularly and elicited HAI antibody to homologous virus and to heterologous viruses 
A/Hong Kong/213/03 (clade 1) but not to A/Vietnam/1203/04 (clade 1) regardless of 
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administration route [217].   Despite the low HAI titers, all vaccinated mice were protected from 
lethal challenge with both the antigenically similar A//Hong Kong/483/97 (clade 0) and the 
antigenically distinct A/Vietnam/1203/04 (clade 1).  This protection corresponded with low virus 
titers in the lungs of challenged mice compared to mock vaccinated controls.   
 Vesicular stomatitis virus vectors that are either replication competent or incompetent 
and express HA from A/Hong Kong/156/97 (clade 0) elicited neutralizing antibodies to 
homologous A/Hong Kong/156/97 (clade 0) virus and also to heterologous viruses:  
A/Vietnam/1203/04 (clade 1) and A/Indonesia/5/05 viruses (clade 2.1) [218].  Vaccinated mice 
were also protected from challenge with the antigenically similar A/Hong Kong/483/97 (clade 0) 
virus up to 7.5 months post vaccination.  Newcastle disease virus is another vector that has 
been engineered to express HA from an H5N1 virus, A/Bar-headed goose/Qinghai/3/2005 
(clade 2.2) [219].  Highly pathogenic Newcastle disease virus is a threat to poultry across the 
world and naturally occurring strains are used as vaccines on a regular basis.  By combining 
H5N1 antigens with these vaccine strains, it is proposed that poultry could be protected from 
two different threats with a single vaccine.  The vaccine elicited HAI antibodies to homologous 
virus and low levels of HAI antibodies to a heterologous virus, A/Duck/Fujian/13/02 (clade 3).  
Vaccinated mice and chickens were all protected from challenge with both homologous virus 
and heterologous virus with low levels of virus replication compared to mock vaccinated 
animals.   
 Vector delivery of H5N1 vaccines is an effective way to elicit cross-reactive immunity.  
However, using replication competent viruses for delivery is dangerous due to potential 
pathogenicity of the vehicle.  Pre-existing immunity to the vehicle is a challenge that limits the 
effectiveness of using viruses as vectors because the vector could be neutralized before it 
infects and delivers the antigen to the host.  Some serotypes of adenovirus have low prevalence 
in the human population and vesicular stomatitis virus is not prevalent in humans, which makes 
these two vectors good candidates for vaccine delivery.  Using replicating virus as a delivery 
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system may be ideal for immunizing poultry flocks because the vaccinated birds could spread 
the vaccine by natural viral replication.    
 
1.10.4.4 Virus-Like Particle Vaccines.  Virus-like particles (VLP) are self-assembling, 
nonpathogenic, genomeless particles that are similar in size and morphology to intact virions 
[220].  Influenza VLP vaccines have been made that include the influenza proteins matrix, 
hemagglutinin and neuraminidase.  These vaccines are usually produced in a baculovirus 
expression system and consist of particles that have hemagglutination and neuraminidase 
activities.  VLP vaccines have the advantage that they are particulate in nature and therefore 
generate a better immune response than recombinant protein vaccines and they are 
genomeless which renders them completely noninfectious.  Additionally, VLP vaccines are 
produced in an egg-free system and therefore do not require a large supply of embryonated 
chicken eggs for production and because they are nonpathogenic wild type surface 
glycoproteins can be used in their formulation.  Influenza VLP vaccines have been generated for 
seasonal influenza viruses and they elicit broad immune responses [221].  VLP vaccines to 
H5N1 influenza have been developed using the surface glycoproteins from both 
A/Vietnam/1203/04 (clade 1) and A/Indonesia/5/05 (clade 2.1) viruses [222].  These vaccines 
elicited strong HAI antibody titers to both homologous virus and heterologous virus.  Upon 
challenge with a lethal dose of reassortant viruses, animals vaccinated with either vaccine were 
protected from death from both homologous and heterologous virus.  VLP vaccines elicit high 
titer, cross-protective immune responses in the absence of adjuvant.  These vaccines have the 
advantage that they are produced in a cell-based system and do not require high 
biocontainment for their production.  They also have the advantage that they do not have to be 
inactivated because VLPs are genomeless and noninfectious.   
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1.10.5 Alternative Targets 
 
1.10.5.1 Neuraminidase.  Although immunity against hemagglutinin has been the primary focus 
of vaccines discussed thus far, other viral proteins are receiving attention as possible antigens 
on which to base a vaccine.  Data indicate that immunity directed at neuraminidase can provide 
significant cross-protection of antigenically diverse viruses within a given subtype [223].  
Although NA antibody does not protect against initial infection, it can reduce severity of disease 
by limiting viral replication.  Current seasonal vaccines contain NA but the concentrations are 
not standardized like the HA concentrations and HA may dominate the immune response.  To 
target NA specifically, a DNA vaccine expressing A/New Caledonia/20/99 (H1N1) NA was used 
to vaccinate mice [224].  Vaccinated animals developed high titer antibodies to homologous 
H1N1 NA but did not develop significant antibodies to heterologous H5N1 NA.  Challenges with 
PR8 reassortant viruses having the NA from A/New Caledonia/20/99 (PR8-huN1) or 
A/Vietnam/1203/04 (PR8-avN1) and the remaining 7 genes from PR8 resulted in NA vaccinated 
animals being completely protected from homologous virus (PR8-huN1) and partially protected 
from heterologous virus (PR8-avN1).  Furthermore, wild type A/Vietnam/1203/04 (clade 1) virus 
was used for challenges and mice were partially protected as would be expected from the 
reassortant viruses.  Because DNA vaccines can elicit potent T cell responses, passive transfer 
of humoral immunity was also evaluated.  Recipient animals were all protected from 
homologous (PR8-huN1) challenge and partially protected from heterologous (wild type 
A/Vietnam/1203/04; clade 1) challenge at a rate that is comparable to directly vaccinated mice.  
Additionally, human serum samples were analyzed for the presence of anti-neuraminidase 
activity and found high penetrance of high titer NA inhibition to A/New Caledonia/20/99 and low 
penetrance, low titer NA inhibition to avian isolates (A/Hong Kong/213/03; clade 1 and 
A/Vietnam/1203/04; clade 1).  The results of the animal vaccinations indicate that anti-NA 
humoral immunity to recent vaccine strains is partially effective at protecting animals 
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experimentally infected with H5N1.  By standardizing the amount of NA currently in vaccine 
formulations, it is possible that cross-protective immunity could be elicited thereby reducing the 
morbidity and mortality classically associated with influenza pandemics. 
 
1.10.5.2 M2.  Immunity to influenza that is mediated by antibody responses to HA and NA is 
very effective for antigenically matched strains, but can be ineffective against different subtypes 
or even within subtypes that have significant drift.  Another surface protein in influenza, M2, has 
been the subject of recent vaccine strategies.  M2 is an ion channel that functions in viral entry 
via facilitating the dissociation of vRNPs from matrix.  M2 has a short ectodomain that is 
exposed to antibodies as well as a long cytoplasmic tail.  Anti-M2 monoclonal antibody has 
been shown to reduce viral replication and identifies M2 as a viable vaccine candidate [17].  A 
DNA vaccine encoding a full length M2 with a consensus ectodomain was constructed and used 
to evaluate M2 immunity in mice [179].  Vaccinated mice had specific antibodies to H1N1 M2 
that matched the consensus (PR8 and A/FM/1/47) as well as antibodies to H5N1 M2 that 
diverged from the consensus (A/Thailand/SP-83/2004; clade 1).  When the DNA vaccine was 
followed with an M2-expressing adenoviral boost, animals were completely protected from 
matched virus (PR8 and A/FM/1/47), as well as partially protected from H5N1 virus 
(A/Thailand/SP-83/2004; clade 1).  M2 as a vaccine antigen is efficacious and is able to elicit 
broad immunity.  The ectodomain is not perfectly conserved with the H5N1 virus A/Hong 
Kong/213/03 (clade 1) being quite divergent and the consensus vaccine does not elicit 
antibodies that are specific for M2 of H5N1.  Alternative strategies of using M2 in the context of 
vaccine development are also in progress. 
 Since M2 plays such a crucial role in viral uncoating following infection, it presents an 
attractive target for altering to generate live-attenuated viruses.  M2 cytoplasmic tail deletion 
mutants were evaluated in mice for use as live-attenuated vaccines [16].  A panel of M2 deletion 
mutant viruses was evaluated for their ability to replicate in mice. In contrast to viruses with wild-
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type M2, viruses with an 11 cytoplasmic amino acid deletion in M2 (M2del11) replicated to low 
titers in the lungs and did not spread to the brain.  This M2del11 was combined with a mutant 
HA (HAavir) that was made trypsin dependent by the removal of the polybasic cleavage site and 
then rescued via reverse genetics with wild type A/Vietnam/1203/04 (M2del11-HAavir; clade 1).  
The M2del11-HAavir (clade 1) virus was highly attenuated in mice and was restricted to the 
respiratory tract where it replicated to low titers.  Mice that were immunized with M2del11-
HAavir (clade 1) had wild type A/Vietnam/1203/04 (clade 1) virus specific antibodies in both the 
serum and lungs.  These antibodies were not neutralizing to either A/Vietnam/1203/04 (clade 1) 
or A/Indonesia/7/05 (clade 2.1).  Despite a lack of neutralization, M2del11-HAavir (clade 1) 
vaccinated mice were protected from challenge with both homologous A/Vietnam/1203/04 
(clade 1) virus and heterologous A/Indonesia/7/05 (clade 2.1) virus.  This survival corresponded 
to no detectable virus titer in A/Vietnam/1203/04 (clade 1) challenged mice and very low virus 
titer in A/Indonesia/7/06 (clade 2.1) challenged mice.  M2 is an attractive vaccine candidate as 
both a direct target for immunity and also as a target for attenuation.  Highly conserved proteins 
such as M2 are appealing for vaccine design due to the possibility of eliciting broad immunity 
and this strategy has been used to target other highly conserved proteins in addition to M2 
 
1.10.5.3 Nucleoprotein and Matrix.  A major reason for the need to update the seasonal 
influenza vaccine annually is the poor antigenic match between the vaccine strains.  Humoral 
immunity is generally accepted to be the major correlate of protection, but continuous antigenic 
drift enables influenza to escape antibodies elicited to prior strains.  Because drift within a 
subtype is enough to lower the efficacy of prior vaccines of the same subtype, emergence of a 
novel subtype into the population could have devastating effects.  In the absence of a matched 
humoral response, cytotoxic T lymphocytes (CTL) may mediate protection and impact disease 
severity and mortality.  CTL responses are directed towards conserved epitopes of internal 
proteins like nucleoprotein (NP) and matrix.  These internal proteins are well conserved within 
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subtypes and can even be conserved between subtypes.  To elicit effective CTL responses, 
antigens must be delivered efficiently to the cytosol in order to access the MHC Class I 
processing pathway and be presented to CTL.  Vaccine strategies that ensure this delivery 
include live attenuated vaccines and DNA vaccines due to their ability to replicate within the 
cells of the host or virosomes and VLPs that are able to fuse with cellular membranes and 
deliver contents to the cytosol.  To evaluate the role of CTL in eliciting cross-protective 
immunity, a live-attenuated vaccine was compared to a DNA prime-adenovirus boost strategy 
[225].  A live-attenuated H3N2 (A/Alaska/6/77) on a cold adapted H2N2 (A/Ann Arbor/6/60) 
background was compared to DNA prime-adenovirus boost vaccines expressing PR8 
nucleoprotein with M2 (A/NP+M2).  Both vaccine strategies elicited CTL responses as 
measured by IFN-  ELISpot with A/NP+M2 having a better response.  Upon challenge with 
A/Vietnam/1203/04 (clade 1), A/NP+M2 protected much better than live-attenuated (80% and 
20% survival, respectively).  While CTL immunity to conserved proteins is certainly important in 
generating cross-protective immune responses, CTL can also be directed towards HA. 
 To compare the efficacy of NP DNA vaccines to HA DNA vaccines, both were given to 
chickens to evaluate protective efficacy [226].  The HA from both A/Turkey/Ireland/83 (H5N8) 
and A/Chick/Victoria/1/85 (H7N7) was used to generate single vaccines as well as the NP from 
A/Turkey/Ireland/83.  Chickens that received the NP vaccine were partially protected (~50%) 
from both A/Turkey/Ireland/83 and A/Chick/Victoria/1/85.  The HA vaccines did not elicit HAI 
antibodies to either virus, but when administered alone they were protective when challenged 
with the homologous virus.  Interestingly, when the HA DNA vaccines were administered 
together the protection was to both A/Turkey/Ireland/83 and A/Chick/Victoria/1/85.  Consensus 
DNA sequences is another way of immunizing for CTL while attempting to broaden the antigenic 
range of the immunogen.  A consensus sequence is a version of a gene not found in nature but 
rather assembled in silico to contain the most common amino acid in a given population at each 
residue.  Consensus DNA immunogens have been shown in HIV research to induce strong T 
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cell responses that are more cross-reactive than their components [178].  Consensus HA, NA, 
and matrix were all used as DNA vaccines to determine if cellular immunity could be elicited 
[180].  All constructs tested elicited CTL immunity as measured by IFN-  ELISpot to custom 
peptide pools of the respective immunogen.  Additionally, the HA consensus vaccine elicited low 
titer antibodies to the recombinant consensus protein.  When this recombinant protein was used 
as a vaccine with complete Freund’s adjuvant, the consensus HA was able to protect mice from 
A/Hanoi/30408/05 challenge [180].  CTL immunity is important to generating cross-protective 
immunity to influenza in the absence of an antigenically matched humoral response.  Although 
CTL cannot prevent infection, cell-mediated immune responses can reduce the morbidity and 
mortality associated lethal influenza infection.  Additionally, CTL immunity can reduce 
transmission of the virus by decreasing the level of replication and the duration of infection.   
 
 
 
1.11 CONCLUDING REMARKS 
 
Influenza pandemics occur sporadically and are characterized by the introduction of novel 
surface glycoproteins into circulating strains.  This event results in viruses to which the 
population has little or no humoral immunity and the viruses are therefore able to spread 
unchecked.  H5N1 influenza has emerged as a potential pandemic virus because it is highly 
pathogenic and there is little pre-existing immunity in the human population.  Geographic spread 
of H5N1 in avian species is continuing and, subsequent human infections are affecting more of 
the globe.  Several challenges exist in the development of vaccines to H5N1 influenza, such as 
the high pathogenicity of the virus, antigenic variation within the subtype, poor immunogenicity, 
and no established immune correlates of protection [188, 190].  Despite these obstacles, 
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progress is being made toward developing vaccines that protect against both the homologous 
virus and also heterologous viruses of the same and even different subtypes. 
 Vaccine strategies that have successfully elicited broad immunity include inactivated 
virus, live-attenuated virus, viral vectors, virus-like particles, and DNA vaccines [180, 205, 214, 
217, 222].  These strategies can be further enhanced by the use of adjuvants and alternative 
routes of inoculation.  The Novartis adjuvant MF59 is particularly effective at eliciting cross-
reactive immunity.  The vaccine formulation is safe in human volunteers and this same 
formulation protects ferrets from lethal challenge with antigenically distinct viruses [204, 205].  
The intranasal route of vaccination also improves cross-reactivity.  When combined with a 
mucosal adjuvant, Ampligen, seasonal subtype whole inactivated virions were able to protect 
mice from lethal challenge with H5N1 viruses [207, 208].  Use of adjuvants and intranasal 
administration of H5N1 vaccines is proving to be a successful way of eliciting broad immunity.  
Targeting internal proteins of influenza is also an effective way of eliciting cross-reactive 
immunity and although this immunity does not prevent infection, it may be effective at reducing 
the duration and severity of illness [227].    
 Data on long term safety of new adjuvants is lacking and as patient cohorts age more 
information will become available.  The future of broadly reactive pandemic vaccines is open to 
new discoveries.  Lessons learned from seasonal vaccine development should be applicable to 
pandemic vaccine development, such as the important concept of polyvalency.  Seasonal 
influenza vaccines are able to elicit protective immunity to three strains of influenza each year 
and it is reasonable to explore the idea of generating polyvalent pandemic vaccines.  Because 
avian isolates other than H5N1 have infected humans (H7N7 and H9N2), a polyvalent vaccine 
that includes all three subtypes could be the future of pandemic vaccines.  Of course, the 
antigenic diversity of H5N1 alone could warrant the development of a polyvalent vaccine to 
multiple clades within a single subtype.  When developing a pandemic vaccine, it is prudent to 
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consider subtypes that have previously infected humans and but are no longer circulating in 
humans, such as H2N2.  Pre-existing immunity to influenza of any subtype also appears to 
provide some protection to H5N1 infection.  Infection or prior vaccination with seasonal 
influenza induces CTL responses and could generate NA antibodies that may reduce disease 
severity in the event of a pandemic.  The roles of pre-existing immunity to a novel subtype are 
ongoing questions with great relevance to public health.  Establishing correlates of protection is 
a crucial step in comparing vaccines.  Protection in the absence of hemagglutination inhibition 
or virus neutralization complicates evaluation of vaccine candidates and evaluating immunity in 
human trials must have an interpretable result other than protection.  While H5N1 has not 
caused wide spread infections in humans to date, information learned about pandemic 
preparedness and vaccine cross-protection will certainly benefit in the event of a pandemic 
caused by any subtype of influenza. 
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2.0 MATERIALS AND METHODS 
 
 
 
2.1 ANTIGEN CONSTRUCTION AND SYNTHESIS 
 
Influenza A HA nucleotide sequences from viruses isolated during human infections were 
downloaded from the NCBI Influenza Virus Resource database [51].  129 full length sequences 
from H5N1 clade 2 human infections collected from 2004-2006 were acquired and used for 
subsequent consensus generations (Table 2).  Nucleotide sequences were translated into 
protein sequences using the standard genetic code and alignments were performed using 
protein sequences.  For each round of consensus generation, multiple alignment analysis was 
applied and the consensus sequence was generated using AlignX software (Vector NTI).  The 
sequences were first grouped into subclades and then further divided into outbreak groups 
based upon time and location of isolation.  Primary consensus sequences were generated 
based upon outbreak groups within each subclade.  Next, primary consensus sequences within 
each subclade were aligned and used to generate secondary consensus sequences for the 
respective subclades.  Finally, the secondary, subclade-specific, consensus sequences were 
aligned and the resulting consensus sequence was termed computationally optimized broadly 
reactive antigen (COBRA; Figure 11).  The COBRA protein sequence was reverse translated 
and optimized for expression in mammalian cells, including codon usage and RNA optimization 
(GeneArt; Regensburg, Germany).  The resulting construct was then synthesized and inserted 
into the pTR600 expression vector.  
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Table 2: COBRA input sequences 
Strain Clade Accession Host Country Year 
 A/Indonesia/534H/2006  2.1.2  EU146737  Human  Indonesia  2006 
 A/Indonesia/535H/2006  2.1.2  EU146753  Human  Indonesia  2006 
 A/Indonesia/536H/2006  2.1.2  EU146754  Human  Indonesia  2006 
 A/Indonesia/538H/2006  2.1.2  EU146745  Human  Indonesia  2006 
 A/Indonesia/546bH/2006  2.1.2  EU146793  Human  Indonesia  2006 
 A/Indonesia/546H/2006  2.1.2  EU146755  Human  Indonesia  2006 
 A/Indonesia/560H/2006  2.1.2  EU146785  Human  Indonesia  2006 
 A/Indonesia/CDC594/2006  2.1.2  CY014272  Human  Indonesia  2006 
 A/Indonesia/CDC595/2006  2.1.2  CY014280  Human  Indonesia  2006 
 A/Indonesia/CDC596/2006  2.1.2  CY014288  Human  Indonesia  2006 
 A/Indonesia/CDC597/2006  2.1.2  CY014296  Human  Indonesia  2006 
 A/Indonesia/CDC599/2006  2.1.2  CY014303  Human  Indonesia  2006 
 A/Indonesia/CDC599N/2006  2.1.2  CY014477  Human  Indonesia  2006 
 A/Indonesia/CDC625/2006  2.1.2  CY014433  Human  Indonesia  2006 
 A/Indonesia/CDC625L/2006  2.1.2  CY014465  Human  Indonesia  2006 
 A/Indonesia/160H/2005  2.1.3  EU146648  Human  Indonesia  2005 
 A/Indonesia/175H/2005  2.1.3  EU146640  Human  Indonesia  2005 
 A/Indonesia/177H/2005  2.1.3  EU146680  Human  Indonesia  2005 
 A/Indonesia/195H/2005  2.1.3  EU146656  Human  Indonesia  2005 
 A/Indonesia/239H/2005  2.1.3  EU146664  Human  Indonesia  2005 
 A/Indonesia/245H/2005  2.1.3  EU146672  Human  Indonesia  2005 
 A/Indonesia/283H/2006  2.1.3  EU146681  Human  Indonesia  2006 
 A/Indonesia/286H/2006  2.1.3  EU146688  Human  Indonesia  2006 
 A/Indonesia/292H/2006  2.1.3  EU146713  Human  Indonesia  2006 
 A/Indonesia/298H/2006  2.1.3  EU146697  Human  Indonesia  2006 
 A/Indonesia/304H/2006  2.1.3  EU146705  Human  Indonesia  2006 
 A/Indonesia/321H/2006  2.1.3  EU146721  Human  Indonesia  2006 
 A/Indonesia/341H/2006  2.1.3  EU146729  Human  Indonesia  2006 
 A/Indonesia/5/2005  2.1.3  EF541394  Human  Indonesia  2005 
 A/Indonesia/542H/2006  2.1.3  EU146777  Human  Indonesia  2006 
 A/Indonesia/567H/2006  2.1.3  EU146801  Human  Indonesia  2006 
 A/Indonesia/569H/2006  2.1.3  EU146809  Human  Indonesia  2006 
 A/Indonesia/583H/2006  2.1.3  EU146817  Human  Indonesia  2006 
 A/Indonesia/604H/2006  2.1.3  EU146825  Human  Indonesia  2006 
 A/Indonesia/7/2005  2.1.3  EU146632  Human  Indonesia  2005 
 A/Indonesia/CDC184/2005  2.1.3  CY014197  Human  Indonesia  2005 
 A/Indonesia/CDC194P/2005  2.1.3  CY014168  Human  Indonesia  2005 
 A/Indonesia/CDC287E/2005  2.1.3  CY014198  Human  Indonesia  2005 
 59 
 
Table 2 (continued) 
 A/Indonesia/CDC287T/2005  2.1.3  CY014199  Human  Indonesia  2005 
 A/Indonesia/CDC292N/2005  2.1.3  CY014200  Human  Indonesia  2005 
 A/Indonesia/CDC292T/2005  2.1.3  CY014201  Human  Indonesia  2005 
 A/Indonesia/CDC326/2006  2.1.3  CY014204  Human  Indonesia  2006 
 A/Indonesia/CDC326N/2006  2.1.3  CY014202  Human  Indonesia  2006 
 A/Indonesia/CDC326N2/2006  2.1.3  CY014203  Human  Indonesia  2006 
 A/Indonesia/CDC326T/2006  2.1.3  CY014205  Human  Indonesia  2006 
 A/Indonesia/CDC329/2006  2.1.3  CY014206  Human  Indonesia  2006 
 A/Indonesia/CDC357/2006  2.1.3  CY014207  Human  Indonesia  2006 
 A/Indonesia/CDC370/2006  2.1.3  CY014209  Human  Indonesia  2006 
 A/Indonesia/CDC370E/2006  2.1.3  CY014210  Human  Indonesia  2006 
 A/Indonesia/CDC370P/2006  2.1.3  CY014211  Human  Indonesia  2006 
 A/Indonesia/CDC370T/2006  2.1.3  CY014212  Human  Indonesia  2006 
 A/Indonesia/CDC390/2006  2.1.3  CY014213  Human  Indonesia  2006 
 A/Indonesia/CDC523/2006  2.1.3  CY014311  Human  Indonesia  2006 
 A/Indonesia/CDC523E/2006  2.1.3  CY014368  Human  Indonesia  2006 
 A/Indonesia/CDC523T/2006  2.1.3  CY014376  Human  Indonesia  2006 
 A/Indonesia/CDC582/2006  2.1.3  CY014384  Human  Indonesia  2006 
 A/Indonesia/CDC610/2006  2.1.3  CY014393  Human  Indonesia  2006 
 A/Indonesia/CDC623/2006  2.1.3  CY014401  Human  Indonesia  2006 
 A/Indonesia/CDC623E/2006  2.1.3  CY014409  Human  Indonesia  2006 
 A/Indonesia/CDC624/2006  2.1.3  CY014417  Human  Indonesia  2006 
 A/Indonesia/CDC624E/2006  2.1.3  CY014425  Human  Indonesia  2006 
 A/Indonesia/CDC634/2006  2.1.3  CY014441  Human  Indonesia  2006 
 A/Indonesia/CDC634P/2006  2.1.3  CY014449  Human  Indonesia  2006 
 A/Indonesia/CDC634T/2006  2.1.3  CY014457  Human  Indonesia  2006 
 A/Indonesia/CDC644/2006  2.1.3  CY014518  Human  Indonesia  2006 
 A/Indonesia/CDC644T/2006  2.1.3  CY014510  Human  Indonesia  2006 
 A/Indonesia/CDC669/2006  2.1.3  CY014481  Human  Indonesia  2006 
 A/Indonesia/CDC669P/2006  2.1.3  CY014489  Human  Indonesia  2006 
 A/Indonesia/CDC699/2006  2.1.3  CY014497  Human  Indonesia  2006 
 A/Indonesia/CDC7/2005  2.1.3  CY014177  Human  Indonesia  2005 
 A/Indonesia/CDC739/2006  2.1.3  CY014529  Human  Indonesia  2006 
 A/Indonesia/CDC759/2006  2.1.3  CY014543  Human  Indonesia  2006 
 A/Indonesia/CDC835/2006  2.1.3  CY017662  Human  Indonesia  2006 
 A/Indonesia/CDC836/2006  2.1.3  CY017670  Human  Indonesia  2006 
 A/Indonesia/CDC836T/2006  2.1.3  CY017678  Human  Indonesia  2006 
 A/Indonesia/CDC887/2006  2.1.3  CY017688  Human  Indonesia  2006 
 A/Indonesia/CDC938/2006  2.1.3  CY017638  Human  Indonesia  2006 
 A/Indonesia/CDC938E/2006  2.1.3  CY017646  Human  Indonesia  2006 
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Table 2 (continued) 
 A/Indonesia/CDC940/2006  2.1.3  CY017654  Human  Indonesia  2006 
 A/Indonesia/TLL001/2006  2.1.3  EU015403  Human  Indonesia  2006 
 A/Indonesia/TLL002/2006  2.1.3  EU015404  Human  Indonesia  2006 
 A/Indonesia/TLL003/2006  2.1.3  EU015405  Human  Indonesia  2006 
 A/Indonesia/TLL004/2006  2.1.3  EU015406  Human  Indonesia  2006 
 A/Indonesia/TLL005/2006  2.1.3  EU015407  Human  Indonesia  2006 
 A/Indonesia/TLL006/2006  2.1.3  EU015408  Human  Indonesia  2006 
 A/Indonesia/TLL007/2006  2.1.3  EU015409  Human  Indonesia  2006 
 A/Indonesia/TLL008/2006  2.1.3  EU015410  Human  Indonesia  2006 
 A/Indonesia/TLL009/2006  2.1.3  EU015411  Human  Indonesia  2006 
 A/Indonesia/TLL010/2006  2.1.3  EU015412  Human  Indonesia  2006 
 A/Indonesia/TLL011/2006  2.1.3  EU015413  Human  Indonesia  2006 
 A/Indonesia/TLL012/2006  2.1.3  EU015414  Human  Indonesia  2006 
 A/Indonesia/TLL013/2006  2.1.3  EU015415  Human  Indonesia  2006 
 A/Indonesia/TLL014/2006  2.1.3  EU015416  Human  Indonesia  2006 
 A/Djibouti/5691NAMRU3/2006  2.2  DQ666146  Human  Djibouti  2006 
 A/Egypt/7021-NAMRU3/2006  2.2  CY062439  Human  Egypt  2006 
 A/human/Iraq/207-NAMRU3/2006  2.2  DQ435202  Human  Iraq  2006 
 A/Iraq/1/2006  2.2  EU146870  Human  Iraq  2006 
 A/Iraq/659/2006  2.2  EU146876  Human  Iraq  2006 
 A/Iraq/754/2006  2.2  EU146877  Human  Iraq  2006 
 A/Iraq/755/2006  2.2  EU146869  Human  Iraq  2006 
 A/Iraq/756/2006  2.2  EU146878  Human  Iraq  2006 
 A/Turkey/12/2006  2.2  EF619982  Human  Turkey  2006 
 A/Turkey/15/2006  2.2  EF619989  Human  Turkey  2006 
 A/Turkey/651242/2006  2.2  EF619990  Human  Turkey  2006 
 A/Turkey/65596/2006  2.2  EF619998  Human  Turkey  2006 
 A/Xinjiang/1/2006  2.2  FJ492886  Human  China  2006 
 A/Egypt/14724-NAMRU3/2006  2.2.1  EF200512  Human  Egypt  2006 
 A/Egypt/14725-NAMRU3/2006  2.2.1  EF200513  Human  Egypt  2006 
 A/Egypt/2782-NAMRU3/2006  2.2.1  DQ464377  Human  Egypt  2006 
 A/Egypt/2991-NAMRU3/2006  2.2.1  EU095023  Human  Egypt  2006 
 A/Egypt/2992-NAMRU3/2006  2.2.1  EU095024  Human  Egypt  2006 
 A/Egypt/902782/2006  2.2.1  EU146867  Human  Egypt  2006 
 A/Egypt/902786/2006  2.2.1  EU146868  Human  Egypt  2006 
 A/Anhui/1/2005  2.3.4  DQ371928  Human  China  2005 
 A/Anhui/2/2005  2.3.4  DQ371929  Human  China  2005 
 A/China/2006  2.3.4  EF624256  Human  China  2006 
 A/China/GD01/2006  2.3.4  DQ835313  Human  China  2006 
 A/Fujian/1/2005  2.3.4  FJ492882  Human  China  2005 
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Table 2 (continued) 
 
 
 
2.2 COBRA FUNCTIONAL CHARACTERIZATION 
 
2.2.1 Protein Expression 
 
To evaluate protein expression, 1x106 Human embryonic kidney (HEK) 293T cells were 
transiently transfected with 3 g DNA expressing COBRA.  Cells were incubated for 72 h at 
37oC, supernatants were removed, the cells were lysed with 1% Triton-X 100 and cell lysates 
were collected. Cell lysates were electrophoresed on a 10% SDS-PAGE gel and transferred to a 
PVDF membrane. The blot was probed with mouse polyclonal antisera pooled from mice 
infected with 6:2 reassortant H5N1 viruses with the surface glycoproteins derived from either 
A/Vietnam/1203/2004 or A/Whooper Swan/244/2005 and the HA-antibody complexes were 
detected using a goat  anti-mouse IgG conjugated to horse radish peroxidase (HRP) (Southern 
Biotech; Birmingham, AL, USA).  HRP was detected by chemiluminescent substrate (Pierce 
Biotechnology; Rockford IL, USA) and exposed to X-ray film (ThermoFisher; Pittsburgh, PA, 
USA). 
 A/Guangdong/1/2006  2.3.4  FJ492884  Human  China  2006 
 A/Guangxi/1/2005  2.3.4  DQ371930  Human  China  2005 
 A/human/China/GD02/2006  2.3.4  EU263981  Human  China  2006 
 A/Hunan/1/2006  2.3.4  FJ492879  Human  China  2006 
 A/Jiangxi/1/2005  2.3.4  FJ492885  Human  China  2005 
 A/Shanghai/1/2006  2.3.4  AB462295  Human  China  2006 
 A/Shenzhen/406H/2006  2.3.4  EF137706  Human  China  2006 
 A/Sichuan/1/2006  2.3.4  FJ492881  Human  China  2006 
 A/Vietnam/UT30850/2005  2.3.4  HM114537  Human  Viet Nam  2005 
 A/Zhejiang/1/2006  2.3.4  FJ492880  Human  China  2006 
 A/Zhejiang/16/2006  2.3.4  DQ643809  Human  China  2006 
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Figure 11: COBRA nucleotide and corresponding amino acid sequences 
 
2.2.2 Receptor Binding 
 
To determine receptor binding characteristics, virus-like particles (VLPs) containing COBRA HA 
proteins were purified from the supernatants of mammalian cell lines.  HEK 293T cells were 
transiently transfected with plasmids expressing HIV Gag, COBRA HA and neuraminidase (NA, 
A/Thailand/1(KAN-1)/2004) and incubated for 72 h at 37oC. Supernatants were collected and 
VLPs were purified via ultracentrifugation (100,000 X g through 20% glycerol, weight per 
volume) for 4 h at 4oC. The pellets were subsequently resuspended in phosphate buffered 
saline PBS, pH 7.2 and stored at -80oC until use.  Protein concentration was determined by 
Micro BCATM Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA).   COBRA 
HA VLPs were prepared in various amounts as measured by total protein and each individual 
preparation was two-fold serially diluted in v-bottom microtiter plates.  An equal volume of either 
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1% turkey or 1% horse erythrocytes (RBC) (Lampire; Pipersville, PA, USA) in PBS was added 
to the diluted VLPs and incubated for 30-60 minutes at room temperature.  The HA titer was 
determined by the reciprocal dilution of the last well which contained agglutinated RBC. 
 
2.2.3 Cell Fusion 
 
To determine endosomal fusion characteristics, COBRA-pseudotyped lentiviral vectors 
expressing a luciferase reporter gene were produced as described [228].  Briefly, 293T cells 
were co-transfected by using the following plasmids: 7 g of pCMVdeltaR8.2, 7 g of pHR CMV-
Luc, 3 g pCMV/R N1(Kan-1) (all kindly provided by Dr. G. Nabel) and 3 g pTR600 COBRA.  
Cells were transiently transfected and incubated for 72h at 37oC.  Supernatants were harvested, 
centrifuged to clear cell debris, filtered through a 0.22 m syringe filter, aliquotted, and used 
immediately or frozen at -80°C. For fusion assays, 100 l of pseudoviruses were added to 
confluent MDCK cells in 48-well plates (~30,000 cells per well). Plates were incubated at room 
temperature for 30 min, washed, and fresh medium added. Forty-eight hours after infection, 
cells were lysed in mammalian cell lysis buffer (Promega; Madison, WI, USA). A standard 
quantity of cell lysate was used in a luciferase assay with luciferase assay reagent (Promega; 
Madison, WI, USA) according to the manufacturer’s protocol. 
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2.3 VACCINE PREPARATION 
 
2.3.1 Virus-like Particle Purification 
 
HEK 293T cells were transiently transfected with plasmids expressing M1 (A/Puerto 
Rico/8/1934, optimized for expression in mammalian cells), NA (A/Thailand/1(KAN-1)/2004, 
optimized for expression in mammalian cells) and various HA and incubated for 72h at 37oC. 
Supernatants were collected and cell debris removed by low speed centrifugation followed by 
vacuum filtration through a 0.22 m sterile filter.  VLPs were purified via ultracentrifugation 
(100,000 X g through 20% glycerol, weight per volume) for 4 h at 4C. The pellets were 
subsequently resuspended in PBS pH 7.2 and stored in single use aliquots at -80C until use.  
Total protein concentration was determined by Micro BCATM Protein Assay Reagent Kit (Pierce 
Biotechnology, Rockford, IL, USA). 
 
2.3.2 HA Quantification 
 
HA specific content was determined by western blot and densitometry.  Purified recombinant HA 
matched to the respective VLP and purified VLPs were prepared in standard total protein 
amounts (2 g to 0.15 g for purified protein and 5 g to 10 mg for VLPs) and were 
electrophoresed on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The blot was 
probed with mouse polyclonal antisera pooled from mice infected with 6:2 reassortant H5N1 
viruses with the surface glycoproteins derived from either A/Vietnam/1203/2004 or A/Whooper 
Swan/244/2005 and the HA-antibody complexes were detected using a goat  anti-mouse IgG 
conjugated to horse radish peroxidase (HRP) (Southern Biotech; Birmingham, AL, USA).  HRP 
was detected by chemiluminescent substrate (Pierce Biotechnology; Rockford IL, USA) and 
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exposed to X-ray film (ThermoFisher; Pittsburgh, PA, USA). Density of bands was determined 
using ImageJ software (NIH) [229].  Density of recombinant HA bands were used to calculate a 
standard curve and the density of the purified VLPs was interpolated using the results from the 
recombinant HA.  Experiments were performed in triplicate and multiple exposure times were 
analyzed for all iterations. 
 
 
 
2.4 ANIMAL EXPERIMENTS 
 
2.4.1 Mouse Studies 
 
BALB/c mice (Mus musculis, females, 6–8 weeks) were purchased from Harlan Sprague 
Dawley, (Indianapolis, IN, USA) and housed in microisolator units and allowed free access to 
food and water and were cared for under USDA guidelines for laboratory animals.  For dosing 
studies, mice (5 mice per group) were vaccinated with one of two doses of purified VLPs (1.5 g 
or 0.3 g), based upon HA content from the densitometry assay, via intramuscular injection at 
week 0 and then boosted with the same dose at week 3.  For comparison studies, mice (20 
mice per group) were vaccinated with purified VLPs (3 g), based upon HA content from the 
densitometry assay, via intramuscular injection at week 0 and then boosted with the same dose 
at week 3.  Vaccines at each dose were formulated with Imject® alum adjuvant (Imject® Alum, 
Pierce Biotechnology; Rockford, IL, USA) according to the manufacturer’s protocol or vehicle 
alone.  Fourteen to twenty-one days after each vaccination, blood was collected from 
anesthetized mice via the retro-orbital plexus and transferred to a microfuge tube. Tubes were 
centrifuged and sera was removed and frozen at -20 ± 5°C.   
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 Three weeks after final vaccination, mice were challenged intranasally with 5x103 plaque 
forming units (PFU) of either highly pathogenic wildtype H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (n=20/group) or 6:2 reassortant virus with internal genes from the 
mouse adapted virus A/Puerto Rico/8/1934 and the surface proteins HA and NA from 
A/Vietnam/1203/2004 (n=10/group) in a total volume of 50 l.  Challenge doses for both viruses 
were established independently and represent approximately 50LD50 (data not shown).  After 
infection, mice were monitored daily for weight loss, disease signs and death for 14 days after 
infection. Individual body weights, sickness scores and death were recorded for each group on 
each day after inoculation. Sickness score was determined by evaluating activity (0=normal, 
1=reduced, 2=severely reduced), hunched back (0=absent, 1=present) and ruffled fur 
(0=absent, 1=present) [230].  Experimental endpoint was determined by >20% weight loss or 
display of neurological disease such as hind limb paralysis.  All highly pathogenic wild type 
H5N1 influenza virus studies were performed under high-containment biosafety level 3 
enhanced conditions (BSL3+).  All procedures were in accordance with the NRC Guide for the 
Care and Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in 
Microbiological and Biomedical Laboratories. 
 
2.4.2 Ferret Studies 
 
Fitch ferrets (Mustela putorius furo, female, 6-12-months of age), influenza naïve and 
descented, were purchased from Marshall Farms (Sayre, PA, USA).  Ferrets were pair housed 
in stainless steel cages (Shor-line, Kansas City, KS, USA) containing Sani-chips Laboratory 
Animal Bedding (P.J. Murphy Forest Products, Montville, NJ, USA). Ferrets were provided with 
Teklad Global Ferret Diet (Harlan Teklad, Madison, WI, USA) and fresh water ad libitum.  The 
VLPs were diluted in PBS, pH 7.2 to achieve final concentration.  Ferrets (n=9) were vaccinated 
with 15 g of purified VLPs, based upon HA content as determined by densitometry assay, via 
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intramuscular injection in the quadriceps muscle in a volume of 0.50 ml at week 0 and then 
boosted with the same dose at week 3.  Vaccines were stored at -80°C prior to use and 
formulated with Imject® alum adjuvant (Imject® Alum; Pierce Biotechnology, Rockford, IL, USA) 
immediately prior to use according to manufacturer’s protocol.   Animals were monitored for 
adverse events including weight loss, temperature, loss of activity, nasal discharge, sneezing 
and diarrhea weekly during the vaccination regimen. Prior to vaccination, animals were 
confirmed by HAI assay to be seronegative for circulating influenza A (H1N1 and H3N2) and 
influenza B viruses.  Fourteen to twenty-one days after each vaccination, blood was collected 
from anesthetized ferrets via the anterior vena cava and transferred to a microfuge tube. Tubes 
were centrifuged and sera was removed and frozen at -20 ± 5°C.   
 Three weeks after final vaccination, ferrets were challenged intranasally with 1x106 
plaque forming units (PFU) of the highly pathogenic H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (clade 2.2) in a volume of 0.5 ml in each nostril for a total infection 
volume of 1 ml. After infection, ferrets were monitored daily for weight loss, disease signs and 
death for 14 days after infection. Individual body weights, sickness scores, and death were 
recorded for each group on each day after inoculation. Sickness score was determined by 
evaluating activity (0=normal, 1=alert and active with stimulation, 2=alert but not active after 
stimulation, 3=not alert or active after stimulation), nasal discharge (0=absent, 1=present), 
sneezing (0=absent, 1=present), decreased food intake (0=absent, 1=present), diarrhea 
(0=absent, 1=present), dyspnea (0=absent, 1=present) and neurological symptoms (0=absent, 
1=present).  Nasal washes were performed by instilling 3 ml of PBS into the nares of 
anesthetized ferrets each day for 14 days after inoculation.  Washes were collected and stored 
at -80°C until use.  Experimental endpoint was defined as >20% weight loss, development of 
neurological symptoms, or an activity score of 3 (not active or alert after stimulation).  All H5N1 
influenza virus studies were performed under high-containment biosafety level 3 enhanced 
conditions (BSL3+).  All procedures were in accordance with the NRC Guide for the Care and 
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Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in 
Microbiological and Biomedical Laboratories. 
 
2.4.3 Non-Human Primate Studies 
 
Cynomolgus macaques (Macaca  fascicularis, male, 3-5 years old) were vaccinated with 15 g 
(based upon HA content) of purified VLPs (n=7 per group), via intramuscular injection at weeks 
0, 3 and 6.  Vaccines at each dose were formulated with alum adjuvant (Imject Alum, Pierce 
Biotechnology; Rockford, IL, USA) immediately prior to use.  Twenty-one days after each 
vaccination, blood was collected from anesthetized macaques via the femoral vein and 
transferred to a serum separator tube. After clotting, tubes were centrifuged and sera removed 
and frozen at -80 ± 5°C.   
Three weeks after final vaccination, macaques were placed into BSL3+ isolator units 
(Bioqual, Inc., Rockville, MD) and then challenged by a multi-route of infection (ocular, nasal, 
tracheal) as previously described [132, 231, 232] using 1x106 plaque forming units (PFU) of the 
highly pathogenic H5N1 virus, A/Whooper Swan/Mongolia/244/2005 (clade 2.2), in a volume of 
1 ml at each location for a total infection dose of 1x106 PFU in a total volume of 3 ml.  Macaques 
were monitored daily for weight loss, signs of disease, and mortality until 7 days after infection. 
Individual body weights, sickness scores (based upon lethargy, temperature change, nasal 
discharge, lack of appetite, dehydration, lack of responsiveness), and death were recorded for 
each group.  Nasal and tracheal washes were performed at day 0, 1, 3, 5, and 7 post-infection.  
In addition, subsets of monkeys were sacrificed following administration of anesthesia and 
necropsies were performed according to standard procedures. 
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2.5 SEROLOGICAL ANALYSIS 
 
2.5.1 ELISA Assay 
 
The ELISA assay was used to assess total antibody titer and IgG isotype titer to the HA.  High 
binding, 96-well polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 
50ng/well of recombinant HA.  Coating antigens were derived from the following representative 
viral isolates: A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Whooper 
Swan/244/2005 (clade 2.2) and A/Anhui/1/2005 (clade 2.3).  Plates were blocked with 5% milk 
diluted in PBS with 0.05% Tween 20.  Serum samples were diluted in blocking buffer and added 
to plates.  Serum was two-fold serially diluted and allowed to incubate for 1 hour at room 
temperature.  Plates were washed and species specific antibody against IgG, IgG1, IgG2a, 
IgG2b or IgG3 and linked to horseradish peroxidase (HRP) (Southern Biotech; Birmingham, AL, 
USA) were diluted in blocking buffer and added to plates.  Plates were incubated for 1 hour at 
room temperature.   Plates were washed and HRP was developed with TMB substrate (Sigma-
Aldrich; St. Louis, MO, USA).  Plates were incubated in the dark for 15 minutes and then the 
reaction was stopped with 2N H2SO4.  Optical densities at a wavelength of 450nm  (OD450) were 
read by a spectrophotometer (BioTek; Winooski, VT, USA) and end point dilution titers were 
determined.  End point titers were determined as the reciprocal dilution of the last well which 
had an OD450 above the mean OD450 plus two standard deviations of naïve animal sera. 
 
2.5.2 Hemagglutination Inhibition (HAI) Assay 
 
The HAI assay was used to assess functional antibodies to the HA able to inhibit agglutination 
of horse erythrocytes.  The protocol was adapted from the CDC laboratory-based influenza 
surveillance manual [233].  To inactivate non-specific inhibitors, sera were treated with receptor 
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destroying enzyme (RDE; Denka Seiken, Co., Japan) prior to being tested [234-238].  Briefly, 
three parts RDE was added to one part sera and incubated overnight at 37°C.  RDE was 
inactivated by incubation at 56°C for ~30 min. RDE treated sera was two-fold serially diluted in 
v-bottom microtiter plates. An equal volume of wild type or reassortant virus, adjusted to 
approximately 8 HAU/50μl, was added to each well.  The plates were covered and incubated at 
room temperature for 20 min followed by the addition of 1% horse erythrocytes (HRBC) 
(Lampire Biologicals, Pipersville, PA, USA) in PBS.  Red blood cells were stored at 4°C and 
used within 72 h of preparation. The plates were mixed by agitation, covered, and the RBCs 
were allowed to settle for 1 h at room temperature [239]. The HAI titer was determined by the 
reciprocal dilution of the last well which contained non-agglutinated RBC. Positive and negative 
serum controls were included for each plate.  All mice were negative (HAI ≤1:10) for pre-existing 
antibodies to currently circulating human influenza viruses prior to vaccination. 
 
2.5.3 Virus Microneutralization Assay 
 
Serum neutralizing antibody titers were determined by microneutralization (mVN) assays 
performed on Madin Darby Canine Kidney (MDCK) cells following an adaptation of the 
procedure of Rowe et al [240]. Briefly, individual heat inactivated serum samples were serially 
diluted 2-fold (starting at a 1:10 dilution) in MDCK diluent buffer in a cell culture plate followed 
by the addition of a pre-determined amount (100 TCID50) of each virus. Sera and viruses were 
mixed and incubated at 37 °C for 2 hours. After the incubation the virus antibody mixtures were 
added to plate containing MDCK cells and were incubated for 2 hours at 37 °C in a 5% CO2 cell 
culture incubator. The virus antibody was then removed and cells were incubated until CPE was 
observed.  Cells were then fixed in 10% formalin and stained with 1% crystal violet to quantify 
CPE.  The neutralizing antibody titers are expressed as the reciprocal of the highest dilution of 
serum that gave 50% neutralization of 100 TCID50 of virus in MDCK cells. Positive serum control 
 72 
 
and negative cell controls with no serum were included on each plate. Geometric mean 
neutralizing antibody titers were calculated for each group. 
 
 
 
2.6 VIROLOGICAL ASSAYS 
 
For mouse infections, lung virus titers were evaluated.  For ferret infections, nasal wash virus 
titers were used to assess viral burden.  Both lungs and nasal wash virus titers were determined 
using a plaque assay [241, 242].  Briefly, lungs from mice infected with virus were harvested 
post infection, snap-frozen and stored at -80°C until use.  Samples were thawed, weighed and 
single cell suspensions were prepared via passage through a 70 m mesh (BD Falcon, Bedford, 
MA, USA) in an appropriate volume of DMEM supplemented with penicillin-streptomycin 
(iDEME) as to achieve 100mg/ml final concentration.  Cell suspensions were centrifuged at 
2000 rpm for 5 min and the supernatants were collected.   
 Madin-Darby Canine Kidney (MDCK) cells were plated (5 x 105) in each well of a 6 well 
plate.  Samples (lung supernatants for mice and nasal washes for ferrets) were diluted (dilution 
factors of 1 x 101 to 106) and overlayed onto the cells in 100 l of iDMEM and incubated for 1hr.  
Virus-containing medium was removed and replaced with 2 mls of L15 medium plus 0.8% 
agarose (Cambrex, East Rutherford, NJ, USA) and incubated for 96 hrs at 37°C with 5% CO2.  
Agarose was removed and discarded.  Cells were fixed with 10% buffered formalin, and then 
stained with 1% crystal violet for 15 min.  Following thorough washing in dH2O to remove 
excess crystal violet, plates were allowed to dry, plaques counted, and the plaque forming units 
(PFU)/g for or PFU/ml for nasal washes were calculated. 
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2.7 CELLULAR ASSAYS 
 
2.7.1 Interferon Gamma Enzyme-Linked Immunospot 
 
The number of anti-influenza specific cells secreting interferon gamma (IFN- ) was determined 
in mice by enzyme-linked immunospot (ELISpot) assay (R&D systems, Minneapolis, MN, USA) 
following the manufacturer’s protocol.  Mice were sacrificed at 6 days post infection (DPI) and 
spleens and lungs were harvested and prepared in single cell suspensions.  Briefly, pre-coated 
anti-IFN  plates were blocked with RPMI plus 10% FCS and antibiotics (cRPMI) for 30 minutes 
at room temperature.  Media was removed from wells and 105 cells were added to each well.  
Cells were stimulated with purified recombinant HA from A/Vietnam/1203/2004 (truncated at 
residue 530; 1 g/well), inactivated 6:2 reassortant virus A/Vietnam/1203/2004 (1:100 dilution of 
inactivated stock; 100 l/well) or the immunodominant H2-Kd CD8+ T cell epitope in H5 HA: 
HA533 (IYSTVASSL; 1 g/well) (Pepscan Presto, Leystad, Netherlands).  Additional wells were 
stimulated with PMA (50ng/well) and ionomycin (500ng/well) as positive controls or Ova257 
(SIINFEKL; 1 g/well) (Pepscan Presto, Leystad, Netherlands) as negative controls.  
Additionally, IL-2 (10U/ml) was added to each well.  Plates were incubated at 37°C for 48 hours.  
After incubation, plates were washed four times with R&D wash buffer and were incubated at 
4°C overnight with biotinylated anti-mouse IFN . Plates were washed as before and incubated 
at room temperature for 2 hours with streptavidin conjugated to alkaline phosphatase.  Plates 
were washed as before and spots were developed by incubating at room temperature for 1 hour 
in the dark with BCIP/NBT chromogen substrate.   The plates were washed extensively with DI 
H2O and allowed to dry overnight prior to spots being counted using an ImmunoSpot ELISpot 
reader (Cellular Technology Ltd., Cleveland, OH, USA). 
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2.7.2 Antibody Secreting Cell Assay 
 
The number of mouse anti-HA and anti-NA specific antibody secreting cells was determined by 
B cell ELISpot assay as previously described [243-245].   Mice were sacrificed at 6 DPI and 
spleens and lungs were harvested and prepared in single cell suspensions.  Briefly, 0.45 m 
PVDF membrane plates (Millipore, Billerica, MA, USA) were coated with either purified 
recombinant HA from A/Vietnam/1203/2004 or purified recombinant NA from A/Thailand/1(KAN-
1)/2004 (250ng/well) and incubated at 4oC overnight.  Plates were washed three times with PBS 
and blocked with cRPMI for at 37°C for 3-4 hours.  Media was removed from wells and 105 cells 
were added to each well.  Plates were incubated at 37oC for 48 hours.  After incubation, plates 
were washed as before and incubated at room temperature for 2 hours with horse radish 
peroxidase conjugated anti-mouse IgG or IgA (Southern Biotech, Birmingham, AL, USA).  
Plates were washed as before and spots were developed at room temperature for 1 hour in the 
dark with detection substrate (NovaRED™; Vector Labs, Burlingame, CA, USA).  The plates 
were washed extensively with DI H2O and allowed to dry overnight prior to spots being counted 
using an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA). 
 
 
 
2.8 PASSIVE TRANSFER OF SERA 
 
Serum from vaccinated mice was pooled and passively transferred into 9 week old recipient 
BALB/c mice (n=5/group).  Equal amounts of serum from each mouse in a particular vaccine 
group were pooled and heat inactivated for 30 minutes at 56oC.  200 l of pooled and 
inactivated serum was transferred to recipient mice via IP injection.  24 hours post transfer, mice 
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were infected with 6:2 reassortant virus with internal genes from the mouse adapted virus 
A/Puerto Rico/8/1934 and surface antigens from A/Vietnam/1203/2004 as described above. 
  
   
76 
 
 
 
 
3.0 SPECIFIC AIMS 
 
 
 
3.1 OVERALL OBJECTIVE AND RATIONALE 
 
The overall objective of this project was to develop a broadly reactive vaccine for highly 
pathogenic H5N1 influenza.  The antigenic diversity of circulating H5N1 viruses makes it highly 
unlikely that a vaccine derived from a single primary isolate would be able to elicit cross-reactive 
immune responses in the event of an emerging pandemic.  Antibodies capable of blocking the 
functions of the viral hemagglutinin (HA) are the only immune response capable of preventing 
influenza infection and represent the standard measure for predicting influenza vaccine efficacy.  
At the beginning of this dissertation research, there had been no reports of an H5N1 vaccine 
eliciting broadly reactive receptor blocking antibodies.  The focus of this work was the 
development of a centralized HA vaccine that will elicit broad antibody responses to 
antigenically diverse H5N1 influenza viruses.  Increasing the breadth of influenza vaccines 
represents a significant advancement for both pandemic and seasonal influenza vaccine 
development.  Broadly reactive pre-pandemic vaccines would enable effective stock-piling in 
anticipation of the next pandemic.  Additionally, increasing the breadth of seasonal vaccines 
would improve the vaccine efficacy and decrease influenza-related morbidity and mortality 
during inter-pandemic periods.  
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3.1.1 H5N1 Clade 2 Vaccines 
 
Although H5N1 is separated into 10 phylogenetic clades, clade 2 is the most prevalent, diverse 
and widespread of all clades (see Section 1.10.3).  Clade 2 is separated into antigenically 
distinct subclades, of which clades 2.1, 2.2 and 2.3 have caused human disease.  The 
centralized antigen for this work was designed to specifically address the diversity within clade 
2.  The molecular determinants of host-switch and emergence of avian influenza virus into the 
human population are not fully elucidated, but HA properties, such as receptor specificity and 
cleavage site, are proposed to be involved (see Section 1.6.2).  Only HA sequences from 
human isolates were used in centralized antigen generation.  Unidentified characteristics in the 
HA molecule that enable human infection are expected to be conserved.  Increasing the breadth 
of influenza vaccines is traditionally achieved via polyvalency.  Therefore, a clade 2-focused 
polyvalent vaccine was used as the standard strategy against which the centralized antigen was 
compared (see Section 1.9).  The polyvalent vaccine components were chosen from primary 
isolates in clades 2.1, 2.2 and 2.3.  The selected strains were primarily isolated from human 
infections.  Furthermore, all selected polyvalent vaccine components were individually 
recommended by WHO for vaccine development and therefore are expected to be antigenically 
matched to their respective subclade.  Until this dissertation, the breadth of centralized and 
polyvalent influenza vaccines had never been directly compared. 
 
3.1.2 Test Antigens 
 
The primary test antigens used to evaluate antibody responses were representative isolates 
from subclades 2.1, 2.2 and 2.3.  The selected test antigens represent unique viral strains that 
do not elicit cross-reactive antibodies between subclades.  Furthermore, the primary test 
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antigens were matched to the components of the polyvalent vaccine.  The panel of primary 
antigens used to initially evaluate antibody breadth meets or exceeds the standard measures 
established in prior reports.  In some of the studies described here, additional antigens were 
used to more thoroughly evaluate receptor blocking antibody breadth.  These antigens were not 
included in either the centralized or polyvalent vaccine designs, and were therefore useful as a 
measure of additional antibody breadth.  The panels of test antigens used to evaluate antibody 
breadth are the most diverse and comprehensive analysis of H5N1 vaccine breadth to date. 
 
3.1.3 Challenge Viruses 
 
The vaccines evaluated in this project were all designed to address the diversity within clade 2 
of H5N1.  Therefore, the primary challenge virus used to evaluate vaccine efficacy was a clade 
2.2 isolate: A/Whooper Swan/Mongolia/244/2005.  The virus was a wild type, highly pathogenic 
avian influenza virus isolated from an avian host.  Wild type clade 2 viruses isolated from human 
hosts were not available when these studies were conducted.  Additionally, the challenge virus 
was matched to the clade 2.2 component of the polyvalent vaccine.  The pathogenicity of the 
challenge virus used in most of these studies was compared to a clade 1 virus 
(A/Vietnam/1203/2004) isolated from a human infection.  The viruses resulted in equivalent 
disease in mice and ferrets.  Additionally, cross-clade protection from centralized and polyvalent 
vaccines was evaluated using the A/Vietnam/1203/2004 (clade 1) virus. 
 
3.1.4 Animal Models 
 
Mice and ferrets are the most commonly used animal models in influenza virus vaccine and 
infection studies.  Although infection of mice with influenza virus usually requires extensive 
species-specific adaptation of the virus, highly pathogenic viruses such as 1918 or H5N1 cause 
   
79 
 
severe disease without prior adaptation.  Mice provide several advantages for the analysis of 
vaccine induced immune responses due to the limited genetic variation and extensive, multi-
disciplinary use.  These advantages include, but are not limited to, the availability of reagents for 
determining the antibody isotype profile and evaluating cellular immune responses in an antigen 
specific manner.   
 Ferrets are the traditional animal model for influenza infection and demonstrate a 
disease course that is similar to human infection.  Additionally, ferrets are susceptible to 
infection with human influenza viruses without prior adaptation and transmit the virus.  The 
analysis of immune responses in ferrets is restricted due to the genetic variability and relatively 
limited scientific use.  Although assays to evaluate cellular immunity are being developed, they 
are not widely available and therefore analysis of vaccine immune response is limited to 
antibody breadth. 
 Non-human primates (NHP) were also used as models to evaluate the centralized 
vaccine antigen.  Similar to ferrets, NHP have high levels of genetic variability, but generally 
have more reagents available for immune response analysis.  Importantly, pre-clinical findings 
in NHPs are more likely to translate to humans than those from either mice or ferrets.  NHP 
were utilized in this work to further evaluate the breadth of antibody responses elicited by the 
centralized antigen. 
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3.2 OVERALL HYPOTHESIS AND AIMS 
 
Overall Hypothesis:  A synthetic consensus clade 2 H5N1 HA vaccine will elicit broad 
immunity and protective efficacy against diverse H5N1 viral isolates. 
 
SPECIFIC AIM I: Design and characterize a consensus HA H5N1 vaccine. 
Hypothesis: The consensus HA (COBRA) sequence will be a fully functional protein that is 
antigenically matched to a diverse panel of H5N1 viruses. 
 
SPECIFIC AIM II: Evaluate the breadth and intensity of immune responses elicited by a 
consensus HA H5N1 vaccine. 
Hypothesis: A virus-like particle containing the COBRA HA will elicit broad immune responses to 
a diverse panel of H5N1 viral isolates. 
 
SPECIFIC AIM III: Determine the protective efficacy of a consensus HA H5N1 vaccine against 
H5N1 influenza challenge. 
Hypothesis: The COBRA HA vaccine will protect animals following virus challenge with H5N1 
viruses. 
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3.3 SPECIFIC AIM I 
 
Goal: Design and functionally characterize a consensus HA H5N1 vaccine. 
Hypothesis: The consensus HA sequence will be a fully functional protein that is antigenically 
matched to a diverse panel of H5N1 viruses. 
Summary: A consensus HA was generated using all available, full length sequences isolated 
from H5N1 clade 2 human infections from 2004-2006.  To avoid sampling bias, a layered 
consensus building approach was developed that used multiple rounds of consensus 
generation.  Sequences were first grouped into phylogenetic subclades and then further divided 
into outbreak groups within each subclade based on time and location of isolation. A primary 
consensus sequence was generated for each individual outbreak group.  Primary consensus 
sequences within each subclade were then aligned and secondary consensus sequences were 
generated representing each subclade.  Secondary consensus sequences were then aligned 
and used to generate a final consensus sequence representing all of the input sequences.  This 
final consensus sequence was termed Computationally Optimized Broadly Reactive Antigen 
(COBRA) and was used for all subsequent studies.  The expression of COBRA HA was 
confirmed by transient transfection of HEK 293T cells.  To verify the functional activity of 
COBRA, lentiviral pseudoparticles were generated and used in receptor binding and cell fusion 
assays.  COBRA receptor binding was demonstrated by hemagglutination assay.  COBRA-
mediated cell fusion was independent of trypsin and was as efficient as that observed with a 
primary isolate-derived HA.  Taken together, COBRA was demonstrated to retain all of the 
functions of a natural hemagglutinin protein.  In addition to the functional characterization of 
COBRA, the antigenicity was also determined using ferret antisera.  Antisera elicited against 
both clade 1 and clade 2 viruses had hemagglutination inhibition (HAI) activity against COBRA 
pseudoparticles indicating conservation of binding epitopes.  After the COBRA HA protein was 
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characterized, the virus-like particle (VLP) vaccines were produced and further characterized.  
To determine the HA content of VLP vaccines, a novel quantification assay was developed.  
Multiple dilutions of purified HA protein matched to an individual VLP were analyzed by SDS-
PAGE followed by an immunoblot for the HA.  The relative density of each dilution was 
calculated and used to generate a standard curve.  The curve was then used to interpolate the 
amount of HA in the VLPs using the density of the HA band in VLP lanes. 
Conclusion: The consensus HA (termed COBRA) was a functional protein that was 
antigenically matched to multiple H5N1 viruses.  H5N1 vaccines were purified and a novel 
method of antigen quantification was developed. 
 
 
 
3.4 SPECIFIC AIM II 
 
Goal: Evaluate the breadth and intensity of immune responses elicited by a consensus HA 
H5N1 vaccine. 
Hypothesis: A virus-like particle containing the COBRA HA will elicit broad immune responses 
to a diverse panel of H5N1 viral isolates. 
Summary: The immunogenicity of HA from H5N1 is lower than that of seasonal influenza and 
vaccines require higher doses or adjuvant inclusion to elicit HAI responses.  Serum HAI 
antibodies are the standard measure for influenza vaccine immunogenicity.  For H5N1 vaccines, 
vaccinated mice and ferrets that fail to develop detectable HAI titer are often protected from 
severe disease and death upon H5N1 challenge.  However, the human correlate for protection 
in H5N1 remains unknown and HAI antibodies are considered the most consistent predictor of 
protection.  Therefore, the HAI assay was the standard measure used to determine antibody 
breadth.  Various doses of COBRA VLPs were evaluated for the elicitation of immune 
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responses alone or co-administered with adjuvants in BALB/c mice.  Although lower doses of 
COBRA VLPs elicited broad antibody responses when formulated with alum adjuvant, the 
greatest breadth of antibody response was elicited when using a high dose (1.5 g HA) together 
with alum adjuvant.  Therefore, the high dose and alum adjuvant was used in subsequent 
vaccinations.  Dosing studies in ferrets had similar results: the highest dose (15 g HA) together 
with alum elicited the greatest antibody breadth and this formulation was used for additional 
ferret experiments.  Next, the breadth of the antibody response elicited by the COBRA HA was 
compared to a vaccine derived from a primary clade 2.2 isolate (A/Whooper 
Swan/Mongolia/244/2005).  In mice, both vaccines elicited similar high titers of total IgG to 
diverse HA coating antigens.  However, the COBRA VLP vaccinated mice had both higher titers 
and increased breadth of HAI antibodies compared to those vaccinated with the clade 2.2 VLPs.  
Similar results were found in ferrets: both COBRA and clade 2.2 VLPs elicited similar total IgG 
levels, but only those animals that received the COBRA vaccine had broadly reactive HAI 
antibody responses.  NHP were also vaccinated to evaluate the breadth of antibody responses 
of COBRA VLPs.  For these studies, a larger panel was utilized with test antigens within and 
outside of clade 2.  COBRA vaccinated NHP had antibody responses that were more broadly 
reactive than clade 2.2 vaccinated animals and included HAI activity against viruses from clades 
1, 2.1, 2.2.1, 2.2.2, 2.3.4, and 7.   
 Having established the increased breadth of COBRA-based vaccines in comparison to a 
clade 2.2 vaccine, COBRA was then compared to a polyvalent formulation.  BALB/c mice 
vaccinated with either COBRA or polyvalent vaccines developed similar high titer total IgG 
against multiple HA antigens.  Additionally, the polyvalent vaccine elicited HAI antibodies to all 
of the clade 2 test antigens (all were homologous to the vaccine components), but the COBRA 
vaccine elicited higher titer HAI antibodies and extended the reactivity to clade 1.  Similar results 
were found in ferrets: equivalent levels of total IgG titers between vaccine groups, but increased 
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breadth and titer of HAI antibodies in the COBRA vaccinated animals.  Although humoral 
immunity is the most potent immune response in protecting against influenza infection, cellular 
mediated immune responses can limit the severity and duration of infection (see Section 1.7).  
Cellular immune responses were compared for COBRA and polyvalent vaccinated mice.  Both 
COBRA and polyvalent vaccines elicited cellular immune responses that were detected by IFN-  
ELISpot when stimulated with the BALB/c immunodominant H2-Kd CD8+ T cell epitope in H5 
HA.  Additionally, stimulation with overlapping peptides spanning the HA molecule did not reveal 
any novel epitopes in the COBRA HA.  This finding confirmed the results from epitope prediction 
software indicating that COBRA did not contain any novel T cell epitopes. 
Conclusion: COBRA VLPs elicit broadly reactive antibody responses of increased breadth and 
intensity compared to the immune responses elicited by both clade 2.2 and polyvalent VLPs.  
Additionally, cellular mediated immune responses were equivalent between COBRA and 
polyvalent vaccines. 
 
 
 
3.5 SPECIFIC AIM III 
 
Goal: Determine the protective efficacy of a consensus HA H5N1 vaccine against H5N1 
influenza challenge. 
Hypothesis: The COBRA HA will protect animals following challenge with H5N1 viruses. 
Summary: The most important factor for evaluating influenza vaccines is the protective efficacy 
against virus challenge.  H5N1 vaccine efficacy is primarily evaluated in the context of 
protection from severe disease and death.  These are undoubtedly crucial factors in determining 
the success of a vaccine, but fail to account for a vaccine’s ability to control viral burden.  Higher 
levels of viral replication increase the opportunities for virus evolution and transmission.  
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Morbidity, mortality and viral burden were all factors used to evaluate vaccine efficacy.  
Vaccines were designed to specifically address the diversity within clade 2 and as such the 
primary challenge virus was a clade 2.2 isolate: A/Whooper Swan/Mongolia/244/2005 (WS/05).  
Prior to its use in vaccine studies, the virus was first titered to determine relative lethality and 
disease course compared to a well-characterized clade 1 virus: A/Vietnam/1203/2004 (VN/04).  
At the same infectious dose, 5000 plaque forming units (PFU), weight loss and viral replication 
in the lung were similar for the two viruses indicating that the WS/05 virus is indeed highly lethal 
to mice.  This dose was calculated as approximately 50 LD50 and was used in all subsequent 
studies.  Having established the challenge parameters, vaccine efficacy was then evaluated.  
Mice receiving various doses of COBRA VLPs with and without adjuvant were challenged with 
WS/05 and all vaccinated animals were completely protected from weight loss and death.  
Additionally, when COBRA and clade 2.2 vaccinated animals were challenged, they also were 
protected from disease.  Similar to the mice, all vaccinated ferrets were protected from sickness 
and death.  However, when NHP were challenged, the infection did not result in visible illness in 
unvaccinated control animals.  This was not because of the isolate (WS/05) used in the infection 
because additional animals infected with VN/04 also failed to develop visible signs of disease.  
Although no visible disease was observed in challenged animals, histopathological analysis of 
the lungs revealed focal inflammation and detection of viral antigen in unvaccinated animals that 
was greatly reduced in COBRA vaccinated animals.  Mice and ferrets vaccinated with the 
polyvalent formulation were then compared to COBRA vaccinated animals using a WS/05 
challenge.  Once again, all vaccinated animals were protected from sickness and death.  When 
lungs (mice) and nasal washes (ferrets) were assayed for virus, COBRA vaccinated animals 
had decreased viral burdens compared to polyvalent vaccinated animals.  The decrease in viral 
replication was observed in both magnitude of virus titer and duration of replication.  To further 
evaluate the breadth of protection elicited by COBRA and polyvalent vaccines, mice were 
challenged with the clade 1 virus VN/04.  All vaccinated animals were protected from sickness 
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and death with viral burdens again being decreased in the COBRA vaccinated animals.  These 
results indicated that although both COBRA and polyvalent vaccines protect animals from 
severe disease, the COBRA vaccine more efficiently restricted viral replication.  Finally, to 
determine whether serum factors were sufficient to protect animals from severe disease, 
immune sera from COBRA and polyvalent vaccinated animals were transferred to naïve 
recipient mice.  All mice receiving sera from VLP vaccinated animals were protected from death 
during VN/04 challenge.  All mice lost weight and displayed signs of illness, however, these 
symptoms were decreased in the cohort receiving COBRA-immune serum.   
Conclusion: COBRA VLPs effectively protected vaccinated animals from multiple H5N1 virus 
challenges.  Polyvalent vaccines also protected animals from overt disease and death.  
However, the COBRA vaccine more efficiently restricted viral replication compared to the 
polyvalent vaccine.  Additionally, COBRA-immune serum recipient animals displayed reduced 
signs and duration of illness compared to polyvalent-immune serum recipients. 
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4.1 FOREWORD 
 
The work described in this chapter addresses features of Specific Aims I, II and III (see Sections 
3.3, 3.4 and 3.5).  The design and functional characterization of the consensus hemagglutinin 
outlined in Specific Aim I is detailed in this chapter and the work presented here encompasses 
all of Specific Aim I.  Additionally, the vaccine dosing and clade 2.2 comparison studies 
evaluating vaccine immunogenicity that are outlined in Specific Aim II are included in this 
chapter.  The challenge studies evaluating the protective efficacy of the various vaccine 
formulations that are outlined in Specific Aim III are also contained in this chapter.  Therefore, 
the work presented here is the entirety of Specific Aim I with additional studies involving 
features of both Specific Aims II and III. 
 
 
 
4.2 ABSTRACT 
 
Pandemic outbreaks of influenza are caused by the emergence of a pathogenic and 
transmissible virus to which the human population is immunologically naïve.  Recent outbreaks 
of highly pathogenic avian influenza (HPAI) of the H5N1 subtype are of particular concern 
because of the high mortality rate (60% case fatality rate) and novel subtype.  In order to 
develop a vaccine that elicits broadly reactive antibody responses against emerging H5N1 
isolates, we utilized a novel antigen design technique termed computationally optimized broadly 
reactive antigen (COBRA).  The COBRA HA sequence was based upon HA amino acid 
sequences from clade 2 H5N1 human infections and the expressed protein retained the ability 
to bind the receptor, as well as mediate particle fusion.  Non-infectious recombinant VLP 
vaccines using the COBRA HA were purified from a mammalian expression system.  Mice and 
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ferrets vaccinated with COBRA HA H5N1 VLPs had protective levels of HAI antibodies to a 
representative isolates from each subclade of clade 2.  Furthermore, VLP vaccinated animals 
were completely protected from a lethal challenge of the clade 2.2 H5N1 virus A/Whooper 
Swan/Mongolia/244/2005.  This is the first report describing the use of COBRA-based antigen 
design.  The COBRA HA H5N1 VLP vaccine elicited broadly reactive antibodies and is an 
effective influenza vaccine against HPAI virus. 
 
 
 
4.3 INTRODUCTION 
 
The swine-origin H1N1 pandemic of 2009 reminded the worldwide community of the ever-
present threat of pandemic influenza.  Pandemic outbreaks of influenza are caused by the 
emergence and spread of a pathogenic and transmissible virus to which the human population 
is immunologically naïve [183].  Although predicting an emerging pandemic subtype of influenza 
is difficult, outbreaks of highly pathogenic avian influenza of the H5N1 subtype are of particular 
concern because of the high mortality rate (60% case fatality rate) and novel subtype [246].  To 
date, H5N1 influenza has not transmitted efficiently from person to person, but accumulation of 
mutations or reassortment with a human transmissible virus could result in a highly 
transmissible H5N1 virus [247].  H5N1 and contemporary H3N2 seasonal influenza viruses are 
able to generate stable reassortant viruses although the pathogenic potential of the reassortant 
viruses is less than that of the highly pathogenic H5N1 virus [248, 249].  Additionally, a recent 
report has demonstrated that not only can H1N1 pandemic viruses and highly pathogenic H5N1 
viruses efficiently reassort, but these reassortants can replicate to higher titers than the source 
   
90 
 
H5N1 virus [250].  The genetic compatibility between the influenza viruses, combined with the 
continued spread of both novel H1N1 in humans and highly pathogenic H5N1 in wild birds, 
highlights the potential for a new emerging H5N1 influenza infecting the human population and 
therefore, the need to develop effective vaccines against H5N1 isolates. 
 One of the challenges to developing effective H5N1 vaccines is the antigenic diversity 
within the subtype.  H5N1 viruses are separated into distinct clades based upon phylogenetic 
distance among the hemagglutinin (HA) genes [195].  The clades are geographically diverse 
and are evolving under unique pressures specific to each respective location [251].  The 
majority of human infections were identified within the antigenically distinct clades 1 and 2, with 
clade 2 infections spanning over 60 countries and moving westward from Asia into Africa and 
the Middle East [252].  Genetic diversity within clade 2 has resulted in distinct subclades 
including 2.1, 2.2, 2.3, 2.4 and 2.5 with some subclades being further divided into additional 
sub-subclades [195].  Despite high levels of HA protein sequence homology between clades 
(>90%), there is little receptor blocking antibody cross-reactivity across clades and even within 
subclades [195].  Developing vaccines that are able to overcome the challenge of H5N1 
antigenic diversity is a crucial step in pandemic preparedness.   
 The antigenic diversity of all subtypes of influenza is a challenge to influenza vaccine 
development in general.  The current seasonal influenza vaccine uses a polyvalent formulation 
to address the issue of multiple subtypes simultaneously circulating in the human population.  
Even though a representative vaccine strain is selected and is expected to represent the most 
common strain for each subtype in a given season, vaccine escape occurs and yearly 
epidemics continue to happen.  A recent report has demonstrated that a polyvalent H5N1 
vaccine with components derived from various clades can elicit cross-clade antibody cross-
reactivity and protective efficacy [161].  Alternative strategies that have been investigated for 
addressing the challenge of antigenic diversity include targeting conserved viral proteins, such 
as the M2 ion channel or nucleoprotein (NP) and targeting conserved domains of HA [105, 179, 
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226, 253].  Additionally, engineering synthetic antigens that capture common immune epitopes 
from a population of primary viruses has the potential to overcome antigenic diversity. 
 Consensus-based H5N1 antigens have been generated for several influenza proteins 
including HA, neuraminidase (NA) and matrix (M1) and each has elicited cross-reactive immune 
responses [180-182, 254].  Consensus sequences are traditionally generated by aligning a 
population of sequences and selecting the most common residue at each position.  These 
sequences are expected to effectively capture conserved linear epitopes and elicit cross-
reactive cellular immune responses [180, 255-257].  Furthermore, consensus-based H5N1 HA 
immunogens expressed from DNA plasmids elicit broad antibody responses [181, 254].  
However, consensus-based antigen design is inherently influenced by the input sequences 
used to generate the synthetic molecule and as such is subject to sampling bias.  Using the 
NCBI Influenza Virus Resource database, the vast majority of HA sequences from both human 
and environmental isolates are from clades 1 and 2 [51].  Furthermore, within clade 2 the 
majority of human isolates are from infections in Indonesia and the subclade 2.1.  The 
predominance of certain isolates, i.e. a majority of clade 2.1 isolates from Indonesia, can bias 
the output consensus sequence generated and may not accurately reflect the genetic diversity 
of H5N1 influenza viruses.  In order to overcome these limitations, we report a new 
methodology of antigen design using multiple rounds of consensus generation termed 
computationally optimized broadly reactive antigen (COBRA).  This method was designed to 
address the diversity specifically within clade 2 and utilized global surveillance efforts to 
generate a vaccine with the potential to elicit increased breadth of antibody responses within 
this antigenically diverse clade.   
 In this study, COBRA HA antigens are expressed on virus-like particles (VLPs) and 
purified as vaccine immunogens. VLPs are self-assembling, nonpathogenic, genomeless 
particles that are similar in size and morphology to intact virions [258].  VLPs can be produced 
in a variety of eukaryotic expression systems including yeast, insect and mammalian cells.  
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Importantly, A VLP-based vaccine which protects against human papillomavirus has been 
approved for human use [259].  Influenza virus VLP vaccines are attractive alternatives to 
traditional split vaccines because they do not require the use of any live virus at any step of  the 
vaccine production process [222].  Additionally, VLPs present surface antigens in their native 
oligomeric structures which are important for maintaining conformational epitopes.. 
 We hypothesized that the COBRA HA delivered in the context of a VLP will elicit an 
antibody response that demonstrates increased breadth when compared to that of a VLP 
containing an HA molecule derived from a primary isolate.  Here, we report the COBRA HA is a 
functional molecule, elicits broadly reactive antibody responses, and completely protects mice 
and ferrets from a heterologous, highly pathogenic H5N1 virus challenge. 
 
 
 
4.4 MATERIALS AND METHODS 
 
4.4.1 Antigen construction and synthesis 
 
Influenza A HA nucleotide sequences isolated from human H5N1 infections were downloaded 
from the NCBI Influenza Virus Resource database (see Section 2.1) [51].  Nucleotide 
sequences were translated into protein sequences using the standard genetic code.  Full length 
sequences from H5N1 clade 2 human infections from 2004 to 2006 were acquired and used for 
subsequent consensus generations.  For each round of consensus generation, multiple 
alignment analysis was applied and the consensus sequence was generated using AlignX 
(Vector NTI).  The final amino acid sequence, termed computationally optimized broadly 
reactive antigen (COBRA), was reverse translated and optimized for expression in mammalian 
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cells, including codon usage and RNA optimization (GeneArt; Regensburg, Germany).  This 
construct was then synthesized and inserted into the pTR600 expression vector [238]. 
 
4.4.2 In vitro expression 
 
Human embryonic kidney (HEK) 293T cells (1x106) were transiently transfected with 3 g DNA 
expressing COBRA.  Cells were incubated for 72 h at 37oC, supernatants were removed, the 
cells were lysed with 1% Triton-X 100 and cell lysates were collected. Cell lysates were 
electrophoresed on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The blot was 
probed with mouse polyclonal antisera pooled from mice infected with 6:2 reassortant H5N1 
viruses with the surface glycoproteins derived from either A/Vietnam/1203/2004 (clade 1) or 
A/Whooper Swan/244/2005 (clade 2.2) and the HA-antibody complexes were detected using a 
goat  anti-mouse IgG conjugated to horse radish peroxidase (HRP) (Southern Biotech; 
Birmingham, AL, USA).  HRP was detected by chemiluminescent substrate (Pierce 
Biotechnology; Rockford IL, USA) and exposed to X-ray film (ThermoFisher; Pittsburgh, PA, 
USA). 
 
4.4.3 Functional characterization 
 
To determine receptor binding characteristics, virus-like particles (VLPs) containing COBRA HA 
proteins were purified from the supernatants of mammalian cell lines.  HEK 293T cells were 
transiently transfected with plasmids expressing HIV Gag, COBRA HA and neuraminidase (NA, 
A/Thailand/1(KAN-1)/2004) and incubated for 72 h at 37oC. Supernatants were collected and 
VLPs were purified via ultracentrifugation (100,000 X g through 20% glycerol, weight per 
volume) for 4 h at 4oC. The pellets were subsequently resuspended in phosphate buffered 
saline PBS, pH 7.2 and stored at -80oC until use.  Protein concentration was determined by 
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Micro BCATM Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA).   COBRA 
HA VLPs were prepared in various amounts as measured by total protein and each individual 
preparation was two-fold serially diluted in v-bottom microtiter plates.  An equal volume of either 
1% turkey or 1% horse erythrocytes (RBC) (Lampire; Pipersville, PA, USA) in PBS was added 
to the diluted VLPs and incubated for 30-60 minutes at room temperature.  The HA titer was 
determined by the reciprocal dilution of the last well which contained agglutinated RBC. 
 To determine endosomal fusion characteristics, COBRA-pseudotyped lentiviral vectors 
expressing a luciferase reporter gene were produced as described [228].  Briefly, 293T cells 
were co-transfected by using the following plasmids: 7 g of pCMV R8.2, 7 g of pHR CMV-Luc, 
3 g pCMV/R N1(Kan-1) (all kindly provided by Dr. G. Nabel) and 3 g pTR600 COBRA.  Cells 
were transiently transfected and incubated for 72h at 37oC.  Supernatants were harvested, 
centrifuged to clear cell debris, filtered through a 0.22 m syringe filter, aliquotted, and used 
immediately or frozen at -80°C. For fusion assays, 100 l of pseudoviruses were added to 
confluent MDCK cells in 48-well plates (~30,000 cells per well). Plates were incubated at room 
temperature for 30 min, washed, and fresh medium added. Forty-eight hours after infection, 
cells were lysed in mammalian cell lysis buffer (Promega; Madison, WI, USA). A standard 
quantity of cell lysate was used in a luciferase assay with luciferase assay reagent (Promega; 
Madison, WI, USA) according to the manufacturer’s protocol. 
 
4.4.4 Vaccine preparation 
 
HEK 293T cells were transiently transfected with plasmids expressing M1 (A/Puerto 
Rico/8/1934, optimized for expression in mammalian cells), NA (A/Thailand/1(KAN-1)/2004, 
optimized for expression in mammalian cells) and COBRA HA and incubated for 72h at 37oC. 
Supernatants were collected and cell debris removed by low speed centrifugation followed by 
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vacuum filtration through a 0.22 m sterile filter.  VLPs were purified via ultracentrifugation 
(100,000 X g through 20% glycerol, weight per volume) for 4 h at 4C. The pellets were 
subsequently resuspended in PBS pH 7.2 and stored in single use aliquots at -80C until use.  
Total protein concentration was determined by Micro BCATM Protein Assay Reagent Kit (Pierce 
Biotechnology, Rockford, IL, USA). 
 HA specific content was determined by western blot and densitometry.  Purified 
recombinant COBRA HA and purified VLPs were prepared in standard total protein amounts 
and were electrophoresed on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The 
blot was probed with mouse polyclonal antisera pooled from mice infected with 6:2 reassortant 
H5N1 viruses with the surface glycoproteins derived from either A/Vietnam/1203/2004 or 
A/Whooper Swan/244/2005 and the HA-antibody complexes were detected using a goat  anti-
mouse IgG conjugated to horse radish peroxidase (HRP) (Southern Biotech; Birmingham, AL, 
USA).  HRP was detected by chemiluminescent substrate (Pierce Biotechnology; Rockford IL, 
USA) and exposed to X-ray film (ThermoFisher; Pittsburgh, PA, USA). Density of bands was 
determined using ImageJ software (NIH) [229].  Density of recombinant HA bands were used to 
calculate a standard curve and the density of the purified VLPs was interpolated using the 
results from the recombinant HA.  Experiments were performed in triplicate and multiple 
exposure times were analyzed for all iterations.  
 
4.4.5 Mouse studies 
 
BALB/c mice (Mus musculis, females, 6–8 weeks) were purchased from Harlan Sprague 
Dawley, (Indianapolis, IN, USA) and housed in microisolator units and allowed free access to 
food and water and were cared for under USDA guidelines for laboratory animals.  For dosing 
studies, mice (5 mice per group) were vaccinated with one of two doses of purified VLPs (1.5 g 
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or 0.3 g), based upon HA content from the densitometry assay, via intramuscular injection at 
week 0 and then boosted with the same dose at week 3.  For comparison studies, mice (20 
mice per group) were vaccinated with purified VLPs (3 g), based upon HA content from the 
densitometry assay, via intramuscular injection at week 0 and then boosted with the same dose 
at week 3.  Vaccines at each dose were formulated with Imject® alum adjuvant (Imject® Alum, 
Pierce Biotechnology; Rockford, IL, USA) according to the manufacturer’s protocol or vehicle 
alone.  Fourteen to twenty-one days after each vaccination, blood was collected from 
anesthetized mice via the retro-orbital plexus and transferred to a microfuge tube. Tubes were 
centrifuged and sera was removed and frozen at -20 ± 5°C.   
 Three weeks after final vaccination, mice were challenged intranasally with 5x103 plaque 
forming units (PFU) of the highly pathogenic H5N1 virus A/Whooper Swan/Mongolia/244/2005 
(Clade 2.2) in a volume of 50 l. The challenge dose represents approximately 50LD50 in mice.  
After infection, mice were monitored daily for weight loss, disease signs and death for 14 days 
after infection. Individual body weights, sickness scores and death were recorded for each 
group on each day after inoculation.  Sickness score was determined by evaluating activity 
(0=normal, 1=reduced, 2=severely reduced), hunched back (0=absent, 1=present) and ruffled 
fur (0=absent, 1=present) [230].  Experimental endpoint was defined as >20% weight loss or 
display of neurological disease such as hind limb paralysis.   All H5N1 influenza virus studies 
were performed under high-containment biosafety level 3 enhanced conditions (BSL3+).  All 
procedures were in accordance with the NRC Guide for the Care and Use of Laboratory 
Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in Microbiological and Biomedical 
Laboratories. 
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4.4.6 Ferret studies 
 
Fitch ferrets (Mustela putorius furo, female, 6-12-months of age), influenza naïve and 
descented, were purchased from Marshall Farms (Sayre, PA, USA).  Ferrets were pair housed 
in stainless steel cages (Shor-line, Kansas City, KS, USA) containing Sani-chips Laboratory 
Animal Bedding (P.J. Murphy Forest Products, Montville, NJ, USA). Ferrets were provided with 
Teklad Global Ferret Diet (Harlan Teklad, Madison, WI, USA) and fresh water ad libitum.  The 
VLPs were diluted in PBS, pH 7.2 to achieve final concentration.  Ferrets (n=9) were vaccinated 
with 15 g of purified VLPs, based upon HA content as determined by densitometry assay, via 
intramuscular injection in the quadriceps muscle in a volume of 0.50ml at week 0 and then 
boosted with the same dose at week 3.  Vaccines were stored at -80°C prior to use and 
formulated with Imject® alum adjuvant (Imject® Alum; Pierce Biotechnology, Rockford, IL, USA) 
immediately prior to use according to manufacturer’s protocol.   Animals were monitored for 
adverse events including weight loss, temperature, loss of activity, nasal discharge, sneezing 
and diarrhea weekly during the vaccination regimen. Prior to vaccination, animals were 
confirmed by HAI assay to be seronegative for circulating influenza A (H1N1 and H3N2) and 
influenza B viruses.  Fourteen to twenty-one days after each vaccination, blood was collected 
from anesthetized ferrets via the anterior vena cava and transferred to a microfuge tube. Tubes 
were centrifuged and sera was removed and frozen at -20 ± 5°C.   
 Three weeks after final vaccination, ferrets were challenged intranasally with 1x106 
plaque forming units (PFU) of the highly pathogenic H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (Clade 2.2) in a volume of 0.5ml in each nostril for a total infection 
volume of 1 ml. After infection, ferrets were monitored daily for weight loss, disease signs and 
death for 14 days after infection. Individual body weights, sickness scores, and death were 
recorded for each group on each day after inoculation. Sickness score was determined by 
evaluating activity (0=normal, 1=alert and active with stimulation, 2=alert but not active after 
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stimulation, 3=not alert or active after stimulation), nasal discharge (0=absent, 1=present), 
sneezing (0=absent, 1=present), decreased food intake (0=absent, 1=present), diarrhea 
(0=absent, 1=present), dyspnea (0=absent, 1=present) and neurological symptoms (0=absent, 
1=present).  Nasal washes were performed by instilling 3ml of PBS into the nares of 
anesthetized ferrets each day for 14 days after inoculation.  Washes were collected and stored 
at -80°C until use.  Experimental endpoint was defined as >20% weight loss, development of 
neurological symptoms, or an activity score of 3 (not active or alert after stimulation).  All H5N1 
influenza virus studies were performed under high-containment biosafety level 3 enhanced 
conditions (BSL3+).  All procedures were in accordance with the NRC Guide for the Care and 
Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in 
Microbiological and Biomedical Laboratories. 
 
4.4.7 ELISA assay 
 
The ELISA assay was used to assess total antibody titer and IgG isotype titer to the HA.  High 
binding, 96-well polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 
50ng/well of recombinant HA.  Coating antigens were derived from the following representative 
viral isolates: A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Whooper 
Swan/244/2005 (clade 2.2) and A/Anhui/1/2005 (clade 2.3).  Plates were blocked with 5% milk 
diluted in PBS with 0.05% Tween 20.  Serum samples were diluted in blocking buffer and added 
to plates.  Serum was two-fold serially diluted and allowed to incubate for 1 hour at room 
temperature.  Plates were washed and species specific antibody against IgG, IgG1, IgG2a, 
IgG2b or IgG3 and linked to horseradish peroxidase (HRP) (Southern Biotech; Birmingham, AL, 
USA) were diluted in blocking buffer and added to plates.  Plates were incubated for 1 hour at 
room temperature.   Plates were washed and HRP was developed with TMB substrate (Sigma-
Aldrich; St. Louis, MO, USA).  Plates were incubated in the dark for 15 minutes and then the 
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reaction was stopped with 2N H2SO4.  Optical densities at a wavelength of 450nm (OD450) were 
read by a spectrophotometer (BioTek; Winooski, VT, USA) and end point dilution titers were 
determined.  End point titers were determined as the reciprocal dilution of the last well which 
had an OD450 above the mean OD450 plus two standard deviations of naïve animal sera. 
 
4.4.8 Hemagglutination inhibition (HAI) assay  
 
The HAI assay was used to assess functional antibodies to the HA able to inhibit agglutination 
of horse erythrocytes.  The protocol was adapted from the CDC laboratory-based influenza 
surveillance manual [233].  To inactivate non-specific inhibitors, sera were treated with receptor 
destroying enzyme (RDE; Denka Seiken, Co., Japan) prior to being tested [234-238].  Briefly, 
three parts RDE was added to one part sera and incubated overnight at 37°C.  RDE was 
inactivated by incubation at 56°C for ~30 min. RDE treated sera was two-fold serially diluted in 
v-bottom microtiter plates. An equal volume of reassortant virus, adjusted to approximately 8 
HAU/50μl, was added to each well. The reassortant viruses contained the internal genes from 
the mouse adapted strain A/Puerto Rico/8/1934 and the surface proteins HA and NA from the 
following representative viral isolates: A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/2005 
(clade 2.1), A/Whooper Swan/244/2005 (clade 2.2) and A/Anhui/1/2005 (clade 2.3).  The plates 
were covered and incubated at room temperature for 20 min followed by the addition of 1% 
horse erythrocytes (HRBC) (Lampire Biologicals, Pipersville, PA, USA) in PBS.  Red blood cells 
were stored at 4°C and used within 72 h of preparation. The plates were mixed by agitation, 
covered, and the RBCs were allowed to settle for 1 h at room temperature [239]. The HAI titer 
was determined by the reciprocal dilution of the last well which contained non-agglutinated 
RBC. Positive and negative serum controls were included for each plate.  All mice were 
negative (HAI ≤1:10) for pre-existing antibodies to currently circulating human influenza viruses 
prior to vaccination. 
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4.4.9 Plaque assay 
 
Madin-Darby Canine Kidney (MDCK) cells were plated (5 x 105) in each well of a 6-well plate.  
Samples were diluted (final dilution factors of 100 to 10-6) and overlayed onto the cells in 100 l 
of DMEM supplemented with penicillin-streptomycin and incubated for 1hr.  Samples were 
removed, cells were washed twice and media was replaced with 2 ml of L15 medium plus 0.8% 
agarose (Cambrex; East Rutherford, NJ, USA) and incubated for 72 h at 37°C with 5% CO2.  
Agarose was removed and discarded.  Cells were fixed with 10% buffered formalin, and then 
stained with 1% crystal violet for 15 min.  Following thorough washing in dH2O to remove 
excess crystal violet, plates were allowed to dry, plaques counted, and the plaque forming units 
(PFU)/ml were calculated. 
 
4.4.10 Statistical analysis 
 
Statistical significance of the antibody data was determined using a two-way analysis of 
variance (ANOVA) with Bonferroni’s post-test to analyze differences between each vaccine 
group for the different test antigens (multiparametric).  Differences in weight loss, sickness 
score, and viral titers were analyzed by two-way ANOVA, followed by Bonferroni's post-test for 
each vaccine group at multiple time points.  Significance was defined as p < 0.05. Statistical 
analyses were done using GraphPad Prism software.  
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4.5 RESULTS 
 
4.5.1 Computationally optimized broadly reactive antigen design 
 
To address the challenge of antigenic diversity present in H5N1 influenza, we designed a 
computationally optimized broadly reactive antigen (COBRA).  For the first step of antigen 
generation, 129 unique hemagglutinin (HA) sequences were downloaded from the NCBI 
Influenza Virus Resource (IVR) sequence database [51] representing clade 2 H5N1 viruses 
isolated from human infections between 2004 and 2006.  The sequences were first grouped into 
phylogenetic subclades and then further divided into individual outbreak groups within each 
subclade based upon geographic location and time of isolation.  HA amino acid sequences for 
each individual outbreak group were aligned and the most common amino acid at each position 
was determined resulting in primary consensus sequences representing each outbreak group 
within each subclade (Figure 12A).  Primary consensus sequences within each subclade were 
then aligned and the most common amino acid was chosen resulting in secondary consensus 
sequences representing each subclade (Figure 12A).  The secondary consensus sequences 
were aligned and the most common amino acid at each position was selected resulting in the 
final consensus sequence referred to as clade 2 COBRA HA (Figure 12A).  Phylogenetic 
analysis of the COBRA HA with all human isolates of H5N1 HA proteins indicated that COBRA 
retained a clade 2-like sequence without being grouped specifically within any clade 2 subclade 
cluster (Figure 12B).  Furthermore, a BLAST search using the COBRA HA sequence revealed 
that it is a unique sequence that has not been isolated from the environment (data not shown). 
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Figure 12: COBRA HA Design.  Schematic to describe how the COBRA HA molecule was 
designed (A).  The phylogenetic tree was inferred from hemagglutinin amino acid sequences 
using the maximum likelihood method and clade/sub-clade groupings were identified.  Primary 
consensus sequences were generated for each outbreak group.  Secondary consensus 
sequences were then generated for each subclade using the primary sequences as input.  The 
secondary consensus sequences were then aligned and the resulting consensus, designated 
COBRA, was generated.  Phylogenetic analysis of the COBRA HA (B).  The unrooted 
phylogenetic tree was inferred from hemagglutinin amino acid sequences from human H5N1 
infections isolated from 2004 to 2009 and the clade/sub-clade groupings are indicated.  The star 
represents the COBRA HA sequence relative to human H5N1 infections. 
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4.5.2 Characterization of COBRA 
 
Since COBRA is a fully synthetic protein, the retention of natural hemagglutinin function was 
confirmed.  Initially, COBRA expression was verified by transient transfection of mammalian 
cells.  Analysis of the total cell lysate demonstrated that the COBRA HA migrates at its 
predicted molecular weight of approximately 73kDa (Figure 13A).  Because the poly-basic 
cleavage site was retained in the COBRA HA sequence, both HA0 and the HA1 subunits were 
detected by immunoblot at similar molecular weights as recombinant HA and the HA on the 
H5N1 virion (Figure 13A).   Virus-like particles (VLPs) with COBRA HA on the surface bound 
sialic acid in a dose-dependent manner and this binding was specific to COBRA, since empty 
lentiviral core alone did not bind to the receptor (Figure 13B).   
 To determine if the COBRA HA was functional, the protein was pseudotyped onto 
lentiviral Gagp24 to generate pseudoparticles [192, 260].  COBRA HA containing pseudoparticles 
mediated cell fusion as efficiently as H5N1 control pseudoparticles without the requirement for 
trypsin.  In contrast, H1N1 pseudoparticles did require trypsin and pseudoparticles without 
surface HA produced luciferace at similar levels as the cell only controls (Figure 13C).   Taken 
together, these results demonstrate that although the COBRA HA is a synthetic protein not 
found in nature, it retains all of the functions of a natural hemagglutinin protein. 
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Figure 13: COBRA HA Functional Characterization.  COBRA HA was translated in vitro and 
the cell culture lysates were analyzed by SDS-PAGE (A).  Lane designations: 1) H5N1 
recombinant HA; 2) COBRA HA; 3) Expression vector; 4) H5N1 reassortant virus.  The COBRA 
HA (lane 2) migrates at its expected molecular weight confirming expression of the synthetic 
protein.  COBRA HA VLPs were prepared in various amounts, serially diluted, and incubated 
with 1% erythrocytes to evaluate receptor binding (B).  HA titer was determined as the last well 
in which the RBCs remained suspended in a lattice structure.  COBRA HA and control lentiviral 
pseudoparticles packaging a CMV-Luc gene were generated in HEK 293T cells and used to 
infect MDCK cells with or without trypsin (C).  Particle fusion was determined by luciferace 
production by infected cells. 
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4.5.3 Mouse Dosing Immunizations 
 
Mice (BALB/c; n=5) were vaccinated (week 0 and 3) via intramuscular injection with purified 
COBRA VLPs at either a high dose (1.5ug HA) or low dose (0.3ug HA) with and without Imject® 
alum adjuvant.  At week 5, all COBRA VLP-vaccinated animals had anti-HA antibodies that 
recognized heterologous recombinant HA derived from both clade 1 and also subclades of 
clade 2 (Figure 14A and 14B).  Imject® alum significantly increased anti-HA antibody titers in 
both low and high dose groups as compared to the non-adjuvanted groups (p<0.01).  The IgG 
isotype subclasses elicited by the VLP vaccines against a clade 2.1 coating antigen consisted 
mainly of IgG1 and IgG2a, indicating a mixed T helper response (Figure 14C and 14D).  Similar 
results were found for additional coating antigens representing clade 1, clade 2.2 and clade 2.3 
(data not shown).  In addition to recognizing HA, antibodies were also evaluated for the ability to 
block virus from binding its receptor via inhibition of viral-induced agglutination of horse 
erythrocytes (HAI).  All mice administered Imject® alum adjuvanted vaccines, regardless of 
dose, had HAI titers >1:40 to viruses expressing HA from clades 2.1 and 2.2 and 90% of the 
mice had titers >1:40 to a clade 2.3 representative virus (Figure 14E and 14F).  Non-adjuvanted 
vaccines elicited generally lower HAI antibody titers with 100% of high dose animals achieving 
titers >1:40 only against clade 2.1 viruses.  Imject® alum adjuvanted vaccines elicited 
significantly higher HAI antibody titers to clade 2.2 and clade 2.3 viruses regardless of dose as 
compared to non-adjuvanted vaccines (p<0.05 for high dose and p<0.001 for low dose, 
respectively).  Subsequent vaccine formulations utilized a high dose and included Imject® alum 
as adjuvant because of the increased antibody breadth observed in these experiments.  None of 
the vaccines elicited high HAI titer antibodies to a clade 1 virus. 
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Figure 14: COBRA HA Mouse Dosing Immunogenicity.  BALB/c mice (n=5/group) were 
vaccinated at 0 and 3 weeks with blood collected at 14 to 21 days after each vaccination.  
Vaccines were formulated at high (1.5ug HA), and low (0.03ug HA) doses; with and without 
Imject® alum and delivered intramuscularly.  Total IgG at week 5 was determined via ELISA for 
each vaccine group (A and B).  Values represent the geometric mean titer (+95% confidence 
interval) of log10 transformed endpoint titers.  IgG isotypes were evaluated via ELISA for each 
vaccine group (C and D).  Values represent the mean OD450 of a 1:200 dilution of serum.  
Hemagglutination inhibition (HAI) serum antibody titer for each vaccine group was determined at 
week 5 using representative reassortant viruses (E and F).  Values represent the geometric 
mean titer (+95% confidence interval) of log2 transformed titers.  The dotted line represents the 
1:40 titer.  Significant differences were determined by two-way ANOVA with Bonferroni’s post-
test to evaluate differences between the vaccine formulations for each test antigen.  A p value of 
less than 0.05 was considered significant. 
 
 
4.5.4 Mouse Dosing Challenge 
 
Mice that received the COBRA VLP vaccines or mock vaccinated control mice were challenged 
intranasally with a lethal dose of clade 2.2 H5N1 highly pathogenic avian influenza (A/Whooper 
Swan/Mongolia/244/2005) to evaluate the protective efficacy of the different COBRA vaccine 
formulations.  All COBRA vaccinated mice, regardless of dose or the presence of adjuvant, 
were protected from weight loss and death following lethal challenge, while all mock vaccinated 
animals rapidly lost weight and required euthanasia by day 6 post infection (Figure 15A and 
15B).  Additionally, COBRA VLP vaccinated mice had no signs of disease, while mock 
vaccinated animals developed such symptoms as ruffled fur, hunched back, and lethargy 
(Figure 15C and 15D). 
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Figure 15: COBRA HA Mouse Dosing Efficacy.  BALB/c mice (n=5/group) were vaccinated 
with COBRA HA VLPs with or without adjuvant.  Mice were infected with 5x103 PFU of the 
highly pathogenic clade 2.2 H5N1 virus A/Whooper Swan/Mongolia/244/2005.  Mice were 
followed to monitor weight loss (A and B) and sickness (C and D).  Sickness score was 
determined by evaluating activity (0=normal, 1=reduced, 2=severely reduced), hunched back 
(0=absent, 1=present) and ruffled fur (0=absent, 1=present).  All mock vaccinated mice reached 
the experimental endpoint and required euthanasia by 6 days post infection.   
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4.5.5 Mouse Comparison Immunizations 
 
To determine if the COBRA HA vaccine elicits a broader antibody response compared to a 
vaccine derived from a primary isolate, an additional set of mice were vaccinated with either 
COBRA VLPs or clade 2.2 (A/Whooper Swan/Mongolia/244/2005) VLPs.  Mice (BALB/c; n=20) 
were vaccinated (week 0 and 3) via intramuscular injection with either COBRA VLPs or clade 
2.2 VLPs at a high dose (3ug HA) with Imject® alum adjuvant.  At week 5, all COBRA VLP-
vaccinated mice and all clade 2.2 VLP-vaccinated mice had anti-HA antibodies that recognized 
heterologous recombinant HA derived from both clade 1 and various subclades of clade 2 
(Figure 16A).  Although no significant differences were found in total IgG titers between vaccine 
groups, COBRA VLP-vaccinated animals had higher HAI antibody titers against all viruses 
tested as compared to clade 2.2 VLP-vaccinated animals (p<0.01; Figure 16B).  Furthermore, 
COBRA VLP-vaccinated animals had an increased frequency of HAI titers of >1:40 compared to 
clade 2.2 VLP-vaccinated animals (Table 3).  
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Figure 16: Mouse Comparison Immunogenicity.  BALB/c mice (n=20/group) were vaccinated 
at 0 and 3 weeks with blood collected at 14 to 21 days after each vaccination.  Vaccines were 
formulated at a high dose (3 g HA) with Imject® alum and delivered intramuscularly.  Total IgG 
at week 5 was determined via ELISA for each vaccine group (A).  Values represent the 
geometric mean titer (+95% confidence interval) of log10 transformed endpoint titers.  
Hemagglutination inhibition (HAI) serum antibody titer for each vaccine group was determined at 
week 5 using representative reassortant viruses (B).  Values represent the geometric mean titer 
(+95% confidence interval) of log2 transformed titers.  The dotted line represents the 1:40 titer.  
Significant differences were determined by two-way ANOVA with Bonferroni’s post-test to 
evaluate differences between the vaccine formulations for each test antigen.  A p value of less 
than 0.05 was considered significant. 
 
Table 3: Mouse seroconversion frequency.
 
Percentage of VLP-vaccinated mice achieving an HAI titer of >1:40 to each test antigen 
 
a A/Vietnam/1203/2004 
b A/Indonesia/5/2005 
c A/Whooper Swan/Mongolia/244/2005 
d A/Anhui/1/2005 
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4.5.6 Mouse Comparison Challenge 
 
Mice that received the COBRA VLP vaccine, clade 2.2 VLP vaccine or mock vaccinated control 
mice were challenged intranasally with a lethal dose of clade 2.2 H5N1 highly pathogenic avian 
influenza (A/Whooper Swan/Mongolia/244/2005) to evaluate the protective efficacy of the VLP 
vaccines.  All VLP-vaccinated mice were protected from weight loss and death following lethal 
challenge while all mock vaccinated animals rapidly lost weight and required euthanasia by day 
6 post infection (Figure 17A).  Additionally, VLP vaccinated mice did not show signs of disease, 
while mock vaccinated animals developed ruffled fur, hunched back, and lethargy (Figure 17B).  
Even though the clade 2.2 VLP was matched to the challenge virus, no significant differences 
were found between COBRA VLP and clade 2.2 VLP vaccinated mice in any of the parameters 
analyzed indicating that the COBRA VLP vaccine protected animals as efficiently as the 
homologous vaccine. 
Figure 17: Mouse Comparison Efficacy.  BALB/c mice (n=20/group) were vaccinated with 
VLPs with adjuvant.  Mice were infected with 5x103 PFU of the highly pathogenic clade 2.2 
H5N1 virus A/Whooper Swan/Mongolia/244/2005.  Mice were followed to monitor weight loss 
(A) and sickness (B).  Sickness score was determined by evaluating activity (0=normal, 
1=reduced, 2=severely reduced), hunched back (0=absent, 1=present) and ruffled fur 
(0=absent, 1=present).  All mock (adjuvant-only) vaccinated mice reached the experimental 
endpoint and required euthanasia by 6 days post infection. 
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4.5.7 Ferret Comparison Immunizations 
 
Ferrets are the most relevant model for influenza disease and as such the COBRA vaccine was 
tested in this more rigorous animal model.  Ferrets (Fitch; n=9) were vaccinated (week 0 and 3) 
via intramuscular injection with COBRA VLPs or clade 2.2 VLPs at a high dose (15ug HA) with 
Imject® alum adjuvant.  Serum was collected from ferrets at week 5 and antibody responses to 
the COBRA vaccines were evaluated.  All vaccinated ferrets had anti-HA antibodies that 
recognized heterologous recombinant HA derived from both clade 1 and also subclades of 
clade 2 (Figure 18A).  No significant difference in anti-HA antibody was found between the 
COBRA VLP vaccine and the clade 2.2 VLP vaccine for any of the antigens tested (p>0.05).  In 
addition to recognizing HA, antibodies were also evaluated for HAI activity.  COBRA VLP-
vaccinated animals had higher HAI antibody titers against clade 2.1 and clade 2.3 viruses as 
compared to clade 2.2 VLP-vaccinated animals (p<0.01 Figure 18B).  Similar to the mice, 
COBRA VLP-vaccinated ferrets displayed an increased rate of achieving HAI titers >1:40 when 
compared to clade 2.2 VLP-vaccinated ferrets (Table 4). Although both COBRA and clade 2.2 
VLP vaccines elicited anti-HA binding antibody to a clade 1 virus that was of equivalent titer to 
that of the clade 2 viruses, neither of the vaccines elicited high HAI titer antibodies to a clade 1 
reassortant virus.  
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Figure 18: Ferret Immunogenicity.  Ferrets (n=9/group) were vaccinated with VLPs (15ug HA) 
with Imject® alum at weeks 0 and 3 and serum collected at week 5.  Total IgG at week 5 was 
determined via ELISA for each vaccine group (A).  Values represent the geometric mean titer 
(+95% confidence interval) of log10 transformed endpoint titers.  Hemagglutination inhibition 
(HAI) serum antibody titer for each vaccine group was determined at week 5 using 
representative reassortant viruses (B).  Values represent the geometric mean titer (+95% 
confidence interval) of log2 transformed titers.  The dotted line represents the 1:40 titer.  
Significant differences were determined by two-way ANOVA with Bonferroni’s post-test to 
evaluate differences between the vaccine formulations for each test antigen.  A p value of less 
than 0.05 was considered significant. 
 
Table 4: Ferret seroconversion frequency 
 
Percentage of VLP-vaccinated ferrets achieving an HAI titer of >1:40 to each test antigen 
a A/Vietnam/1203/2004 
b A/Indonesia/5/2005 
c A/Whooper Swan/Mongolia/244/2005 
d A/Anhui/1/2005 
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4.5.8 Ferret Comparison Challenge 
 
Ferrets that received the COBRA VLP vaccines, clade 2.2 VLP vaccines or mock vaccinated 
control animals were challenged intranasally with clade 2.2 H5N1 highly pathogenic avian 
influenza (A/Whooper Swan/Mongolia/244/2005) to evaluate the protective efficacy of the 
COBRA vaccine in the ferret model of influenza infection.  All VLP vaccinated ferrets were 
protected from weight loss and death following viral challenge, while all mock vaccinated 
animals rapidly lost weight and 78% (7/9) of mock vaccinated animals required euthanasia by 
day 7 post-infection (Figure 19A and 19B).  Additionally, both COBRA VLP-vaccinated and 
clade 2.2-vaccinated ferrets were protected from acute fever and failed to develop significant 
signs of disease while mock vaccinated animals had an elevated body temperature and 
developed such symptoms as lethargy, diarrhea and decreased food and water intake (Figure 
19C and 19D).  In addition to monitoring outward signs of disease progression, nasal washes 
were collected for determination of viral replication in the upper respiratory tract.  Ferrets 
vaccinated with either COBRA VLPs or clade 2.2 VLPs did not have detectable virus at any 
point after infection, while mock vaccinated animals had high levels of viral replication for the 
first five days of the infection (Figure 19E).  Importantly, no significant differences were found 
between COBRA VLP and clade 2.2 VLP vaccinated ferrets in any of the challenge parameters 
analyzed confirming the findings in mice that the COBRA VLP vaccine protected animals as 
efficiently as the homologous vaccine. 
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Figure 19: Ferret Efficacy.  Ferrets (n=9/group) were vaccinated with VLPs formulated with 
adjuvant.  Ferrets were challenged with 1x106 PFU of the highly pathogenic clade 2.2 H5N1 
virus A/Whooper Swan/Mongolia/244/2005. Animals were monitored daily for weight loss (A), 
survival (B), temperature (C) and clinical symptoms (D). Relative sickness scores were 
determined by measuring lethargy (0-3), runny nose (0-1), sneezing (0-1), loss of appetite (0-1) 
and diarrhea (0-1). Animals reaching experimental endpoint were euthanized according to 
institutional guidelines.  Nasal washes were collected serially post infection and virus titers 
determined via plaque assay (E). Statistical significance was determined using a two-way 
ANOVA with Bonferroni’s post test. A p value of less than 0.05 was considered significant. 
   
116 
 
4.6 DISCUSSION 
 
In this study, we investigated the efficacy of a computationally optimized broadly reactive 
antigen (COBRA) approach designed for influenza HA as a H5N1 vaccine candidate.  
Centralized vaccines are a potential strategy for inducing broadly reactive immune responses 
and are comprised of synthetic antigens that represent a population of sequences.  These 
vaccine antigens are generated by three different methods: center-of-the tree, ancestral, and 
consensus [169].  Center-of-the tree (COT) sequences are derived by constructing a 
phylogenetic tree and selecting the sequence that is equidistant from all points [170].  Ancestral 
sequences represent the most recent common ancestor for the population of sequences 
selected [171].  Consensus sequences encode the most common amino acid found at each 
position for the selected population [173].  Ancestral and COT sequences are expected to be an 
estimate of an actual sequence that existed in the past while consensus sequences are 
expected to be more relevant to the current epidemic [173].  A recent report has demonstrated 
the efficacy of using ancestral HA and NA sequences to generate infectious virus capable of 
eliciting broadly-reactive antibodies post infection in ferrets [172].  Consensus-based vaccines 
have been previously investigated as strategies for eliciting broadly reactive immune responses 
for multiple pathogens including HIV-1 [174-178] and influenza [179-182].  Although the COBRA 
HA investigated in this report utilized a consensus-based approach, important design features 
differentiate COBRA from prior strategies.  COBRA represents a novel method of sequence 
construction that features a layered building approach that is intended to capture the most 
common antigenic characteristics, while avoiding the complication of differential sequence 
availability that can bias a consensus sequence to the most prevalent antigenic cluster.  
Avoiding this sampling bias is essential to generating a centralized vaccine that accurately 
represents the population of input sequences.  COBRA HA phylogenetic analysis in the context 
of H5N1 human infections demonstrates that using a layered consensus building approach can 
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indeed overcome the challenges of sequence availability and results in a sequence that retains 
similarity to the input without localizing into any one antigenic cluster (Figure 12B).   
 Previously, consensus HA, NA and Matrix sequences developed for H5N1 DNA 
vaccination elicited robust cellular immune responses to each vaccine component, as well as 
antibodies to the HA [180-182].  This consensus HA consisted of 16 input HA sequences, 
primarily clade 1 viruses and derived from fatal human infections [180].  For this study, the 
COBRA antigen utilized over 100 input sequences from human clade 2 infections, which 
represents the more rapidly emerging clade of H5N1 influenza.  Importantly, the work presented 
here confirms the earlier reports of the efficacy of a centralized H5N1 vaccine and extends 
those findings using DNA based vaccinations to a virus-like particle (VLP) platform.  With any 
whole protein derived from a centralized sequence, proper folding and retention of function 
cannot be assumed.  Although COBRA HA is a synthetic sequence, we demonstrated that the 
COBRA HA retained the binding and fusion functions of wild-type HA proteins (Figure 13).   
 Influenza vaccines delivered as VLPs represent a promising new generation of cell-
based candidate vaccines [221, 222, 261].  The high virulence of H5N1 makes growing viral 
stocks for traditional inactivation and generation of split vaccines both difficult and dangerous 
[186].  VLPs are self assembling, nonpathogenic, genomeless particles that are similar in size 
and morphology to intact virions [220, 258].  The influenza VLPs described in these studies 
include the viral proteins HA, NA and matrix and are flexible enough to incorporate a synthetic 
HA without a decrease in stability or function.  The COBRA HA vaccine was evaluated for 
immunogenicity in mice with and without adjuvant at multiple doses (Figure 14).  The COBRA 
vaccine elicited anti-HA total IgG regardless of dose or adjuvant with an isotype profile indicative 
of a mixed T helper response.  IgG1 and IgG2a have been shown to have non-redundant 
actions in influenza immunity with IgG1 associated with virus neutralization and IgG2a 
associated with viral clearance [262].  Inclusion of Imject® alum as an adjuvant did not impact 
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the total IgG titers or isotype profile but resulted in increased HAI antibody responses at all 
doses tested.  Aluminum salts have been used to enhance antibody responses to vaccines for 
almost 100 years [155].  Imject® alum was selected for use in these studies because it is an 
aluminum salt-based adjuvant and its commercial analogs are the most widely used adjuvants 
that have been used in Diphteria, Tetanus, Pertussis and Hepatitis A and B vaccines [263].  
Aluminum salts enhance antigen uptake by antigen presenting cells and stimulate a pro-
inflammatory response via activation of the NOD-like receptor protein 3 inflammasome pathway 
[156].   Inclusion of an adjuvant increased the breadth and intensity of HAI antibody responses 
in mice vaccinated with the COBRA HA compared to non-adjuvanted vaccine recipients.  
Additionally, the relative affinity of the anti-HA antibodies was increased in the adjuvanted 
groups compared to the non-adjuvanted groups (data not shown).  Importantly, the increase in 
breadth of the HAI antibody response was not a non-specific effect of the adjuvant.  An 
adjuvanted vaccine based on the HA of the clade 2.2 virus A/Whooper 
Swan/Mongolia/244/2005 failed to elicit significant HAI antibody titers to heterologous test 
antigens (Figures 16 and 18).   
   One of the challenges in developing a pre-pandemic vaccine for H5N1 is the diversity 
within the subtype.  An important lesson from the novel H1N1 pandemic of 2009 is that 
predicting the origin of a pandemic virus is currently not impossible.  If the next influenza 
pandemic is caused by H5N1, the clade or subclade of the pandemic virus may not be identified 
until the outbreak is well underway.  An effective pre-pandemic vaccine should be immunogenic 
and broadly reactive so as to give the best chance of preventing disease caused by drift 
variants.  Identifying vaccine candidate strains based on HA sequence may not effectively select 
an isolate that will elicit a broad antibody response.  The COBRA HA sequence is similar to the 
clade 2.2 HA used as a vaccine in these studies (95% identity) and the two different HA 
molecules have similar identity profiles to the other test antigens investigated here (Table 5).  
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Despite the high levels of identity between immunogens, structural modeling predicted the 
COBRA sequence to retain the most common structural features found in representative 
sequences while the clade 2.2 HA was divergent in potentially antigenic regions surrounding the 
receptor binding domain (data not shown).  Consistent with these predictions, the COBRA 
based H5N1 vaccine elicited a broader antibody response than the clade 2.2 primary isolate 
based H5N1 vaccine.  Although the breadth of this immunity was limited to clade 2, the antigen 
was designed specifically to address the wide diversity specifically within clade 2.  Further work 
and antigen design is currently underway to include input sequences from more diverse clades 
to address the cross-clade diversity of H5N1.  In addition to the broadened antibody responses, 
the COBRA vaccine protected experimentally infected animals as efficiently as a homologous 
vaccine. 
Table 5: Percent Identity of Test Antigens. 
 
HA amino acid sequences were aligned and percent identity across the entire protein was 
determined for the vaccine immunogens compared to the representative test antigens. 
a A/Vietnam/1203/2004 
b A/Indonesia/5/2005 
c A/Whooper Swan/Mongolia/244/2005 
d A/Anhui/1/2005 
 
 Although the HAI assay has historically been the most commonly used serological assay 
for monitoring influenza immunity, no correlation between HAI titer and protective efficacy 
against H5N1 infection has been reported [200, 201, 206, 214, 215, 217].  For seasonal 
influenza, an HAI titer >1:40 against a seasonal virus protects ~50% of the vaccinated 
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population [264].  Despite the lack of correlation of protection for H5N1 infection, the 1:40 HAI 
titer remains the standard for evaluating vaccine immunogenicity.  Using the 1:40 titer as an 
indicator of positive responses, the adjuvanted COBRA vaccines consistently elicited a high rate 
of seroconversion to diverse clade 2 viruses (Table 3 and 4).  Consistent with prior findings, 
even in the absence of positive HAI titers, vaccinated animals were protected from experimental 
infection (Figure 15, 17 and 19).  Protection could be due to non-neutralizing anti-HA antibodies.  
All COBRA HA immunized animals had total IgG titers to a diverse number of H5N1 HA 
antigens.  Additionally, both anti-NA antibodies and cellular responses elicited by these 
vaccines against influenza proteins could contribute to protection against H5N1 infection [223, 
224, 265, 266].   The COBRA HA sequence does not contain unique epitopes, as predicted by 
immune epitope software (www.immuneepitope.org), compared to representative primary clade 
2 isolates [267].  However, VLPs elicit cellular immune responses [222] and while these 
responses are predicted to be equivalent between the COBRA and primary isolate vaccine 
groups, the protective capacity of the cell-mediated immune responses cannot be ruled out.   
 This is the first report of a consensus-based H5N1 vaccine delivered in the context of a 
virus-like particle.  The COBRA HA represents a new generation of centralized vaccine design 
and elicited a broadly reactive antibody response that protected experimentally infected animals 
from a heterologous H5N1 challenge.  Increasing the breadth of antibody responses is a 
challenge not only for H5N1, but all influenza viruses.  Utilizing COBRA-based vaccine design 
may enable the development of influenza vaccines more resistant to antigenic drift variants and 
warrants further evaluation. 
 
 
 
 
   
121 
 
4.7 ACKNOWLEDGMENTS 
 
This work was supported by an NIH training grant award T32AI060525 to BMG, NIH/NIAID 
award U01AI077771 to TMR, the Center for Vaccine Research and a collaborative research 
grant from PATH Vaccine Solutions.  The authors would like to thank Brianne Stein and Corey 
Crevar for technical assistance.  In addition, we thank Ruben Donis and Richard Webby for 
providing the H5N1 reassortant viruses. 
  
   
122 
 
 
 
 
5.0 
A COMPUTATIONALLY-OPTIMIZED HEMAGGLUTININ VLP VACCINE ELICITS BROADLY-
REACTIVE ANTIBODIES THAT PROTECT MONKEYS FROM H5N1 INFECTION. 
 
 
 
 
 
 
 
 
 
 
Brendan M. Giles1,3, Corey J. Crevar 1, Donald M. Carter 1,  
Stephanie J. Bissel4, Stacey Schultz-Cherry5, Clayton A. Wiley4 and Ted M. Ross1,2,3 
 
 
 
 
 
 
 
 
1Center for Vaccine Research, 2Department of Microbiology and Molecular Genetics and 
3Graduate Program in Immunology, 
University of Pittsburgh, Pittsburgh, PA, USA, 
 
4Division of Neuropathology, Department of Pathology, 
University of Pittsburgh, Pittsburgh, PA, USA,  
 
5Department of Infectious Diseases, 
St. Jude Children's Research Hospital, Memphis, TN, USA, 
 
  
   
123 
 
5.1 FOREWORD 
 
The work presented in this chapter addresses features of Specific Aims II and III (see Sections 
3.4 and 3.5).  Specifically, the non-human primate immunogenicity studies described in Specific 
Aim II are detailed in this chapter.  This work includes consensus and clade 2.2 vaccine 
comparisons and features the more detailed analysis of antibody breadth within and outside of 
clade 2.  Additionally, non-human primate efficacy studies outlined in Specific Aim III are 
described in this chapter.  Therefore, the work presented here describes studies encompassed 
by both Specific Aims II and III. 
 
 
 
5.2 ABSTRACT 
 
Highly pathogenic H5N1 avian influenza viruses continue to spread via waterfowl across Asia, 
Europe, and Africa causing lethal infections in humans.  Vaccines can prevent the morbidity and 
mortality associated with pandemic influenza isolates, but predicting the specific isolate that 
may emerge from one of the 10 H5N1 clades is a tremendous challenge for vaccine design.  In 
this study, we generated a synthetic hemagglutinin (HA) molecule based upon a new 
methodology, computationally optimized broadly reactive antigen (COBRA), which utilizes 
worldwide sequencing and surveillance efforts and is specifically focused on sequences from 
H5N1 clade 2 human isolates.  Cynomolgus macaques vaccinated with COBRA clade 2 HA 
H5N1 VLPs had hemagglutination-inhibition antibody titers that recognized a broader number of 
representative isolates from each subclade of clade 2, as well as other divergent clades, 
compared to monkeys vaccinated with a clade 2.2 HA VLP based upon A/Whooper 
Swan/Mongolia/244/2005 (WS/05).  Furthermore, all vaccinated animals were protected from 
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WS/05 virus challenge with no virus detected in the nasal or tracheal washes, however, COBRA 
VLP vaccinated monkeys had greatly reduced lung inflammation and gross pathology compared 
to WS/05 VLP vaccines.  These results demonstrate that the COBRA clade 2 HA H5N1 VLP 
elicits broad humoral immunity against multiple H5N1 isolates from different clades, which was 
more effective against a HPAI virus challenge than a homologous vaccine.  
 
 
 
5.3 INTRODUCTION 
 
Despite the attention devoted to the 2009 outbreak, highly pathogenic avian influenza virus still 
represents a considerable threat to global public health.  Since the first identified cases of H5N1 
influenza in Hong Kong [268], the World Health Organization (WHO) influenza surveillance 
network increased its intensive monitoring of both human and avian populations for influenza 
infections  [269].  Following the resurgence of H5N1 influenza in 2004 and subsequent spread 
across Asia, the Middle East, Africa, and Europe, there has been an intense need for vaccine 
strategies that elicit broadly reactive immunity against H5N1 isolates in light of its pandemic 
potential.  Currently, efficient human to human transmission of H5N1 is limited, however, 
reassortment with a human seasonal influenza strain or adaptation to human cells could easily 
result in a virus that can transmit efficiently from human to human.  Vaccination is a potent and 
cost-effective counter-measure to the threat of seasonal or pandemic outbreaks of influenza 
[233].  However, there are several challenges for designing an effective vaccine against H5N1 
influenza, including the phylogenetic characterization and sequence homology in HA that 
groups H5N1 viruses into 10 clades as defined by the WHO/OIE/FAO H5N1 Evolution Working 
Group [270] with additional subclades and sub-subclades having been identified [271] (Figure 
20).  Human infections have been limited to clades 0, 1, 2 and 7.  Clade 2 has several 
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subclades that continue to circulate and evolve independently [269].  Antibodies that inhibit virus 
receptor binding or neutralize infection are often clade-specific and do not always recognize 
isolates within even subclades of the same clade [269].  The clades are geographically diverse 
and are evolving under unique pressures specific to each respective location.  The viruses 
isolated during the 1997 outbreak in Hong Kong represent clade 0.   Clade 1 viruses were 
isolated between 2003–2005 in Vietnam and Thailand, and clade 2.1 viruses are attributed to 
human outbreaks in Indonesia.  Viruses in clade 2.3 and clade 7 are predominantly isolated in 
southern China [272]. In this study, we chose to focus on a clade 2.2 virus, A/Whooper 
Swan/Mongolia/244/2005, as a challenge virus to analyze the protective responses to H5N1 
challenge because the clade 2.2 viruses are the most geographically widespread of the H5N1 
isolates having spread from Qinghai Lake in China throughout Asia, Europe, the Middle East, 
and Africa [273-276]. 
 For vaccine manufacturers, it is unclear which clade(s) or subclade(s) of H5N1 may 
eventually emerge and cause pandemic, therefore designing an effective H5N1 vaccine in 
advance of an outbreak is challenging.  To address the sequence diversity inherent in H5N1 
isolates circulating in avian populations, consensus strategies have been designed for vaccine 
development [180, 277].  Our research group has expanded upon the consensus strategy and 
developed computationally-optimized broadly reactive antigen (COBRA) strategies to overcome 
pathogen sequence diversity.  Traditional consensus sequences are generated by aligning a 
population of sequences and selecting the most common residue at each position.  These 
sequences are expected to effectively capture conserved epitopes and elicit cross-reactive 
immune responses [180, 255-257].  The COBRA methodology of antigen design uses multiple 
rounds of consensus generation to address antigenic diversity, specifically within clade 2 H5N1 
hemagglutinin (HA) sequences.   
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Figure 20: Phylogenetic diversity of H5N1 influenza.  The unrooted phylogenetic tree was 
inferred from HA amino acid sequences derived from 8 to 10 representative isolates in all clades 
and subclades and also the COBRA HA using the maximum likelihood method.  Clade/subclade 
clusters were identified and are indicated in the shaded ovals.  The star identifies where the 
COBRA antigen is located relative to the various representative isolates.  Sequences were 
aligned with MUSCLE 3.7 software and the alignment was refined by Gblocks 0.91b software.  
Phylogeny was determined using the maximum likelihood method with PhyML software.  Trees 
were rendered using TreeDyn 198.3 software [278].  The NCBI accession numbers for the HA 
sequences used in phylogeny inference were obtained through the Influenza Virus Resource 
[51]. 
 
 Candidate H5N1 vaccines have been previously tested in mice and ferret models.  While 
these models are effective for seasonal influenza vaccine studies [206, 221, 237, 279-281], they 
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are not as informative for determining protective efficacy by H5N1 vaccines.   There is often a 
lack of correlation between HAI activity and protection against H5N1 challenge [200, 201, 206, 
221, 222].  Unvaccinated mice or ferrets that are challenged with H5N1 influenza viruses quickly 
succumb to disease, however, when these animals are vaccinated with an H5N1 hemagglutinin-
bearing HA, they are protected against challenge that does not always correlate with HAI titers.  
Therefore, we chose to use a non-human primate model to determine the breadth of HAI activity 
and the ability to protect against H5N1 infection and pathology.  Monkey models have been 
effectively used for H5N1 (clades 0 and 1) [282], as well as the reconstructed 1918 H1N1 
influenza virus [132], since they have similar pathology to humans when infected with these 
highly pathogenic influenza viruses.  However, there is currently no published non-human 
primate model based upon an avian clade 2 H5N1 isolate demonstrating the pathology or 
immune responses induced following infection of vaccinated or unvaccinated macaques. 
 In this report, COBRA HA proteins were displayed on the surface of a virus-like particle 
(VLP) and used to vaccinate cynomolgus macaques.  The elicited immune responses were 
directly compared to a VLP with the HA from a clade 2.2 isolate, A/Whooper 
swan/Mongolia/244/2005 (WS/05).  The COBRA HA VLP not only elicited broader antibody 
responses against H5N1, but also protected monkeys from clade 2.2 H5N1 challenge more 
efficiently than the homologous vaccine. 
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5.4 MATERIAL AND METHODS 
 
5.4.1 Expression and purification of virus-like particles 
 
The COBRA HA sequence has been described [283].  Briefly, the sequence was generated by 
aligning amino acid sequences of all available HA proteins isolated from clade 2 H5N1 human 
infections (2004-2007) and deposited in the Influenza Virus Resource (IVR) database available 
through NCBI.  293T cells were transiently transfected with plasmids expressing HA, M1, and 
NA using Lipofectamine 2000 in low serum media, incubated for 72h at 370C, and purified by 
ultracentrifugation through a 20% glycerol cushion as previously described [283].  All VLP 
vaccines were engineered using the same NA from A/Thailand/1(KAN-1)/2004.  HA content was 
quantified as previously described [283].  Two different VLP preparations were purified, each 
containing one of the HA influenza gene products: WS/05 or the COBRA HA. 
 
5.4.2 Primate immunizations and H5N1 challenges 
 
Cynomolgus macaques (Macaca  fascicularis, male, 3-5 years old) were vaccinated with 15 g 
(based upon HA content) of purified COBRA HA VLPs (n=7), WS/05 VLPs (n=7) or vehicle 
alone (n=6), via intramuscular injection at weeks 0, 3 and 6.  Vaccines were prepared in PBS 
and formulated with alum adjuvant (Imject Alum, Pierce Biotechnology; Rockford, IL, USA) 
immediately prior to use.  Twenty-one days after each vaccination, blood was collected from 
anesthetized macaques via the femoral vein and transferred to a serum separator tube. After 
clotting, tubes were centrifuged and sera removed and frozen at -80 ± 5°C.   
 Three weeks after final vaccination, macaques were placed into BSL3+ isolator units 
(Bioqual, Inc., Rockville, MD) and then challenged by a multi-route of infection (ocular, nasal, 
tracheal) as previously described [132, 231, 232, 283] using 1x106 plaque forming units (PFU) 
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of the highly pathogenic H5N1 virus, A/Whooper Swan/Mongolia/244/2005 (clade 2.2), in a 
volume of 1 ml at each location for a total infection dose of 1x106 PFU in a total volume of 3 ml.  
Macaques were monitored daily for weight loss, signs of disease, and mortality until 7 days after 
infection. Individual body weights, sickness scores (based upon lethargy, temperature change, 
nasal discharge, lack of appetite, dehydration, lack of responsiveness), and death were 
recorded for each group.  
 Nasal and tracheal washes were performed at day 0, 1, 3, 5, and 7 post-infection.  In 
addition, subsets of monkeys were sacrificed following administration of anesthesia and 
necropsies were performed according to standard procedures. These time points for euthanasia 
were chosen because it allowed the assessment of gross pathologic and histopathologic 
changes, as well as the extent of virus replication. 
 
5.4.3 Serological assays 
 
A quantitative ELISA was performed to assess anti-HA specific IgG in immune serum as 
previously described [222, 283].  The hemagglutination inhibition (HAI) assay was used to 
assess functional antibodies to the HA able to inhibit agglutination of horse red blood cells [239].  
The protocol was adapted from the CDC laboratory-based influenza surveillance manual and 
performed as previously described [222, 233].  To inactivate non-specific inhibitors, sera were 
treated with receptor destroying enzyme (RDE; Denka Seiken, Co., Japan) prior to being tested 
[234-238].  The HAI titer was determined by the reciprocal dilution of the last well which 
contained non-agglutinated RBC. Positive and negative serum controls were included for each 
plate.  All monkeys were negative (HAI ≤1:10) for pre-existing antibodies to currently circulating 
human influenza viruses prior to vaccination. 
 Serum neutralizing antibody titers were determined by microneutralization (mVN) assays 
performed on Madin Darby Canine Kidney (MDCK) cells following the procedure [240]. Briefly, 
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individual heat inactivated serum samples were serially diluted 2-fold (starting at a 1:10 dilution) 
in MDCK diluent buffer in a cell culture plate followed by the addition of a pre-determined 
amount (100 TCID50) of each virus. Sera and viruses were mixed and incubated at 37°C for 2 
hours. After the incubation the virus antibody mixtures were added to plate containing MDCK 
cells and were incubated for 2 hours at 37°C in a 5% CO2 cell culture incubator. The virus 
antibody was then removed and cells were incubated until CPE was observed.  Cells were then 
fixed in 10% formalin and stained with 1% crystal violet to quantify CPE.  The neutralizing 
antibody titers are expressed as the reciprocal of the highest dilution of serum that gave 50% 
neutralization of 100 TCID50 of virus in MDCK cells. Positive serum control and negative cell 
controls with no serum were included on each plate. Geometric mean neutralizing antibody 
titers were calculated for each group. 
 
5.4.4 Histopathologic evaluation and immunohistochemical analysis. 
 
Formalin-inflated lungs and trachea were fixed in 10% neutral buffered formalin.  Cross-sections 
of upper and lower left and right lung lobes and trachea were made, concentrating on gross-
lesions.  Tissue was paraffin embedded and 6- m sections were stained with hematoxylin and 
eosin for histologic evaluation. Sequential sections were processed for immunohistochemistry or 
in situ hybridization (ISH).  Immunohistochemistry was performed as described before [284] 
using an immunoperoxidase method with a polyclonal antibody (Maine Biotechnology Services, 
Portland, ME) directed against influenza A virus. A biotinylated donkey anti–goat IgG (Rockland 
Immunochemicals, Gilbertsville, PA) was used as the secondary antibody.  ISH was performed 
as described previously [285] using a 35S-labeled riboprobe synthesized using templates 
derived from 760 bp of influenza A/California/04/2009 (H1N1) matrix protein. 
 
 
   
131 
 
5.4.5 Statistical analysis 
 
Statistical significance of antibody data was determined using a two-way analysis of variance 
(ANOVA) with Bonferroni’s post-test to analyze differences between each vaccine group for the 
different test antigens (multiparametric).  To determine antibody breadth to more divergent test 
antigens, analysis was done with log2 transformed titers.  Significance was defined as p<0.05.  
All statistical analysis were performed using GraphPad Prism software. 
 
 
 
5.5 RESULTS 
 
5.5.1 Vaccine induced antibody responses 
 
To address the challenge of antigenic diversity present in H5N1 influenza, we designed a 
computationally optimized broadly reactive antigen (COBRA) for hemagglutinin.  This HA 
molecule was engineered using 129 unique hemagglutinin sequences representing clade 2 
H5N1 viruses isolated from human infections as previously described [283].  The fully functional 
COBRA HA was pseudotyped, along with neuraminidase, onto influenza M1  to generate 
pseudoparticles (VLPs) to be used as vaccine immunogens.     
 Cynomolgus macaques (3-5 years of age; n=7) were vaccinated intramuscularly with 
15 g purified COBRA VLPs (dose based upon HA content) or WS/05 VLPs formulated with 
Imject® alum at 0, 3 and 6 weeks.  At week 3 post-vaccination, all COBRA VLP-vaccinated 
animals had anti-HA antibodies that recognized recombinant HA derived from three subclades 
of clade 2, which were boosted at week 6 (Figure 21).  There was no statistical difference in the 
anti-HA titers elicited against any of the HA proteins, except monkeys vaccinated with COBRA 
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VLPs had a statistically higher titer against the Indo/05 HA (clade 2.1) compared with monkeys 
vaccinated with the WS/05 VLP (derived from clade 2.2) on week 6. 
 
 
Figure 21: Anti-HA IgG ELISA antibodies.  Total IgG at week 3 (A) and week 6 (B) was 
determined via ELISA for each vaccine group.  Each collected antiserum was assayed for 
antibody binding to representative HA molecules from clade 2.1 (A/Indonesia/5/2005), clade 2.2 
(A/Whooper Swan/Mongolia/244/2005), and clade 2.3 (A/Anhui/1/2005).  Values represent the 
geometric mean titer (+95% confidence interval) of endpoint titers. 
 
 
5.5.2 A single COBRA VLP vaccination induced high titer HAI antibodies to clade 2 H5N1 
viruses. 
 
Monkeys vaccinated with COBRA VLPs (but not with WS/05 VLPs) had hemagglutination-
inhibiting antibodies (HAI) against viruses representing all three clade 2 subclades after a single 
vaccination (Figure 22A).  Four to six monkeys responded to the COBRA VLP vaccine with an 
HAI titer >1:40 for the all of the various test antigens.  In contrast, 4 of 7 monkeys vaccinated 
with the WS/05 VLP responded to the homologous clade 2.2 virus, but none of these vaccinated 
monkeys responded to the clade 2.1 or 2.3 virus.  Following a second vaccination, almost all the 
   
133 
 
monkeys vaccinated with either vaccine responded to all three viruses (Figure 22B).  These 
results were confirmed by microneutralization assay (Figure 22C and 22D). 
 
 
Figure 22 : Hemagglutination inhibition (HAI) and microneutralization (mVN) serum 
antibody titers for representative clade 2 isolates.  Receptor blocking antibody titer at week 
3 (A) and week 6 (B) was determined via HAI for each vaccine group. Values represent the 
geometric mean titer (+95% confidence interval).  The dotted line represents the 1:40 titer.  The 
number of monkeys that responded with a titer greater than 1:40 is listed above each bar.  None 
of the mock vaccinated monkeys responded and no value is listed.  Neutralizing antibody at 
week 3 (C) and week 6 (D) was determined via mVN for each vaccine group.  Values represent 
the geometric mean titer (+95% confidence interval). 
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5.5.3 COBRA VLPs induced HAI antibodies that recognize broader numbers of H5N1 
viruses. 
 
In order to determine if the COBRA HA elicited antibodies that recognized a broader number of 
H5N1 isolates, serum was collected and tested for the ability to inhibit influenza virus induced 
hemagglutination of red blood cells in vitro.  Antisera collected from both vaccinated and 
unvaccinated monkeys were then tested against a broad panel of H5N1 viruses representing 
not only subclades of clade 2, but also non-clade 2 H5N1 virus strains (0, 1, 4, and 7) by HAI.  
Monkeys vaccinated with the COBRA VLP had high average HAI titers against all clade 2 
isolates, regardless of subclade (Figure 23).  In general, all 7 monkeys responded to the 
COBRA VLP vaccine and seroconverted with an HAI titer >1:40 against all the clade 2 viruses.  
In contrast, monkeys vaccinated with the WS/05 VLP vaccine had lower HAI titers against clade 
2 viruses (Figure 23) and fewer number of monkeys responded to the vaccine.  Of the 10 clade 
2 viruses tested in the HAI assay, WS/05 VLP vaccinated monkeys responded more poorly 
(fewer than 4 of 7 monkeys) to 4 of the isolates and none of these monkeys had antibodies that 
responded to the Dk/HU/02 (clade 2.1.1) or Eg/3300/08 (clade 2.2.1) isolates.  The COBRA 
VLPs elicited significantly higher HAI titers against almost all of the clade 2 viruses than the 
WS/05 VLPs (Figure 23). 
 In addition to clade 2 isolates, a minimum of five COBRA VLP vaccinated monkeys had 
HAI antibodies against both clade 1 and 7 virus isolates (Figure 23).  In comparison, almost 
none of the WS/05 VLP vaccinated monkeys had HAI antibodies against clade 1 and clade 7 
viruses. None of the monkeys, regardless of the vaccine, had antibodies that responded to the 
clade 0 or 4 isolates.  None of the mock vaccinated monkeys recognized any of the H5N1 
isolates. 
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Figure 23: HAI serum antibody titers from vaccinated monkeys against a panel of clade 0, 
1, 2, 4, and 7 isolates.  HAI titer for each vaccine group (n=7) was determined at week 6 using 
diverse H5N1 influenza viruses.  Values represent the geometric mean titer (+95% confidence 
interval) of log2 transformed titers.  
 
5.5.4 Challenge of primates with H5N1 clade 2.2 virus. 
  
Three weeks after final vaccination, both VLP vaccinated and mock-vaccinated monkeys were 
transferred to ABSL3+ isolator units and then challenged with highly pathogenic H5N1 virus, 
A/Whooper Swan/Mongolia/244/2005 (clade 2.2) (1x106 pfu), by a multi-route (ocular, nasal, 
tracheal, oral) of infection [132, 231, 232, 283].  There was no significant weight loss or mortality 
in any of the monkeys over the 7 day period of observation.  Unvaccinated monkeys had an 
elevated temperature of ~20 C that was sustained for 5 days post-infection and higher gross 
pathology scores by day 3 post-infection (Table 6).  The lungs of unvaccinated monkeys had 
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mild to moderate acute pneumonia with alveolar pulmonary exudate by day 3 post-infection by 
H&E staining (Figure 24A).  ISH showed focal collections of H5N1 infected cells present at day 
3 post-infection in alveolar spaces and to a lesser extent in bronchial epithelium (Figure 24E).  
These results were similar to unvaccinated monkeys infected with the clade 1 H5N1 virus, 
A/Vietnam/1203/2004.  In contrast, monkeys vaccinated with either the COBRA VLP or the 
WS/05 VLP vaccine had a reduced, but not statistically significant, gross pathology scores of 
2.1-3.3 at day 3 post-infection with a milder increase in body temperature (1.1-1.30C) that spiked 
between days 2-3 post-infection and then returned to pre-infection temperatures (Table 6).  
Vaccinated animals had fewer H5N1 infected cells that were detected primarily on day 1 post-
infection (Figure 24F & G and Table 7).  However, monkeys vaccinated with the COBRA VLP 
had little to no signs of lung inflammation by H&E staining (Figure 24C), while animals 
vaccinated with the WS/05 VLP vaccine had similar signs of inflammation as non-vaccinated 
monkeys (Figure 24B and Table 8).  In addition, unvaccinated monkeys had high titers of virus 
in both the nasal and tracheal washes between days 3 and 5 post-infection. In contrast, no virus 
was detected in either vaccinated groups (Table 6). 
 
Table 6: Monkey H5N1 Infections 
 
a Average gross lung pathology score (3 DPI; n=3/group) 
b Elevated temperature above baseline (days elevated) 
c Log 10 of average viral load at peak PFU/ml (peak day) 
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Figure 24: Histopathology of H5N1 infected lung.  H&E stained sections of lungs from day 3 
post-infection:  (A) unvaccinated, (B) WS/05 VLP, (C) COBRA VLP, (D) unvaccinated, non-
infected.  Influenza ISH from day 1 post-infection:  (E) unvaccinated, (F) WS/05 VLP, (G) 
COBRA VLP. 
 
 
 
Table 7: H5N1 lung infection scores. 
 
ISH for influenza was performed on tissue sections of from upper and lower left and right lung.  
A semi-quantitative scoring system was developed to evaluate the presence of influenza 
infected cells.  Scores were then averaged: 0.2 = rare or occasional cells but <5% of fields, 1 = 
>1/2 to 1/4 low power fields, 2 = >1/4 low power fields, 3 = essentially all low power fields. 
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Table 8: Lung involvement and inflammation scores. 
 
a % lung involvement.  Tissue sections from upper and lower left and right lung were evaluated 
for percent area demonstrating pneumonia.   Scores were then averaged.  Range in 
parentheses.  0 = <10%, 1 = 10-24%, 2 = 25-50%, 3 = >50%.  
b bronchial and alveolar inflammation scores.  Tissue sections from upper and lower left and 
right lung were evaluated for presence of bronchial inflammation and denudation and alveolar 
immune cell infiltration.  Scores were then averages.  0 = absent, 1 = present, 2 = abundant 
 
 
 
5.6 DISCUSSION 
 
Highly pathogenic avian influenza virus represents a considerable threat to global public health.  
Outbreaks of highly pathogenic avian influenza of the H5N1 subtype are of particular concern 
because of the high mortality rate (60% case fatality rate) and novel subtype [286].  This report 
describes the immunogenicity and efficacy of a computationally optimized broadly reactive 
antigen (COBRA) approach designed for H5N1 influenza HA in a non-human primate model.  
The recent spread of the virulent avian H5N1 viruses throughout Asia to North Africa and 
Europe has raised serious concerns about the possibility of a novel human influenza pandemic 
efficiently transmitting to humans [287, 288].  These highly pathogenic H5N1 viruses represent 
isolates from clade 2, which contain distinct subclades, with some subclades being further 
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divided into additional sub-subclades [289].  Several current H5N1 vaccine candidates elicit 
immune responses that are able to neutralize viruses within a homologous clade, but lack the 
ability to neutralize cross-clade.  Developing vaccines that are able to overcome these 
challenges of H5N1 antigenic diversity is a crucial step in pandemic preparedness.  In this 
report, we describe for the first time, a non-human primate model for a clade 2 H5N1 influenza 
virus and use this model to test the protective efficacy induced by the clade 2 COBRA VLP 
vaccine.   
 The COBRA vaccine strategy represents a novel method of sequence construction that 
features a layered building approach that is intended to capture the most common antigenic 
characteristics, while avoiding the complication of differential sequence availability that can bias 
a consensus sequence to the most prevalent antigenic cluster.  Avoiding this sampling bias is 
essential to generating a centralized vaccine that accurately represents the population of input 
sequences.  A COBRA designed HA phylogenetic analysis in the context of H5N1 human 
infections demonstrated that using a layered consensus building approach can indeed 
overcome the challenges of sequence availability and results in a sequence that retains 
similarity to the input without localizing into any one antigenic cluster . 
 Why do COBRA induced antibodies recognize a broader number of H5N1 isolates?  
Several possibilities have been explored.  First, COBRA HA antigens may have a combination 
of antibody epitopes that are not all present in any given wild-type sequence and therefore elicit 
a unique antibody profile.  However, only one low titer linear peptide was identified as having 
differential reactivity (aa. 136-152) by ELISA (data not shown) and therefore, any putative 
epitopes are most likely conformational.  Second, COBRA HA elicited antisera did not readily 
recognize viruses from clade 0 and 4 by HAI assay (Figure 23).  Viruses in these clades have 
conserved HA residues between them, but these residues are divergent from the other HA 
antigens in our panel at several positions reported to be localized in antigenic regions: 100, 140 
(region B), 154 (region A), 171 (region B) and 228 (region D) (Figure 7).  It is possible that these 
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particular residues could play key roles in evading neutralizing antibody responses.  The 
COBRA HA used in this study was based upon HA sequences from clade 2 viruses isolated 
from human infections [283].  The addition of HA sequences from divergent clades may expand 
the breadth of elicited antibodies to recognize viruses in other clades by HAI or mVN assays, 
however, it is not known if this expansion will reduce the reactivity to isolates within clade 2.  In 
addition, antibodies elicited by COBRA HA immunogens may elicit higher affinity antibodies due 
to exposure of unique epitopes on the COBRA molecule that result in neutralization of a broad 
panel of primary virus isolates.  COBRA-based immunogen design could also improve T helper 
epitopes, but high levels of sequence identity between HA molecules (>90%) indicates this is 
likely not occurring.  Furthermore, epitope prediction software has failed to identify the presence 
of any unique linear immune epitopes in the COBRA HA.  T cell responses were not evaluated 
in the course of these studies and cannot be ruled out at this time.  How any of these results 
correlate with human H5N1 vaccination and subsequent protection from challenge is not known 
and the COBRA HA immunogen will need to be tested in future clinical trials. 
 Following vaccination of non-human primates, the H5N1 COBRA HA expressed on the 
surface of a virus-like particle elicited broadly reactive antibody (HAI) titers against not only 
clade 2 (Figure 22), but also across multiple clades of H5N1 (Figure 23).  In general, 
experimental H5N1 vaccines elicit clade-specific HAI titers [161, 290].  Emergence of the novel 
H1N1 isolates in 2009, once again demonstrated that influenza viruses can recombine with 
avian and swine influenza viruses resulting in human transmissible viruses.  Since the clade of 
an emerging, human-transmissible H5N1 isolate cannot be known in advance, a number of 
approaches have been employed to generate vaccines targeting a broad number of H5N1 
isolates/clades, including targeting the highly conserved ion channel protein (M2) and the 
nucleoprotein (NP) [291, 292].  However, these influenza proteins are not highly immunogenic.  
For seasonal influenza viruses, T cells directed against NP and antibodies against NA can be 
effective at preventing viral budding and spread within a host, and thereby reducing symptoms 
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of disease, but only antibodies to HA can prevent infection.  More recently, a vaccine approach 
based upon the stalk region of the influenza virus conferred protection in mice against multiple 
lethal influenza viral challenges representing different subtypes [105].  This approach may have 
merit, since antibodies elicited during the recent 2009 H1N1 outbreak had broadly reactive 
neutralizing activity and cross-reacted against epitopes in the HA stalk and head domain of 
multiple influenza strains [293].  Furthermore, it is possible that vaccines targeting the HA stalk 
region could be improved by using a COBRA based immunogen design.  We demonstrated that 
antibodies elicited by the clade 2 COBRA HA recognized viruses from clades 1, 7, as well as 
isolates representing various subclades of clades 2.1, 2.2, and 2.3 with a larger phylogenetic 
footprint than antibodies elicited by VLPs expressing the clade 2.2-specific HA from A/Whooper 
swan/Mongolia/244/2005, which had a more restricted footprint (Figure 25).  These antibodies 
recognized a subset of isolates within clade 2, and no viruses outside clade 2 (Figure 24).  It 
was recently reported that vaccination with three HA molecules representing clades 1, 2.1, and 
2.3 elicited broadly reactive antibody responses to divergent H5N1 clades [161].  However, the 
COBRA HA used in this study elicited similar antibody breadth using a single HA immunogen.  
The addition of HA gene sequences from other clades may expand the breadth of elicited 
antibodies to more clades of H5N1. 
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Figure 25: Footprint of HAI reactivity.  The unrooted phylogenetic tree was inferred from HA 
amino acid sequences derived from both vaccines and test antigens using the maximum 
likelihood method.  Phylogenetic analysis is the same as described for Figure 20.  Numbers 
above each branch identify the clade/sub-clade of the respective cluster.  The stars identify 
where the two vaccine antigens (COBRA and WS/05) are located relative to the test antigens.  
The shading indicates the footprint of HAI reactivity for the COBRA vaccine (light gray) and 
WS/05 vaccine (dark gray). 
 
 Non-human primates offer some advantages for studying vaccine induced immune 
responses, including the identification of immunological parameters outside of antibodies that 
may correlate with protection induced by experimental influenza vaccines [182, 294-296].  We 
developed this cynomolgus macaque clade 2 infection model to study both H5N1 viral-induced 
pathology, as well as testing vaccine efficacy in a primate immune model.  Grossly, 
unvaccinated monkeys had lung pathology as soon as day 3 post-infection that continued until 
day 7.  Similar results were detected in clade 1 infected monkeys [294].  Hemorrhage and lung 
consolidation were associated with clade 2.2 (WS/05) H5N1 infection.  Monkeys vaccinated with 
either COBRA VLPs or WS/05 VLPs had few signs of disease and greatly reduced viral titers in 
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the lungs upon challenge (Table 5), but COBRA VLP-vaccinated monkeys had little lung 
inflammation and fewer virally infected cells than WS/05 VLP vaccinated animals (Figure 24).  
The COBRA HA was as effective in protecting monkeys from challenge as the homologous 
WS/05 HA, indicating that the COBRA HA can protect against a heterologous clade 2 viral 
challenge.  However, there were few clinical signs associated with infection with this strain of 
clade 2 H5N1 and therefore, differences in vaccine efficacy could only be determined by lower 
viral titers and reduced pathology following necropsy and histopathological staining, which may 
limit the use of this model for vaccine studies. 
 In this report, we hypothesized that the COBRA HA delivered in the context of a VLP will 
elicit an antibody response that would increase the breadth of elicited antibody when compared 
to that of a VLP containing an HA molecule derived from a primary isolate.  This is the first 
report of a COBRA HA eliciting broadly reactive antibody responses across multiple clades of 
H5N1 and also reduces inflammation and pathology in non-human primates from a 
heterologous, highly pathogenic H5N1 virus challenge. 
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6.1 FOREWORD 
 
The work presented in this chapter addresses features of Specific Aims II and III (see Sections 
3.4 and 3.5, respectively).  Specifically, the comparison of the consensus and polyvalent 
vaccines is described here.  Evaluations of both antibody and cellular immune responses 
outlined in Specific Aim II are detailed in this chapter.    For Specific Aim III, the challenge 
studies evaluating vaccine efficacy against both clade 2.2 and clade 1 viral challenges are 
included here.  Additionally, the finding that vaccine-induced serum factors provide protection 
from severe disease is contained in this chapter.  Therefore, the work presented here completes 
the studies outlined in Specific Aims II and III. 
 
 
 
6.2 ABSTRACT 
 
Influenza pandemics occur sporadically and are caused by the emergence of a pathogenic and 
transmissible virus to which the human population is immunologically naïve.  Human infections 
with highly pathogenic avian influenza of the H5N1 subtype were first identified in 1997 and 
have continued to occur through today.  The H5N1 subtype is of particular concern due to the 
novel subtype and high pathogenicity.  One of the challenges for developing an H5N1 vaccine is 
the diversity within the subtype.  H5N1 is separated into 10 phylogenetic clades that are co-
circulating and antigenically distinct.  Vaccines that are able to elicit cross-reactive antibodies to 
multiple strains are needed for effective pre-pandemic stockpiling.  We have previously 
described a novel hemagglutinin using a methodology termed computationally optimized 
broadly reactive antigen (COBRA) that elicited broad antibody responses.  In this report, 
COBRA HA vaccine is compared to a polyvalent H5N1 vaccine.  Polyvalent vaccines are a 
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traditional method for increasing the breadth of antibody responses by influenza vaccines and 
still remain the strategy employed for generating seasonal influenza vaccine formulations.  
COBRA HA elicited higher titer antibody responses to antigens homologous and heterologous 
within the polyvalent formulation.  Both COBRA and polyvalent vaccines protected vaccinated 
animals from experimental infection with highly lethal H5N1 influenza viruses, but COBRA 
vaccinated animals had decreased viral replication and histological involvement in the lungs of 
mice and reduced virus recovery in ferret nasal washes.  Both vaccines had similar cellular 
responses post-challenge indicating that higher titer serum antibody likely restricts the duration 
of viral replication.  Furthermore, passively transferred immune serum from COBRA vaccinated 
mice protected recipient animals more efficiently than immune serum from polyvalent 
vaccinated mice.  This is the first report comparing two strategies for increasing breadth of 
influenza vaccines: centralized and polyvalent.  We show that a single COBRA antigen elicits 
broader antibody responses and is more effective than a polyvalent mixture of primary antigens. 
 
 
 
6.3 INTRODUCTION 
 
In addition to yearly epidemics, pandemic outbreaks of influenza have occurred sporadically 
throughout human history [55, 71].  Pandemics occur when a novel pathogenic and 
transmissible virus emerges into the human population.  A critical factor in the emergence of a 
pandemic virus is that it must be antigenically divergent from circulating strains to evade prior 
immunity in the human population.  Potentially pandemic viruses can therefore emerge from 
novel subtypes, such as H5N1 or H7N7, or divergent strains of currently circulating subtypes, 
such as H1N1.  Indeed, the influenza pandemic of 2009 was caused by the emergence of a 
novel swine-origin H1N1 virus into the human population [72].  Avian viruses of the subtypes 
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H5N1, H7N7 and H9N2 have all demonstrated the ability to directly infect humans [297].  H5N1 
is of particular concern because of the continued cross-species infection and the high 
pathogenicity of the virus (60% mortality) [185].  Although H5N1 has not displayed efficient 
human to human transmission, in vitro studies have established that stable reassortant viruses 
that retain the pathogenic phenotype of H5N1 can be created with both H3N2 and novel H1N1 
viruses [248-250].  Reassortment with transmissible viruses and/or accumulation of mutations 
could result in the emergence of a highly transmissible H5N1 virus.  The genetic compatibility of 
H5N1 with currently circulating human and swine viruses highlights the need for the 
development of effective vaccines against H5N1. 
 Development of pre-pandemic H5N1 vaccines is complicated by the antigenic diversity 
within the subtype.  Phylogenetic distances of the hemagglutinin (HA) genes of H5N1 viruses 
distinguishes the ten distinct clades [196].  HA-based diversity within clade 2 alone has led to 
characterization of distinct subclades and sub-subclades.  Most human infections were by 
isolates belonging to clades 1 or  2 with isolates from clade 2 being detected in over 60 
countries and moving westward into the Middle East and Africa [298].  Although H5N1 HA 
proteins display a high degree of similarity (>90% identity), there is little receptor blocking 
antibody cross-reactivity between clades.  Furthermore, the subclades of clade 2 are also 
antigenically distinct as determined by cross-reactivity of receptor blocking antibodies [196].  
Despite the risk imposed by highly pathogenic H5N1 influenza, the magnitude of diversity within 
the subtype complicates vaccine antigen selection for either pre-pandemic usage or stockpiling.  
Vaccines that are able to overcome the challenge of antigenic diversity are therefore crucial to 
effective pandemic preparedness. 
 Influenza antigenic diversity is not a unique problem for H5N1 vaccine development.  
Rather, simultaneous circulation of diverse influenza A (H1N1 and H3N2) and influenza B 
viruses has been a challenge for seasonal influenza vaccine production for over 30 years.  The 
current seasonal vaccine uses a polyvalent formulation to address the issue of distinct viruses 
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circulating at the same time and therefore is a standard strategy to elicit increased antibody 
breadth by influenza vaccination.  Indeed, multivalent H5N1 vaccines increase the breadth of 
receptor blocking antibody responses [160, 161].  Another strategy for expanding antibody 
breadth involves engineering synthetic centralized antigens that are predicted to capture 
common immune epitopes.  Consensus and ancestral sequences have been used for H5N1 
vaccine antigens and these centralized vaccines are a feasible mechanism by which antibody 
breadth can be expanded [172, 180-182, 254].   Our research group has used a consensus-
based approach to develop a novel strategy termed computationally optimized broadly reactive 
antigen (COBRA) [283].  Traditional consensus sequences are inherently biased by the input 
sequences used in the alignment and subsequent sequence generation.  Because sequencing 
efforts for H5N1 are reactionary to outbreaks rather than systematic, the available input 
sequences to generate any centralized sequence are subject to outbreak dominance and bias.  
COBRA methodology seeks to overcome this limitation by layering together multiple rounds of 
consensus sequence generation.  This method was specifically applied to the diversity of HA 
within clade 2 because this clade is the most antigenically diverse and has been implicated in 
the majority of human infections and has the widest geographic spread. 
 Here, we demonstrate that our previously described COBRA antigen elicits a broader 
receptor blocking antibody response than a clade 2 polyvalent formulation in mice and ferrets.  
Both vaccines were able to protect mice and ferrets from highly pathogenic H5N1 challenge with 
COBRA vaccinated animals showing more efficient viral clearance.  Additionally, both vaccines 
protected mice from a divergent clade 1 challenge and immune serum from COBRA vaccinated 
animals protected animals more efficiently than serum from polyvalent vaccine recipients. 
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6.4 MATERIALS AND METHODS 
 
6.4.1 Vaccine antigens and preparation 
 
The design and characterization of the computationally optimized broadly reactive antigen 
(COBRA) has been described previously [283].  Briefly, the COBRA HA antigen was generated 
by multiple rounds of consensus generation using HA sequences from H5N1 clade 2 human 
infections collected from 2004 to 2006.  Polyvalent vaccine HA antigens were derived via 
reverse transcription from the following 6:2 reassortant H5N1 viruses: A/Indonesia/5/2005 
(clade 2.1; IN/05), A/Whooper Swan/Mongolia/244/2005 (clade 2.2; WS/05) and A/Anhui/1/2005 
(clade 2.3; AN/05).  All HA antigens were cloned into the pTR600 expression vector [238]. 
 Virus-like particles (VLPs) were generated by transiently transfecting HEK 293T cells 
with plasmids expressing M1 (A/Puerto Rico/8/1934), NA (A/Thailand/1(KAN-1)/2004), and a 
single H5N1 HA for each preparation.  Cells were incubated for 72h at 37oC after which 
supernatants were harvested.  Cell debris was cleared by low speed centrifugation followed by 
vacuum filtration through a 0.22 m sterile filter.  VLPs were purified by ultracentrifugation 
(100,000 x g through 20% glycerol, weight to volume) for 4h at 4oC.  Pellets were then 
resuspended in PBS (pH 7.2) and stored in single use aliquots at -80oC until use.  Total protein 
concentration was determined by MicroBCA™ Protein Assay Reagent Kit (Pierce 
Biotechnology, Rockford, IL, USA).  HA specific content of each VLP was determined by 
scanning densitometry as described previously [283].  Briefly, purified HA matched to each VLP 
was electrophoresed with purified VLPs, transferred to a PVDF membrane and probed by 
western blot with H5-specific antisera.  The relative density of the HA band in the purified 
protein lanes was used to calculate a standard curve and the density of the HA in the VLP lanes 
was interpolated.  In total, four different VLP preparations were purified and HA content 
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quantified independently, each containing one of the three wild-type influenza gene products 
(IN/05, WS/05, AN/05) or the COBRA HA.  
 
6.4.2 Mouse studies 
 
BALB/c mice (Mus musculis, females, 6–8 weeks) were purchased from Harlan Sprague 
Dawley, (Indianapolis, IN, USA) and housed in microisolator units and allowed free access to 
food and water and were cared for under USDA guidelines for laboratory animals.  Mice were 
vaccinated with purified COBRA VLPs (3 g HA) or a polyvalent formulation of VLPs consisting 
of 1 g HA each IN/05, WS/05 and AN/05 (3 g HA total) via intramuscular injection at week 0 
and then boosted at week 3.  Vaccines were formulated with Imject® alum adjuvant (Imject® 
Alum, Pierce Biotechnology; Rockford, IL, USA) according to the manufacturer’s protocol. 
Fourteen to twenty-one days after each vaccination, blood was collected from anesthetized 
mice via the retro-orbital plexus and transferred to a microfuge tube. Tubes were centrifuged 
and sera was removed and frozen at -20 ± 5°C.   
 Three weeks after final vaccination, mice were challenged intranasally with 5x103 plaque 
forming units (PFU) of either highly pathogenic wild type H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (n=20/group) or 6:2 reassortant virus with internal genes from the 
mouse adapted virus A/Puerto Rico/8/1934 and the surface proteins HA and NA from 
A/Vietnam/1203/2004 (n=10/group) in a total volume of 50 l.  Challenge doses for both viruses 
were established independently and represent approximately 50LD50 (data not shown).  After 
infection, mice were monitored daily for weight loss, disease signs and death for 14 days after 
infection. Individual body weights, sickness scores and death were recorded for each group on 
each day after inoculation. Sickness scores were determined by evaluating activity (0=normal, 
1=reduced, 2=severely reduced), hunched back (0=absent, 1=present) and ruffled fur 
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(0=absent, 1=present) [230].  Experimental endpoints were determined by >20% weight loss or 
display of neurological disease such as hind limb paralysis.  All highly pathogenic wild type 
H5N1 influenza virus studies were performed under high-containment biosafety level 3 
enhanced conditions (BSL3+).  All procedures were in accordance with the NRC Guide for the 
Care and Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in 
Microbiological and Biomedical Laboratories. 
 
6.4.3 Ferret studies 
 
Fitch ferrets (Mustela putorius furo, female, 6-12-months of age), influenza naïve and 
descented, were purchased from Marshall Farms (Sayre, PA, USA).  Ferrets were pair housed 
in stainless steel cages (Shor-line, Kansas City, KS, USA) containing Sani-chips Laboratory 
Animal Bedding (P.J. Murphy Forest Products, Montville, NJ, USA). Ferrets were provided with 
Teklad Global Ferret Diet (Harlan Teklad, Madison, WI, USA) and fresh water ad libitum.  The 
VLPs were diluted in PBS (pH 7.2) to achieve final concentration.  Ferrets (n=6) were 
vaccinated with purified COBRA VLPs (15 g HA) or a polyvalent formulation of VLPs consisting 
of 5 g HA each IN/05, WS/05 and AN/05 (15 g HA total) via intramuscular injection at week 0 
and then boosted at week 3.  Vaccines were formulated with Imject® alum adjuvant (Imject® 
Alum, Pierce Biotechnology; Rockford, IL, USA) immediately prior to use according to the 
manufacturer’s protocol.  Animals were monitored weekly during the vaccination regimen for 
adverse events including weight loss, temperature, loss of activity, nasal discharge, sneezing 
and diarrhea.  Prior to vaccination, animals were confirmed by HAI assay to be seronegative for 
circulating influenza A (H1N1 and H3N2) and influenza B viruses.  Fourteen to twenty-one days 
after each vaccination, blood was collected from anesthetized ferrets via the anterior vena cava 
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and transferred to a microfuge tube. Tubes were centrifuged and sera was removed and frozen 
at -20 ± 5°C.   
 Three weeks after final vaccination, ferrets were challenged intranasally with 1x106 
plaque forming units (PFU) of the highly pathogenic H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (clade 2.2) in a volume of 0.5ml in each nostril for a total infection 
volume of 1 ml.  After infection, ferrets were monitored daily for weight loss, disease signs and 
death for 14 days after infection. Individual body weights, sickness scores, and death were 
recorded for each group on each day after inoculation.  Sickness scores were determined by 
evaluating activity (0=normal, 1=alert and active after stimulation, 2=alert but not active after 
stimulation, 3=neither active nor alert after stimulation), nasal discharge (0=absent, 1=present), 
sneezing (0=absent, 1=present), decreased food intake (0=absent, 1=present), diarrhea 
(0=absent, 1=present), dyspnea (0=absent, 1=present) and neurological symptoms (0=absent, 
1=present) as previously described [283].  Experimental endpoints were defined as >20% 
weight loss, development of neurological disease or an activity score of 3 (neither active nor 
alert after stimulation).  Nasal washes were performed by instilling 3 ml of PBS into the nares of 
anesthetized ferrets each day for 14 days after inoculation.  Washes were collected and stored 
at -80°C until use.  All highly pathogenic wild type H5N1 influenza virus studies were performed 
under high-containment biosafety level 3 enhanced conditions (BSL3+).  All procedures were in 
accordance with the NRC Guide for the Care and Use of Laboratory Animals, the Animal 
Welfare Act, and the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories. 
 
6.4.4 ELISA assay 
 
The ELISA assay was used to assess total antibody titer to the HA.  High binding, 96-well 
polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 50ng/well of 
recombinant HA.  Coating antigens were derived from the following representative viral isolates: 
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A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Whooper 
Swan/Mongolia/244/2005 (clade 2.2) and A/Anhui/1/2005 (clade 2.3).  Plates were blocked with 
5% milk diluted in PBS with 0.05% Tween 20.  Serum samples were diluted in blocking buffer 
and added to plates.  Serum was two-fold serially diluted and allowed to incubate for 1 hour at 
room temperature.  Plates were washed and horseradish peroxidase (HRP)-linked species 
specific antibody against IgG was diluted in blocking buffer and added to plates.  Plates were 
incubated for 1 hour at room temperature.   Plates were washed and HRP was developed with 
TMB substrate (Sigma-Aldrich; St. Louis, MO, USA).  Plates were incubated in the dark for 15 
minutes and then the reaction was stopped with 2N H2SO4.  Optical densities at a wavelength of 
450nm (OD450) were read by a spectrophotometer (BioTek; Winooski, VT, USA) and end point 
dilution titers were determined as the reciprocal dilution of the last well which had an OD450 
above the mean OD450 plus two standard deviations of naïve animal sera. 
 
6.4.5 Hemagglutination inhibition (HAI) assay  
 
The HAI assay was used to assess functional antibodies to the HA able to inhibit agglutination 
of horse erythrocytes.  The protocol was adapted from the CDC laboratory-based influenza 
surveillance manual [299].  To inactivate non-specific inhibitors, sera were treated with receptor 
destroying enzyme (RDE; Denka Seiken, Co., Japan) prior to being tested [234-238].  Briefly, 
three parts RDE was added to one part sera and incubated overnight at 37°C.  RDE was 
inactivated by incubation at 56°C for ~30 min. RDE treated sera was two-fold serially diluted in 
v-bottom microtiter plates. An equal volume of reassortant virus, adjusted to approximately 8 
HAU/50μl, was added to each well. The reassortant viruses contained the internal genes from 
the mouse adapted strain A/Puerto Rico/8/1934 and the surface proteins HA and NA from the 
following representative viral isolates: A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/2005 
(clade 2.1), A/Whooper Swan/Mongolia/244/2005 (clade 2.2) and A/Anhui/1/2005 (clade 2.3).  
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The plates were covered and incubated at room temperature for 20 min followed by the addition 
of 1% horse erythrocytes (HRBC) (Lampire Biologicals, Pipersville, PA, USA) in PBS.  Red 
blood cells were stored at 4°C and used within 72 h of preparation. The plates were mixed by 
agitation, covered, and the RBCs were allowed to settle for 1 h at room temperature [239]. The 
HAI titer was determined by the reciprocal dilution of the last well which contained non-
agglutinated RBC. Positive and negative serum controls were included for each plate.  All mice 
and ferrets were negative (HAI ≤1:10) for pre-existing antibodies to currently circulating human 
influenza viruses prior to vaccination. 
 
6.4.6 Plaque assay 
 
For mouse infections, lung virus titers were evaluated.  For ferret infections, nasal wash virus 
titers were used to assess viral burden.  Both lungs and nasal wash virus titers were determined 
using a plaque assay [241, 242].  Briefly, lungs from infected mice were harvested post 
infection, snap-frozen and stored at -80°C until use.  Samples were thawed, weighed and single 
cell suspensions were prepared via passage through a 70 m mesh (BD Falcon, Bedford, MA, 
USA) in an appropriate volume of DMEM supplemented with penicillin-streptomycin (iDMEM) as 
to achieve 100mg/ml final concentration.  Cell suspensions were centrifuged at 2000 rpm for 5 
min and the supernatants were collected.   
 Madin-Darby Canine Kidney (MDCK) cells were plated (5 x 105) in each well of a 6 well 
plate.  Samples (lung supernatants for mice and nasal washes for ferrets) were diluted (dilution 
factors of 1 x 101 to 106) and overlayed onto the cells in 100 l of iDMEM and incubated for 1hr.  
Virus-containing medium was removed and replaced with 2 mls of L15 medium plus 0.8% 
agarose (Cambrex, East Rutherford, NJ, USA) and incubated for 96 hrs at 37°C with 5% CO2.  
Agarose was removed and discarded.  Cells were fixed with 10% buffered formalin, and then 
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stained with 1% crystal violet for 15 min.  Following thorough washing in dH2O to remove 
excess crystal violet, plates were allowed to dry, plaques counted, and the plaque forming units 
(PFU)/g for lung supernatants or PFU/ml for nasal washes were calculated. 
 
6.4.7 Histopathological analysis 
 
Left lobes of lungs from infected mice were collected 1, 3 and 5 days post-infection and placed 
into 10% buffered formalin.  After fixation, lungs were paraffin embedded and 6 m sections 
were prepared for histopathological analysis.  Tissue sections were stained with hematoxylin 
and eosin.  For in situ hybridization (ISH), vectors containing 760 bp of 
Influenza/California/04/2009 matrix protein were linearized to create antisense and sense 
templates.  35S-labeled riboprobes were generated using MAXIscript in vitro transcription kit 
(Ambion, Austin, TX).  ISH was performed as described before [300].  Control riboprobes did not 
hybridize to lung tissue at any time point post-infection and non-infected tissue did not show 
hybridization with viral probes.  Hybridized slides were assessed and scored for abundance of 
foci. 
 
6.4.8 Cellular assays 
 
The number of anti-influenza specific cells secreting interferon gamma (IFN- ) was determined 
by enzyme-linked immunospot (ELISpot) assay (R&D systems, Minneapolis, MN, USA) 
following the manufacturer’s protocol.  Mice were sacrificed at 6 days post infection (DPI) and 
spleens and lungs were harvested and prepared in single cell suspensions.  Briefly, pre-coated 
anti-IFN  plates were blocked with RPMI plus 10% FCS and antibiotics (cRPMI) for 30 minutes 
at room temperature.  Media was removed from wells and 105 cells were added to each well.  
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Cells were stimulated with purified recombinant HA from A/Vietnam/1203/2004 (truncated at 
residue 530; 1 g/well), inactivated 6:2 reassortant virus A/Vietnam/1203/2004 (1:100 dilution of 
inactivated stock; 100 l/well) or the immunodominant H2-Kd CD8+ T cell epitope in H5 HA: 
HA533 (IYSTVASSL; 1 g/well) (Pepscan Presto, Leystad, Netherlands).  Additional wells were 
stimulated with PMA (50ng/well) and ionomycin (500ng/well) as positive controls or Ova257 
(SIINFEKL; 1 g/well) (Pepscan Presto, Leystad, Netherlands) as negative controls.  
Additionally, IL-2 (10U/ml) was added to each well.  Plates were incubated at 37°C for 48 hours.  
After incubation, plates were washed four times with R&D wash buffer and were incubated at 
4°C overnight with biotinylated anti-mouse IFN . Plates were washed as before and incubated 
at room temperature for 2 hours with streptavidin conjugated to alkaline phosphatase.  Plates 
were washed as before and spots were developed by incubating at room temperature for 1 hour 
in the dark with BCIP/NBT chromogen substrate.   The plates were washed extensively with DI 
H2O and allowed to dry overnight prior to spots being counted using an ImmunoSpot ELISpot 
reader (Cellular Technology Ltd., Cleveland, OH, USA). 
 The number of anti-HA and anti-NA specific antibody secreting cells was determined by 
B cell ELISpot assay as previously described [243-245].   Mice were sacrificed at 6 DPI and 
spleens and lungs were harvested and prepared in single cell suspensions.  Briefly, 0.45 m 
PVDF membrane plates (Millipore, Billerica, MA, USA) were coated with either purified 
recombinant HA from A/Vietnam/1203/2004 or purified recombinant NA from A/Thailand/1(KAN-
1)/2004 (250ng/well) and incubated at 4oC overnight.  Plates were washed three times with PBS 
and blocked with cRPMI at 37°C for 3-4 hours.  Media was removed from wells and 105 cells 
were added to each well.  Plates were incubated at 37oC for 48 hours.  After incubation, plates 
were washed as before and incubated at room temperature for 2 hours with HRP-conjugated 
anti-mouse IgG or IgA (Southern Biotech, Birmingham, AL, USA).  Plates were washed as 
before and spots were developed at room temperature for 1 hour in the dark with detection 
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substrate (NovaRED™; Vector Labs, Burlingame, CA, USA).  The plates were washed 
extensively with DI H2O and allowed to dry overnight prior to spots being counted using an 
ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA). 
 
6.4.9 Passive transfer of sera 
 
Serum from vaccinated mice was pooled and passively transferred into 9 week old recipient 
BALB/c mice (n=5/group).  Equal amounts of serum from each mouse in a particular vaccine 
group were pooled and heat inactivated for 30 minutes at 56oC.  200 l of pooled and 
inactivated serum was transferred to recipient mice via intraperitoneal (IP) injection.  24 hours 
post transfer, mice were infected with 6:2 reassortant virus with internal genes from the mouse 
adapted virus A/Puerto Rico/8/1934 and surface antigens from A/Vietnam/1203/2004 as 
described above. 
 
6.4.10 Statistical analysis 
 
Statistical significance of the antibody and cellular immunology data was determined using a 
two-tailed Student’s T test to analyze differences between COBRA and polyvalent vaccine 
groups for each of the different test antigens.  Differences in weight loss and sickness scores 
were analyzed by two-way ANOVA, followed by Bonferroni's post test for each vaccine group at 
multiple time points (multiparametric).  Statistical siginificance of viral titer data was evaluated 
using a two-tailed Student’s T test on Log10 transformed values.  Significance was defined as p 
< 0.05. Statistical analyses were done using GraphPad Prism software.   
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6.5 RESULTS 
 
6.5.1 Immunogenicity in mice and ferrets 
 
To expand our previous findings comparing COBRA to clade 2.2 VLPs [283], BALB/c mice were 
vaccinated twice via intramuscular injection with either purified COBRA or polyvalent VLPs and 
two weeks after the second vaccination serum was analyzed for antibody responses.  All 
vaccinated mice had high titer anti-HA antibodies that bound to recombinant HA derived from 
both clade 1 and various subclades of clade 2 (Figure 26A).  Although both COBRA and 
polyvalent vaccines elicited similar total IgG, COBRA vaccinated animals had higher HAI 
antibody titers for all viruses tested (p<0.001; Figure 26B).  In addition to higher HAI titer, 
COBRA vaccinated mice had an increased frequency of HAI titers >1:40 for all viruses tested, 
including those which were components of the polyvalent formulation (TABLE 9). 
 These results were confirmed in ferrets, which are a more rigorous animal model than 
mice.  Similar to the mouse results, all vaccinated ferrets had anti-HA antibodies that bound to 
diverse recombinant HA and the relative total IgG titers were equivalent for both COBRA and 
polyvalent vaccines (Figure 26C).  COBRA vaccinated ferrets demonstrated increased HAI 
antibody titers compared to polyvalent vaccinated animals against all viruses tested, however 
only the antibodies to the clade 2.1 virus were significantly different (p<0.05; Figure 26D).   
Furthermore, the frequency of COBRA vaccinated animals with an HAI titer of >1:40 was 
increased compared to the polyvalent vaccinated ferrets for all test antigens (TABLE 9). 
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Figure 26: Vaccine induced serum antibody responses.  BALB/c mice (n=30/group) (A and 
B) or Fitch ferrets (n=6/group) (C and D) were vaccinated at 0 and 3 weeks with blood collected 
14 days after each vaccination.  Total IgG after the second vaccination was determined via 
ELISA for each vaccine group (A and C).  Receptor blocking antibody titers after the second 
vaccination were determined via hemagglutination inhibition (HAI) for each vaccine group (B 
and D).  Values represent the geometric mean of the reciprocal dilution (+/- 95% confidence 
interval) of the last positive well.  Significant differences between COBRA and polyvalent 
vaccines were determined by a two-tailed Student’s T test and a p value of less than 0.05 was 
considered significant (*). 
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Table 9: Seroconversion frequency.  HAI titers ≥ 1:40.
 
 
6.5.2 Wild type clade 2.2 challenge 
 
To confirm protective efficacy against highly pathogenic H5N1 infection, vaccinated animals 
were challenged with a lethal dose of the wild-type clade 2.2 isolate A/Whooper 
Swan/Mongolia/244/2005.  All VLP vaccinated mice were protected from weight loss and death, 
while mock vaccinated animals rapidly lost weight and reached experimental end-points by 6 
days post infection (DPI; Figure 27A).  COBRA and polyvalent vaccinated mice both had a 
mean maximum weight loss of 4% by 12 and 13 DPI, respectively.  Additionally, all VLP 
vaccinated mice failed to develop any overt signs of disease, while mock vaccinated mice 
developed visible illness (Figure 27B). 
 Similar to the mice, all VLP vaccinated ferrets were protected from death following a 
lethal challenge.  Vaccinated ferrets demonstrated mild weight loss in response to the infection, 
with COBRA vaccinated animals having mean maximum weight loss of 5.5% at 2 DPI and 
polyvalent vaccinated animals losing 6.8% by 3 DPI (Figure 27C).  Both groups rapidly 
recovered weight and failed to develop any significant signs of disease (Figure 27D).  
Furthermore, VLP vaccinated animals had no temperature spikes, while mock vaccinated 
animals had an elevated temperature of ~3oC for 1-3 DPI (data not shown). 
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Figure 27: Highly pathogenic clade 2.2 challenge.  Vaccinated BALB/c mice (n=5/group) 
were infected with 5x103 PFU of the highly pathogenic clade 2.2 H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (WS/05).  Mice were monitored daily for weight loss (A) and sickness 
(B).  Vaccinated Fitch ferrets (n=6/group) were infected with 1x106 PFU of the highly pathogenic 
clade 2.2 WS/05 virus.  Ferrets were monitored daily for weight loss (C) and sickness (D).  
Values represent mean (+/- SEM) for each group. 
 
 To evaluate vaccine efficacy with a more sensitive output than morbidity and mortality, 
we also determined the viral burden of infected animals.  Both COBRA and polyvalent 
vaccinated mice had reduced lung viral titers as soon as 1 DPI when compared to mock 
vaccinated animals.  Furthermore, COBRA vaccinated mice did not have detectable virus by 3 
DPI, while polyvalent vaccinated mice demonstrated prolonged viral replication with 1.8 x 103 
PFU/g detected at 3DPI (p<0.05; Figure 28A).  Additionally, both VLP vaccines prevented extra-
pulmonary spread of the virus, while mock vaccinated animals had detectable virus in both 
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kidney and liver by 3 DPI (data not shown).  Control of virus replication in ferrets was similar to 
that observed in mice, although complete clearance of the virus was delayed (Figure 28B).  All 
VLP vaccinated animals had decreased recovery of virus in nasal washes compared to mock 
vaccinated ferrets at every time point tested (p<0.05).  COBRA vaccinated animals did not have 
detectable virus by 5 DPI.  In contrast, virus replication did not reach undetectable levels until 
9DPI in polyvalent vaccinated ferrets (data not shown).   
 
Figure 28: Clade 2.2 viral loads.  Vaccinated BALB/c mice (n=15/group) were infected with 
5x103 PFU of the highly pathogenic clade 2.2 H5N1 virus A/Whooper Swan/Mongolia/244/2005 
(WS/05).  Cohorts of mice (n=5/group) were sacrificed at 1, 3 and 5 days post infection, lungs 
harvested, and viral load determined by plaque assay (A).  Vaccinated Fitch ferrets (n=6/group) 
were infected with 1x106 PFU of the highly pathogenic WS/05 virus.  Nasal washes were 
collected and viral load determined by plaque assay (B).  Values represent mean (+/- SEM) viral 
titer for each group.  Significant differences between COBRA and polyvalent vaccines were 
determined by a two-tailed Student’s T test and a p value of less than 0.05 was considered 
significant (*). 
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6.5.3 Histopathology of infected lungs. 
 
To evaluate the location and severity of influenza viral replication, ISH for influenza A MP was 
scored on 1, 3 and 5 DPI lung sections.  COBRA vaccinated animals had rare bronchial 
epithelium infection on 1 DPI (Figure 29C), and animals receiving polyvalent vaccines had 
occasional bronchial epithelium infection that was comparable to the COBRA vaccinated 
animals (Figure 29C).  On 3 DPI COBRA vaccinated animals had no detectable viral replication, 
while animals receiving polyvalent vaccines showed some bronchial epithelium infection (Figure 
29A and 29C).  This was in contrast to significant bronchial epithelium infection and replication 
observed in mock animals (Figure 29A and 29C).   
 To determine if vaccination protected animals from lung inflammation, hematoxylin and 
eosin stained sections were evaluated for histopathological changes at 1, 3 and 5 DPI.  COBRA 
vaccinated animals had less lung involvement than polyvalent vaccinated animals at all time 
points examined (Figure 29B and 29D).  COBRA vaccinated animals showed minor bronchial 
inflammation while polyvalent vaccinated animals exhibited slight thickening of the bronchial 
epithelium (Figure 29B).  Both vaccinated groups showed little alveolar involvement compared 
to mock vaccinated animals.  Mock vaccinated animals demonstrated greater lung involvement 
and severe alveolar infiltration (Figure 29B and 29D). 
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Figure 29: Histopathology of infected lungs.  Vaccinated BALB/c mice (n=15/group) were 
infected with 5x103 PFU of the highly pathogenic clade 2.2 H5N1 virus A/Whooper 
Swan/Mongolia/244/2005 (WS/05).  Cohorts of mice (n=5/group) were sacrificed at 1, 3 and 5 
days post infection.  ISH for influenza MP (A) and hematoxylin and eosin staining (B) was 
performed on sections from paraffin embedded lung tissue.  Representative ISH images are 
shown from 3 days post infection.  Severity of influenza ISH foci was accessed in the bronchi at 
1, 3 and 5 DPI (C).  Scoring: 0 = no definitive signal; 1 = occasional focus; 2 = focus in most 
fields; 3 = more than one focus per field.  Percentage of lung involvement was assessed in lung 
sections (D).  Scoring:  0 = <10%; 1 = 10-24%; 2 = 25-50%; 3 = >50%. 
 
6.5.4 Clade 1 challenge 
 
Having established the clade 2.2 protective profile of both the COBRA and polyvalent vaccines, 
we next evaluated the efficacy of these vaccines against a more divergent, clade 1 challenge in 
mice.  COBRA and polyvalent vaccinated mice were challenged with 6:2 reassortant virus 
containing the HA and NA proteins from the clade 1 virus A/Vietnam/1203/2004.  All VLP 
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vaccinated animals were protected from weight loss and death, while mock vaccinated animals 
rapidly lost weight and reached experimental endpoint by 7 DPI (Figure 30A).  Furthermore, 
vaccinated mice also did not develop any signs of disease throughout the course of the study 
(Figure 30B).  Lungs were harvested at 3 DPI for determination of viral burden (Figure 30C).  
COBRA vaccinated animals did not have detectable virus while polyvalent animals had 1.1 x 103 
PFU/g virus (p=0.12).  Importantly, both vaccines had significantly less recoverable virus than 
mock vaccinated animals at 3 DPI (p<0.01). 
 
Figure 30: Clade 1 challenge.  Vaccinated BALB/c mice (n=4/group) were infected with 5x103 
PFU of reassortant virus containing the HA and NA genes from the clade 1 H5N1 virus 
A/Vietnam/1203/2004 (VN/04).  Mice were monitored daily for weight loss (A) and sickness (B).  
Values represent mean (+/- SD) for each group.  An additional cohort of vaccinated mice 
(n=3/group) were infected and lungs were harvested 3 days post infection for analysis of viral 
burden (C).  Values represent mean (+/- SEM) viral titer for each group. 
 
6.5.5 Post-challenge cellular immune responses 
 
The magnitude of influenza specific cellular immune responses in the lungs post-infection was 
evaluated via ELISpot assay for both antibody secreting cells (ASC) and IFN-  producing cells.  
Vaccinated mice were infected with reassortant A/Vietnam/1203/2004 virus as described above 
and lungs were harvested at 6 DPI.  COBRA and polyvalent vaccinated animals had statistically 
equivalent numbers of both IgG and IgA ASC specific for the A/Vietnam/1203/2004 challenge 
virus HA (p>0.05; Figure 31A).  No ASC were detected in mock vaccinated animals indicating 
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that the 6 DPI time point is likely representative of a recall response.  Additionally, the majority 
of the ASC response to infection was specific for HA as lower numbers of cells were detected 
for the NA component of the vaccines. 
 VLP vaccine primed IFN-  secreting cells were also evaluated after infection.  IFN-  
responses were equivalent between VLP vaccine groups regardless of stimulating antigen 
(p>0.05; Figure 31B).  As expected, recombinant HA and inactivated virus were inefficient 
stimulators of IFN-  production compared to the HA533 peptide.  HA533 is the immunodominant, 
HA-derived CD8+ T cell epitope in BALB/c mice and is conserved in all HA vaccine antigens 
used in this study [301].  Overlapping peptide pools spanning the entire HA molecule were also 
used to stimulate cells and no differences were observed between COBRA and polyvalent 
vaccines for any of the pools (data not shown).  Similar to the ASC data, no influenza specific 
IFN-  responses were detectable above background in mock vaccinated animals at 6 DPI. 
 
Figure 31: Post-challenge cellular immune responses.  Vaccinated BALB/c mice 
(n=3/group) were infected with 5x103 PFU of reassortant virus containing the HA and NA genes 
from the clade 1 H5N1 virus A/Vietnam/1203/2004 (VN/04).  Mice were sacrificed 6 days post 
infection, lungs were harvested and the numbers of antibody secreting cells (A) and IFN-  
producing cells (B) were determined by ELISpot assay.  Cells were stimulated with soluble HA 
(sHA), inactivated virus, or class I immunodominant peptide (HA533).  Values represent the 
mean (+/- SEM) spots for each group. 
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6.5.6 Passive transfer of immune sera 
 
The contribution of serum factors to protection from clade 1 challenge was evaluated using a 
passive transfer model.  Nine week old recipient mice were administered pooled sera via IP 
injection from COBRA, polyvalent and mock vaccinated mice.  The next day, recipient mice 
were challenged with the clade 1 reassortant A/Vietnam/1203/2004 virus.  All recipient mice lost 
weight and became visibly ill (Figure 32A and 32B).  Interestingly, COBRA serum recipient mice 
lost less weight than polyvalent recipient mice with maximum losses of 5.2% (6 DPI) and 11.8% 
(7 DPI), respectively (p<0.05 at 7 DPI).  COBRA serum recipient mice also began to resolve the 
clinical symptoms more rapidly than polyvalent recipient mice (p<0.05 at 7 DPI).  Although 
COBRA serum prevented recipient mice from developing illness more efficiently than polyvalent 
serum, both COBRA and polyvalent serum protected all recipient mice from death.  Conversely, 
all mice receiving serum from mock vaccinated mice rapidly lost weight, became visibly ill and 
reached experimental endpoint by 7 DPI.     
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Figure 32: Passive transfer clade 1 challenge.  BALB/c mice (n=10/group) were vaccinated 
at 0 and 3 weeks with blood collected 14 to 21 days after each vaccination.  Serum collected 
after the second vaccination was pooled for each vaccine group and administered to naïve 
recipient mice (n=5/group).  1 day after passive transfer, recipient mice were infected with 5x103 
PFU of reassortant virus containing the HA and NA genes from the clade 1 H5N1 virus 
A/Vietnam/1203/2004 (VN/04).  Mice were monitored daily for weight loss (A) and sickness (B).  
Values represent mean (+/- SD) for each group.  Significant differences were determined by 
two-way ANOVA with Bonferroni’s post-test to evaluate differences between vaccines at each 
day.  A p value of less than 0.05 was considered significant (*). 
 
 
 
6.6 DISCUSSION 
 
In this study, we compared the immunogenicity and efficacy of two strategies proposed to 
increase breadth: computationally optimized broadly reactive antigen (COBRA) and a polyvalent 
mixture of primary antigens.  Polyvalent vaccines have been used as a vaccine strategy to 
increase reactivity for many pathogens including, but not limited to, influenza [160-162], 
monkeypox [163], HIV [164, 165], HPV [166, 167] and pneumococcal disease [168].  Polyvalent 
vaccines consist of a mixture of several antigens and are designed to elicit an immune response 
that is broader than that elicited by any single component.  Seasonal influenza vaccines have 
   
170 
 
traditionally been delivered as polyvalent formulations to address the diversity of currently 
circulating strains of influenza A (H1N1 and H3N2) and influenza B.  Although polyvalent 
vaccine strategies are undoubtedly effective at expanding breadth, several limitations exist.  
First, with any polyvalent vaccine, production must be increased as to include several different 
antigens.  In the context of H5N1 vaccination, doses required for seroconversion are higher than 
seasonal vaccines [188, 204] and to produce multiple vaccines at higher doses could become a 
difficult hurdle for vaccine manufacturers.  Second, strain selection remains critical to polyvalent 
vaccine efficacy as best evidenced by seasonal influenza vaccine escape and continual yearly 
epidemics.  Despite these limitations, the polyvalency strategy remains the standard approach 
for influenza vaccine design.  Therefore, in this study, the breadth of immune responses elicited 
by COBRA HA antigens was compared to a polyvalent mixture of primary H5N1 HA antigens.  
Previous polyvalent vaccines for H5N1 have focused on inclusion of antigens from different 
clades [160, 161].  The COBRA HA antigen used in these studies is designed specifically to 
address the diversity present within clade 2 [283] and therefore selected clade 2 antigens from 
primary H5N1 isolates were generated as the polyvalent vaccine.  Clade 2 is genetically diverse 
and is divided into distinct sub-clades including 2.1, 2.2, 2.3, 2.4 and 2.5 with some subclades 
being further divided into sub-subclades [196].  Furthermore, within clade 2, humans have been 
infected with isolates representing clades 2.1, 2.2 and 2.3 with the most recent human infections 
in Egypt identified as clade 2.2 [196].  To generate a polyvalent mixture covering the most 
prevalent subclades of clade 2, representative isolate were selected from clade 2.1 
(A/Indonesia/5/2005), clade 2.2 (A/Whooper Swan/Mongolia//244/2005) and clade 2.3 
(A/Anhui/1/2005).   
 Both COBRA and polyvalent vaccines efficiently elicited broad binding antibodies in mice 
and ferrets (Figure 26A and 26C).  Even though both vaccines had equivalent levels of binding 
antibodies, the COBRA vaccine elicited a broader profile of receptor blocking antibodies (Figure 
26B and 26D).  Although the COBRA vaccine elicited higher titer receptor blocking antibodies, 
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the polyvalent vaccine did elicit antibodies to each of the components confirming the validity of 
using a polyvalent strategy to increase vaccine breadth (Figure 26B).  Importantly, when any of 
the polyvalent components were used as a monovalent formulation, the receptor blocking 
antibody profile was limited to the homologous test antigen (data not shown).  One reason for 
the decreased receptor blocking antibody titers in the polyvalent VLP vaccinated groups could 
be that each of the components was administered at one third of the total dose.  While this is 
certainly a possible explanation, when individual components are given at a full dose, the titers 
are equivalent to the polyvalent vaccine for the homologous test antigen and remain decreased 
compared to COBRA (data not shown).  Furthermore, prior studies indicated equivalent 
antibody responses and protection profiles for the different HA doses used in these studies, 
both total HA dose and individual component HA doses ([283] and unpublished observations). 
 Both COBRA and polyvalent vaccines protected mice and ferrets from highly pathogenic 
clade 2 H5N1 viral challenge (Figure 27).  All vaccinated animals were protected from significant 
weight loss and did not develop overt signs of disease.  Although protection from severe illness 
and death is certainly critical for pandemic vaccines, decreasing viral replication is also 
important to reduce complications from secondary infections and limit the potential for 
transmission. Efficient human-to-human transmission is an essential factor in pandemic 
influenza emergence and to date, H5N1 does not easily spread between people [302-304].  
However, if H5N1 were to acquire an efficient human transmission phenotype, the ability of a 
vaccine to reduce viral titers and thereby limit potential spread in addition to preventing severe 
disease is an important factor. Animals receiving the COBRA vaccine had decreased levels of 
replicating virus and returned to baseline more rapidly than polyvalent vaccinated animals 
(Figure 28 and 29).  Receptor blocking antibodies are not required to protect experimental 
animals against severe disease and death induced by highly pathogenic H5N1 influenza 
infection [200, 201, 206, 214, 215].  The findings reported here are consistent with those 
reports, but higher receptor blocking antibody titers against the challenge virus did correlate with 
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a reduction in duration of viral replication (Figures 26 and 28).  Therefore, although high titer 
receptor blocking antibodies are not required for protection from severe disease, the presence 
of these antibodies may be predictive of reduced viral burden.  Receptor blocking antibodies 
may be more effective at preventing nascent virions from infecting new cells and thereby limiting 
viral replication within the host.  Viral replication could provide a more sensitive output for 
evaluating H5N1 vaccine efficacy.   
 The goal of these studies was to compare the breadth of two independent broadening 
strategies: COBRA and polyvalent.  Although clade 2 is the most diverse and is spreading 
westward into the Middle East and Africa, clade 1 is still circulating and causing human disease 
in south-east Asia [196].  Clade 1 is not represented as a component of our polyvalent mixture 
nor was it part of the COBRA design and as such it represents a stringent test to evaluate 
vaccine efficacy for both broadening strategies.  Vaccinated animals had anti-clade 1 binding 
antibodies at levels equivalent to that of clade 2 test antigens (Figure 26A and 26C).  Despite 
these high titer binding antibodies, both vaccines elicited low to undetectable levels of anti-clade 
1 receptor blocking antibodies (Figure 26B and 26D).  Consistent with the findings that receptor 
blocking antibodies are not predictive of protection from severe disease, all vaccinated animals 
were protected from weight loss and development of visible illness after challenge with a 
reassortant virus containing the HA and NA antigens derived from a clade 1 virus (Figure 30).  
Furthermore, COBRA vaccinated animals did not have detectable virus after 3 days post 
infection, while polyvalent had low levels of virus present.  Although the differences were robust 
as predicted, the viral replication in COBRA vaccinated animals was below the limit of detection 
of the assay and animals receiving the polyvalent vaccine had recoverable virus 3 days after 
clade 1 challenge.  These results indicate that even though clade 1 sequences were not 
included in the design of COBRA, the synthetic antigen serves as an effective vaccine against a 
divergent virus, even one that is antigenically distinct from the original input sequences. 
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 In the absence of receptor blocking antibody, it is possible that cellular immune 
responses contribute to the protection from severe disease and death [305-307].  Both COBRA 
and polyvalent vaccines elicited similar cellular recall responses at 6 days post infection (Figure 
31).  Both IgG and IgA antibody secreting cells (ASC) specific for the clade 1 HA were recruited 
to the lungs of vaccinated animals and this is likely a recall response as unvaccinated controls 
did not have any ASC above background at 6 days post infection (Figure 31A).  ASC in either 
the spleen or bone marrow were not detectable above the background of the assay in any group 
before or after challenge (data not shown).  Interestingly, the majority of ASC were specific for 
HA rather than NA.  Although the NA content of the vaccines was not standardized, all 
vaccinated animals had high anti-NA serum IgG prior to challenge (data not shown).  It is 
possible that NA-mediated immunity contributes to protection from challenge in the absence of 
receptor blocking antibodies, but the preferential recruitment of anti-HA ASC implies a more 
critical role for anti-HA binding antibodies.  An important limitation of the ASC assay used in this 
report is there was no stimulation of cells ex vivo, so it is possible that equivalent numbers of 
anti-HA and anti-NA memory cells are present, but mainly anti-HA memory cells are activated 
and recruited to the lung in response to infection.  An additional implication for the equivalent 
numbers of ASC for both vaccine groups is that antibody titer is not directly correlated with 
responsible receptor blocking (Figure 26B).  This is not a surprising finding since the titer of 
binding antibody were equivalent between the two vaccine groups (Figure 26A).  Importantly, 
both strategies resulted in recruitment of equivalent numbers of ASC in response to a 
completely heterologous infection. 
 One of the proposed advantages for utilizing centralized antigens is expanding the 
breadth of T cell epitopes [180, 255, 257].  Indeed, a consensus-based H5N1 elicited IFN-  
producing cells in response to multiple peptide pools of HA [181].  Both the COBRA and 
polyvalent vaccines elicited IFN-  responses in the lungs of infected mice by 6 days post 
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infection and the numbers of responding cells between the vaccine groups were equivalent 
regardless of stimulating antigen (Figure 31B).  The immunodominant epitope in HA for BALB/c 
mice, HA533, is conserved in all of the vaccine antigens and may be responsible for the 
equivalent responses between the two vaccine groups.  Additionally, the COBRA vaccine did 
not result in expansion of breadth of T cell reactivity across different regions of HA, as 
measured by stimulation with overlapping peptide pools (data not shown).  COBRA failed to 
expand the breadth of T cell responses in these experiments, which may be a result of the high 
levels of homology between HA antigens.  H5N1 HA antigens are >90% identical amino acids 
between strains and the majority of the diversity is focused on altering antibody binding sites 
that are usually non-linear, conformational epitopes.  Therefore, any potential T cell epitopes are 
not changing due to immune pressure and likely remain highly conserved between strains. 
Indeed, the HA533 BALB/c immunodominant epitope is conserved not only throughout H5N1 
strains but also H1N1 and H9N2.   
 The presence of B and T cell recall responses in the lungs of vaccinated mice after 
challenge could be a potential mechanism for protection rather than serum antibody.  To 
evaluate the role of serum factors in protecting mice from a heterologous challenge, we 
passively transferred immune serum to naïve recipients and challenged with a clade 1 
reassortant virus.  Both COBRA and polyvalent immune serum protected mice from severe 
disease and death (Figure 32).  Therefore, serum antibody was able to protect from lethal 
challenge in the absence of cellular recall responses.  COBRA immune sera recipient animals 
lost less weight and recovered from illness more rapidly than polyvalent recipient animals, most 
likely as a result of moderate levels of anti-clade 1 receptor blocking antibodies in the COBRA 
serum (Figure 26B).  In comparison to directly vaccinated and challenged mice, passive transfer 
recipient mice lost more weight and developed more clinical signs.  One possibility for this 
disparity is that for the transferred antibodies to gain access to the site of infection in the airway, 
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there must first be damage to lung.  Transferred antibodies could then function in several ways: 
direct neutralization of virus, opsonization of viral particles, complement fixation and/or 
impairment of viral egress from infected cells.  The initial damage would then be associated with 
the observed mild weight loss and development of visible sickness and the speed of recovery 
related to the quality and function of the transferred antibody.  Importantly, this is the first 
description of passive transfer-mediated protection by a centralized antigen for H5N1 indicating 
that serum antibody is indeed an important factor in heterologous protection. 
 This is the first report comparing the breadth of a centralized H5N1 antigen, COBRA, 
with the more traditional strategy of a polyvalent mixture.  The COBRA vaccine elicited a more 
robust antibody profile than the polyvalent vaccine or any of its individual components.  This 
immunity was completely protective against both clade 2 and clade 1 virus challenges and 
COBRA vaccinated animals had lower viral burdens and lung involvement compared to 
polyvalent vaccinated animals.  The cellular immune components (ASC and IFN- ) were 
equivalent between the two VLP vaccinated mouse groups, indicating that the enhanced control 
of viral replication observed in the COBRA vaccinated animals is likely antibody mediated.  
Indeed, a passive transfer model demonstrated that animals receiving COBRA immune serum 
were more efficiently protected from disease than those receiving polyvalent immune serum.  
The data presented in this report indicate that although binding antibodies are sufficient for 
protection from severe disease and death, receptor blocking antibodies are essential for 
reducing viral replication.  This observation suggests that in the context of pandemic 
preparedness, vaccines that elicit receptor blocking antibodies to a diverse set of viruses would 
be more effective at limiting viral replication, transmission, and disease impact.  Antigenic 
diversity is a challenge for not only H5N1 influenza, but all influenza subtypes.  Polyvalent 
vaccines are currently utilized to address multiple types and subtypes of influenza 
simultaneously circulating in the human population.  It remains to be determined if COBRA-
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based vaccine design will be able to overcome diversity between subtypes, as greater levels of 
diversity and structural limitations are challenges for antigen design.  Both COBRA and 
polyvalent strategies are effective at expanding antibody breadth in the context of influenza 
vaccination.  These two strategies are not mutually exclusive and an intriguing possibility is a 
combination thereof: a polyvalent mixture of COBRA antigens.  Combining the intrasubtype 
broadening ability of COBRA with the intersubtype advantages of polyvalent mixtures 
represents an interesting strategy for expanding breadth within and between subtypes.  
COBRA-based vaccines are effective at broadening the antibody repertoire against H5N1 and 
applying this design strategy to other subtypes of influenza warrants further investigation. 
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7.1 FOREWORD 
 
The work presented in this chapter is in addition to the studies outlined in the Specific Aims (see 
Chapter 3).  The studies detailed previously (Chapters 4, 5 and 6) focused on broadly reactive 
vaccine development in anticipation of what may be the next influenza pandemic: H5N1.  
However, during the course of the work, the 2009 H1N1 “swine flu” influenza pandemic 
occurred.  The emergence of a novel strain of human influenza is a rare event and provided an 
opportunity to evaluate pandemic influenza vaccines in “real-time.”  Thus, the work presented in 
this chapter describes H1N1 pandemic vaccine studies.  In particular, the longevity and 
mechanism of protective immune responses was evaluated.  Although the work described here 
specifically addresses H1N1, the findings of long lasting immunity can be applied to vaccine 
responses in general and demonstrate that pandemic influenza vaccines have the potential to 
elicit long-lasting immune responses that can protect from pandemic influenza infection years 
after original vaccination. 
 
 
 
7.2 ABSTRACT 
 
The rapid emergence and spread of swine origin H1N1 in 2009 resulted in the first pandemic of 
the 21st century.  It is estimated that the “Spanish” influenza pandemic of 1918 was responsib le 
for 40 to 50 million deaths worldwide and is antigenically similar to the swine lineage of 
influenza that is represented by the 2009 pandemic.  Emergence of the 2009 pandemic from 
swine into humans has raised the possibility that low-levels of cross protective immunity to past 
shared epitopes could confer some protection.  In this study, we have engineered an influenza 
virus-like particle (VLP) expressing the HA and NA genes from the 1918 influenza virus to 
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evaluate the duration of cross-protective efficacy to the 2009 H1N1 pandemic strain by 
vaccinating young mice (8-12 weeks) and then allowing the animals to age to 20 months.  1918 
VLPs were found to elicit protective immunity in adult mice when lethally challenged with the 
reconstructed 1918 influenza virus.  This immunity was long-lasting with homologous receptor 
blocking antibodies detected throughout the lifespan of vaccinated mice.  Furthermore, the 1918 
VLP fully protected aged mice from 2009 pandemic H1N1 virus challenge 16 months after 
vaccination. Histopathological assessment showed that aged vaccinated mice had significant 
protection from alveolar infection, but less protection of the bronchial tissue than adult 
vaccinated mice.  Additionally, passive transfer of immune serum from aged vaccinated mice 
resulted in protection from death, but not morbidity.  This is the first report describing the lifelong 
duration of cross-reactive immune responses elicited by a 1918 VLP vaccine in a murine model.  
The results show that antibody responses elicited early in life are sufficient for protection from 
morbidity and mortality when challenged with an antigenically similar virus 16 months post-
vaccination.  Importantly, these life-long immune responses did not result in decreased total 
viral replication, but did prevent infection of the lower respiratory tract.  These findings 
demonstrate that immunity acquired early in life can restrict the anatomical location of influenza 
viral replication, rather than preventing infection, in the aged. 
 
 
 
7.3 INTRODUCTION 
 
Infections with influenza virus result in ~200,000 hospitalizations and 36,000 deaths for a typical 
endemic season in the United States [64].  In 2009, a novel strain of H1N1 influenza emerged 
from swine and quickly spread among humans resulting in the World Health Organization 
declaring the first pandemic of the 21st century [72].  The 1918 “Spanish” influenza pandemic 
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was the worst pandemic in recorded history and caused severe disease and mortality (675,000 
total deaths) in the United States [308] and killed up to 50 million people worldwide [75].  In 
comparison to 1918, the 2009 pandemic virus is much more moderate with the majority of cases 
being uncomplicated [309].  The most common feature of fatal disease is varying degrees of 
alveolar infection and damage [310-312].  This differs from seasonal influenza, as fatal cases 
rarely involve alveolar cells, with virus located primarily in the major airways such as the trachea 
and bronchioles [313, 314].  Interestingly, the majority of severe cases from the 2009 H1N1 
pandemic were reported in children and young adults, while the elderly population was relatively 
protected from infection and severe disease [309].  This pattern of susceptibility to severe 
disease is in direct contrast to what is normally observed during seasonal influenza epidemics, 
but is similar to what was reported for the 1918 pandemic [315].  Although the 1918 pandemic is 
believed to have emerged from avian species into both swine and humans nearly 
simultaneously, the human and swine lineages quickly diverged.  Sequence analysis indicated 
that the 2009 H1N1 pandemic virus is related to the 1918 H1N1 virus and it has been proposed 
that the swine population has maintained an “antigenically frozen” H1N1 lineage [316].  
Structural analysis demonstrated conservation within antigenic regions of 1918 and 2009 
pandemic hemagglutinin (HA) proteins that is not present in contemporary seasonal H1N1 
viruses [317, 318].   
 Antigenic similarities together with the abnormal protection from severe disease in the 
elderly population have led to the hypothesis that exposure to 1918-like viruses confers cross-
protective immune responses [319, 320].  Several studies have indicated cross-reactive 
antibodies to the 2009 pandemic H1N1 viruses in elderly human populations [321, 322] with 
antibodies derived from survivors of the 1918 pandemic cross-neutralizing the 2009 pandemic 
viruses [323].  Additionally, direct evidence of the cross-protective efficacy elicited by exposure 
to 1918-like viruses has been demonstrated in small animal models [316, 324], but the duration 
of this cross-protective immune response(s) has not been evaluated. 
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 Aging is associated with decreasing ability of the immune system to respond to new 
antigens [325].  Although elderly individuals are impaired in their immune responses, 
immunological memory responses to antigens experienced prior to the onset of decreased 
immune function can be retained and offers protection against re-exposure to similar pathogens.  
Indeed, successful vaccines are usually antibody-based and memory B cell responses, at both 
the cellular and antibody level, can persist for a lifetime [326].  After exposure to antigen, B cells 
can develop into two main types of long lived cells: memory B cells (MBC) and long-lived 
plasma cells (LLPC) [327].  Both subsets generally develop in the germinal center and go 
through differential degrees of affinity maturation: MBC differentiate earlier and have fewer 
somatic mutations while LLPC emerge later with higher affinity [327-329].  Both subsets play 
important roles in preventing reinfection with LLPC producing high affinity antibody in the 
absence of antigen stimulation and MBC being able to respond to a second infection that 
escapes circulating antibody [330].  The evidence of cross-reactive antibodies and decreased 
disease severity in the older human populations indicates that memory B cell responses to 
previously experienced antigens are cross-reactive to the 2009 pandemic virus.  Protection of 
the elderly population has largely been attributed to circulating antibody derived from the LLPC 
arm of the B cell memory response.  Interestingly, infection with 2009 pandemic virus in humans 
led to development of broadly-neutralizing antibody producing cells and it has been suggested 
that these cells were derived from pre-existing MBC [331].  Animal models have confirmed the 
hypothesis that prior exposure to various H1N1 virus strains can indeed protect from 2009 
pandemic challenge, but mechanistic inquiries into the reason for the cross-protection have 
been largely antibody-focused and have thus far failed to evaluate the involvement of the 
cellular component [316, 324].   
 Our research group has developed virus-like particle (VLP) vaccines against a variety of 
viral pathogens [221, 222, 283, 332-334].  These vaccines are composed of non-infectious, non-
replicating VLPs that present functional HA and NA on the surface of a viral particle.  VLPs 
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efficiently elicit high titer immune responses that protect small animals against lethal viral 
challenge [222, 283].  In this study, HA and NA from the 1918 influenza virus, A/South 
Carolina/1/1918, were expressed on the surface of a VLP that was expressed and purified from 
mammalian cells.  Mice were vaccinated at a young age (8-12 weeks) and allowed to age to 
elderly status (20 months).  Antibody titer to the 1918 antigens persisted for the lifetime of the 
animals indicating that the non-replicating VLP vaccine elicits enduring antibody titers.  The 
1918 VLPs efficiently protected the aged mice from 2009 pandemic challenge and prevented 
alveolar infection.  Additionally, the protection involved not only the previously described cross-
reactive antibodies but also a robust cellular recall response. 
 
 
 
7.4 MATERIALS AND METHODS 
 
7.4.1 Purification of virus-like particles 
 
Human embryonic kidney (HEK) 293T cells (1 x 106) were transiently transfected with plasmids 
expressing Gagp24 alone or together with HA and NA and incubated for 72h at 37
oC. Plasmids 
expressing the HIV-1NL4-3 Gag gene products only, pGagp24, was derived from codon-optimized 
sequences (phGag), as previously described [335].  pGagp24 encodes for an immature, 
unprocessed HIV-1 Gag particle.  Plasmids expressing HA (A/South Carolina/1/1918) and NA 
(A/Brevig Mission/1/1918) genes were kindly provided by Dr. A. Garcia-Sastre.  Supernatants 
were collected and cell debris removed by low speed centrifugation followed by vacuum filtration 
through a 0.22 m sterile filter.  VLPs were purified via ultracentrifugation (100,000 X g through 
20% glycerol, weight per volume) for 4 h at 4oC. The pellets were subsequently resuspended in 
phosphate buffered saline (PBS) and stored at -80oC until use.  Protein concentration was 
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determined by Micro BCATM Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, 
USA).   
  
7.4.2 Animals and vaccinations 
 
BALB/c mice (Mus musculis, females, 6–8 weeks) were purchased from Harlan Sprague 
Dawley, (Indianapolis, IN, USA), housed in microisolator units, allowed free access to food and 
water and cared for under USDA guidelines for laboratory animals.  Mice were vaccinated with 
3 g of purified VLPs based upon total protein via intramuscular injection at study weeks 0 and 
3.  Vaccination experiments were initially prepared with and without 10 g CpG oligonucleotides 
(Sigma-Aldrich, St. Louis, MO, USA).  Due to no observed effect of the adjuvant, subsequent 
vaccinations investigating longevity and cross-reactivity were performed without inclusion of 
adjuvant.  14 to 21 days after each vaccination, blood was collected from anesthetized mice via 
the retro-orbital plexus and transferred to a microfuge tube. Tubes were centrifuged and sera 
was removed and frozen at -20°C.  A subset of vaccinated mice was allowed to age to a final 
age of 20 months (~17 months post final vaccination) with blood collected at 10 months and 20 
months of age.  All procedures were in accordance with the NRC Guide for the Care and Use of 
Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in Microbiological and 
Biomedical Laboratories. 
 
7.4.3 ELISA assay 
 
The ELISA assay was used to assess total antibody titer and IgG isotype titer to the 1918 HA.  
High binding, 96-well polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 
50ng/well of recombinant 1918 HA.  Plates were blocked with 5% milk diluted in PBS with 
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0.05% Tween 20.  Serum samples were diluted in blocking buffer and added to plates.  Serum 
was two-fold serially diluted and allowed to incubate for 1 hour at room temperature.  Plates 
were washed and species specific antibody against IgG, IgG1, IgG2a, IgG2b or IgG3 and linked 
to horseradish peroxidase (HRP) (Southern Biotech; Birmingham, AL, USA) were diluted in 
blocking buffer and added to plates.  Plates were incubated for 1 hour at room temperature.   
Plates were washed and HRP was developed with TMB substrate (Sigma-Aldrich; St. Louis, 
MO, USA).  Plates were incubated in the dark for 30 minutes and then the reaction was stopped 
with 2N H2SO4.  Optical densities at a wavelength of 450nm (OD450) were read by a 
spectrophotometer (BioTek; Winooski, VT, USA) and end point dilution titers were determined.  
End point titers were determined as the reciprocal dilution of the last well which had an OD450 
above the mean OD450 plus two standard deviations of naïve animal sera. 
 
7.4.4 Hemagglutination inhibition assay 
 
The hemagglutination inhibition (HAI) assay was used to assess functional antibodies to the HA 
able to inhibit agglutination of turkey erythrocytes.  The protocol was adapted from the CDC 
laboratory-based influenza surveillance manual [233].  To inactivate non-specific inhibitors, sera 
were treated with receptor destroying enzyme (RDE) prior to being tested [234-238].  Briefly, 
three parts RDE was added to one part sera and incubated overnight at 37°C.  RDE was 
inactivated by incubation at 56°C for ~30 min. RDE treated sera was two-fold serially diluted in 
v-bottom microtiter plates. An equal volume of either 1918 VLP or wild type pandemic H1N1 
virus, adjusted to approximately 8 HAU/50μl, was added to each well. 1918 VLPs were 
produced as described above.  Wild type viruses were propagated in eggs and included the 
strains A/California/07/2009 and A/Mexico/4108/2009.  The plates were covered and incubated 
at room temperature for 20 min followed by the addition of 1% turkey erythrocytes (RBC) 
(Lampire Biologicals, Pipersville, PA, USA) in PBS.  Red blood cells were stored at 4°C and 
   
185 
 
used within 72 hours of preparation. The plates were mixed by agitation, covered, and the RBCs 
were allowed to settle for 30 min at room temperature [239]. The HAI titer was determined by 
the reciprocal dilution of the last well which contained non-agglutinated RBC. Positive and 
negative serum controls were included for each plate.  All mice were negative (HAI ≤ 10) for 
pre-existing antibodies to currently circulating human influenza viruses prior to vaccination.  
 
7.4.5 Virus microneutralization 
 
To assess the ability of mouse immune antisera to inhibit replication of live 1918 virus, the virus 
microneutralization assay was used as previously described [336].  Briefly, sera were two-fold 
serially diluted and then incubated with 100 TCID50 of 1918 virus for 60 minutes at room 
temperature.  The serum-virus mixture was then added to MDCK cells and allowed to incubate 
for 2 days at 37°C. Specific neutralizing activity was calculated as the lowest concentration  of 
serum that displayed neutralizing activity. 
 
7.4.6 Viral challenge 
 
To determine the homologous efficacy of the 1918 vaccine, mice were challenged with the 
reconstructed 1918 virus [133, 337].  Briefly, two weeks after the final vaccination, adult animals 
were challenged intranasally with 50 LD50 of 1918 virus in a volume of 50 l.  Mice were 
monitored daily for disease signs and death for 16 days post-infection.  Body weights were 
recorded for individual mice at various days post-inoculation.  All virus challenge experiments 
were performed under the guidance of the U.S. National Select Agent Program in negative-
pressure HEPA-filtered biosafety level 3+ (BSL-3+) enhanced laboratories with the use of a 
battery-powered Racal HEPA filter respirator and according to Biomedical Microbiological and 
Biomedical Laboratory procedures [338]. 
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 To determine the cross-protective efficacy of the 1918 vaccine, mice were infected with 
a 2009 pandemic H1N1 isolate: A/Mexico/4108/2009.  Although this virus is not highly lethal in 
adult BALB/c mice, it does cause 10-20% weight loss and development of clinical illness (data 
not shown).  Briefly, animals were challenged intranasally with 1 x 106 plaque forming units 
(PFU) of A/Mexico/4108/2009 virus in a volume of 50 l.  Mice were monitored daily for disease 
signs and death for 14 days post-infection.  Body weights and sickness scores were recorded 
for individual mice at various days post-infection.  Sickness scores were determined by 
evaluating activity (0=normal, 1=reduced, 2=severely reduced), hunched back (0=absent, 
1=present) and ruffled fur (0=absent, 1=present) [230].  Any animal reaching >20% weight loss 
was humanely euthanized.  All experiments using 2009 pandemic H1N1 virus were performed 
under biosafety level 2 (BSL2) conditions.   
 
7.4.7 Virus titrations 
 
On day 4 post 1918 virus challenge, four mice per group were exsanguinated, euthanized and 
their lungs removed for virus titration. Lungs were homogenized in 1 ml of sterile PBS, and 
clarified homogenate virus titers were determined using a 50% egg infectious dose (EID50) 
method.  Homogenates were titrated for virus infectivity in eggs from initial dilutions of 1:10, and 
EID50 was calculated using the method of Reed and Muench [339].  The limit of virus detection 
was 101.5 EID50/ml. 
 For 2009 pandemic H1N1 virus infections, lung virus titers were determined using a 
plaque assay [241, 242].  Briefly, lungs from infected mice were harvested 4 days post-infection 
(DPI), snap-frozen and stored at -80°C until use.  Samples were thawed, weighed and single 
cell suspensions were prepared via passage through a 70 m mesh (BD Falcon, Bedford, MA, 
USA) in an appropriate volume of PBS as to achieve 100mg/ml final concentration.  Cell 
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suspensions were centrifuged at 2000 rpm for 5 min and the supernatants were collected.  
Madin-Darby Canine Kidney (MDCK) cells were plated (5 x 105) in each well of a 6 well plate.  
Lung supernatants were diluted (dilution factors of 1 x 101 to 106) and overlayed onto the cells in 
100 l of DMEM supplemented with penicillin-streptomycin and incubated for 1hr.  Virus-
containing medium was removed and replaced with 2 mls of L12 medium plus 0.8% agarose 
(Cambrex, East Rutherford, NJ, USA) and incubated for 96 hrs at 37°C with 5% CO2.  Agarose 
was removed and discarded.  Cells were fixed with 10% buffered formalin, and then stained with 
1% crystal violet for 15 min.  Following thorough washing in dH2O to remove excess crystal 
violet, plates were allowed to dry, plaques counted, and the plaque forming units (PFU)/g were 
calculated. 
 
7.4.8 Histopathological analysis 
 
Left lobes of lungs from infected mice were collected 4 days post-infection and placed into 10% 
buffered formalin.  After fixation, lungs were paraffin embedded and 6 m sections were 
prepared for histopathological analysis.  Tissue sections were stained with hematoxylin and 
eosin and examined for bronchial inflammation and denudation and alveolar infiltration.   
Immunohistochemistry was performed as described before [340].  Sections containing 
lung were stained using antibodies against Influenza A virus (1:500; Maine Biotechnology 
Services, Portland, ME), Iba1 (1:500; Wako Pure Chemical Industries, Osaka, Japan), CD3 
(1:500; Dako, Carpinteria, CA), myeloperoxidase (1:250; Abcam, Cambridge, MA), IgA (1:500; 
Sigma), IgG (1:500; Sigma), and IgM (1:1000; Sigma) followed by species appropriate 
secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA and Rockland 
Immunochemicals, Gilbertsville, PA) conjugated to a fluorophore for fluorescent stains or biotin 
for peroxidase-based stains.   Stains were assessed and scored for frequency of influenza-
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infected cells and abundance of CD3+ T cells, Iba1+ macrophages, myeloperoxidase-labeled 
neutrophils, and IgA expressing cells.  
For in situ hybridization (ISH), vectors containing 760 bp of Influenza/California/04/2009 
matrix protein and full-length murine interferon-  (Open Biosystems, Huntsville, AL) were 
linearized to create antisense and sense templates.  35S-labeled riboprobes were generated 
using MAXIscript in vitro transcription kit (Ambion, Austin, TX).  ISH was performed as 
described before (Bissel et al 2011 “Accepted Article” doi: 10.1111/j.1750-3639.2010.00514.x).  
Control riboprobes did not hybridize to lung tissue at any time point post-infection and non-
infected tissue did not show hybridization with viral probes.  Hybridized slides were assessed 
and scored for abundance of foci. 
 
7.4.9 Cellular assays 
 
The number of anti-influenza specific cells secreting interferon gamma (IFN ) was determined 
by enzyme-linked immunospot (ELISpot) assay (R&D systems, Minneapolis, MN, USA) 
following the manufacturer’s protocol.  Mice were sacrificed at 6 DPI and spleens and lungs 
were harvested and prepared in single cell suspensions.  Briefly, pre-coated anti-IFN  plates 
were blocked with RPMI plus 10% FCS and antibiotics (cRPMI) for 30 minutes at room 
temperature.  Media was removed from wells and 105 cells were added to each well.  Cells were 
stimulated with 1918 recombinant HA (truncated at residue 530; 1 g/well), inactivated 
A/Mexico/4108/2009 virus (1:100 dilution of inactivated stock; 100 l/well) or the 
immunodominant H2-Kd CD8+ T cell epitope in H1 HA: HA533 (IYSTVASSL; 1 g/well) (Pepscan 
Presto, Leystad, Netherlands).  Additional wells were stimulated with PMA (50ng/well) and 
ionomycin (500ng/well) as positive controls or Ova257 (SIINFEKL; 1 g/well) (Pepscan Presto, 
Leystad, Netherlands) as negative controls.  Additionally, IL-2 (10U/ml) was added to each well.  
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Plates were incubated at 37°C for 48 hours.  After incubation, plates were washed four times 
with R&D wash buffer and incubated at 4°C overnight with biotinylated anti-mouse IFN . Plates 
were washed as before and incubated at room temperature for 2 hours with streptavidin 
conjugated to alkaline phosphatase.  Plates were washed as before and spots were developed 
by incubating at room temperature for 1 hour in the dark with BCIP/NBT chromogen substrate.   
The plates were washed extensively with DI H2O and allowed to dry overnight prior to spots 
being counted using an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, 
USA). 
 The number of anti-1918 HA specific antibody secreting cells was determined by B cell 
ELISpot assay as previously described [243-245].   Mice were sacrificed at 6 DPI and spleens 
and lungs were harvested and prepared in single cell suspensions.  Briefly, 0.45 m PVDF 
membrane plates (Millipore, Billerica, MA, USA) were coated with 1918 recombinant HA 
(250ng/well) and incubated at 4oC overnight.  Plates were washed three times with PBS and 
blocked with cRPMI for at 37°C for 3-4 hours.  Media was removed from wells and 105 cells 
were added to each well.  Plates were incubated at 37oC for 48 hours.  After incubation, plates 
were washed as before and incubated at room temperature for 2 hours with horse radish 
peroxidase-conjugated anti-mouse IgG (Southern Biotech, Birmingham, AL, USA).  Plates were 
washed as before and spots were developed at room temperature for 1 hour in the dark with 
detection substrate (NovaRED™; Vector Labs, Burlingame, CA, USA).  The plates were 
washed extensively with DI H2O and allowed to dry overnight prior to spots being counted using 
an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA). 
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7.4.10 Passive transfer of sera 
 
Sera from adult and aged vaccinated mice were pooled within the respective age group and 
passively transferred into 9 week old recipient BALB/c mice (n=5/group).  Equal amounts of 
serum from each mouse in a particular vaccine/age group were pooled and heat inactivated for 
30 minutes at 56oC.  200 l of pooled and inactivated serum was transferred to recipient mice 
via IP injection.  24 hours post-transfer, mice were infected with 2009 pandemic H1N1 virus as 
described above. 
 
7.4.11 Statistical analysis 
 
Statistical analyses of immune responses were performed using a One-way analysis of variance 
(ANOVA) with Dunn’s post-test to compare each group. A p-value of <0.05 was considered 
significant.  For challenge experiments, statistical analysis was performed using a two-way 
ANOVA with Bonferroni’s post-test to compare each group at multiple time points.  A p-value of 
<0.05 was considered significant.  All statistical analyses were performed using GraphPad 
Prism software. 
 
 
 
7.5 RESULTS 
 
7.5.1 Homologous immunogenicity of 1918 VLP vaccines in mice 
 
BALB/c mice (6-8 weeks) were vaccinated twice at weeks 0 and 3 via intramuscular injection 
with purified influenza VLP vaccines plus CpG adjuvant.  Two weeks after the final vaccination 
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serum was analyzed for antibody responses.  All mice vaccinated with 1918 VLPs had HAI 
antibodies to the homologous test antigen with a geometric mean titer (GMT) of 1:113 (Figure 
33A).  In contrast, mice receiving Gag VLPs or CpG adjuvant alone failed to generate any HAI 
antibodies to the 1918 VLP (Figure 33A).  To evaluate the ability of the elicited antibody 
response to block live virus infection, serum was tested in a live virus neutralization assay.  
Similar to the 1918 VLP HAI results, all mice vaccinated with 1918 VLPs had neutralizing 
antibodies with a GMT of 1:208, while mice receiving Gag VLPs or CpG alone failed to generate 
any detectable neutralizing antibodies (Figure 33B).  Additional vaccines administered without 
the CpG adjuvant elicited similar HAI titers and therefore CpG adjuvant was removed from 
subsequent vaccine preparations (data not shown).  
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Figure 33: 1918 immunogenicity and protection.  BALB/c mice (n=10/group) were vaccinated 
at 0 and 3 weeks with blood collected 2 weeks after final vaccination.  Hemagglutinin inhibition 
(HAI) serum antibody titers were determined for each vaccine group using 1918 VLPs as the 
test antigen (A).  Bars represent the geometric mean titer (+95% confidence interval).  Virus 
neutralizing (mVN) antibody titer was measured using reconstructed 1918 virus (B).  Bars 
represent the geometric mean titer (+95% confidence interval).  2 weeks after final vaccination, 
mice were infected with a lethal dose of reconstructed 1918 virus (C).  4 days post infection, 
lung virus titers (n=3/group) were determined (D).  Bars represent the log10 transformed mean 
virus titer (+ standard deviation).  A p value of less than 0.05 was considered significant 
(*p<0.05, **p<0.01, ***p<0.001). 
 
 
7.5.2 Protection against 1918 influenza virus challenge   
 
Two weeks after the final vaccination, mice were challenged intranasally with a lethal dose of 
live 1918 virus to evaluate the protective efficacy of the vaccines.  1918 VLP-vaccinated mice 
were protected from weight loss (maximum 5.2% at 2 DPI) while Gag VLP and CpG alone 
vaccinated animals rapidly lost weight (maximum weight loss of 14.2% at 5 DPI and 13.7% at 5 
DPI, respectively) (data not shown).  Furthermore, mice receiving the 1918 VLP vaccine were 
completely protected from death while Gag VLP and CpG alone vaccinated animals completely 
succumbed to infection by 7 DPI (Figure 33C).  To determine the ability of the vaccines to 
control viral replication in the respiratory tract, lungs of infected mice (n=3) were collected at 4 
DPI and analyzed for viral titers (Figure 33D).  Mice vaccinated with 1918 VLPs did not have 
detectable virus while mice receiving the Gag VLPs or CpG alone had significantly higher viral 
loads (p<0.001). 
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7.5.3 Longevity of the antibody response 
 
To determine the duration of the antibody response elicited by the 1918 VLP, mice (n=15) were 
vaccinated twice with 3 g of purified 1918 VLP without adjuvant and allowed to age.  Serum 
was collected at 3 months (two weeks post-final vaccination), 10 months and 20 months of age 
and analyzed for antibody responses to the 1918 VLP (Figure 34A).  Homologous antibody 
responses were detected in vaccinated mice over the lifetime of the animals.  Although the HAI 
GMT decreased from 1:127 to 1:88 to 1:54 at 3, 10 and 20 months, respectively, the observed 
differences were not significant (p>0.05) indicating that the 1918 VLPs elicited lifelong 
homologous antibody responses. 
 
 
Figure 34: Duration of cross-reactive antibody response.  BALB/c mice were vaccinated in 
the first 12 weeks of life with blood collected at 3 months, 10 months and 20 months.  
Hemagglutination inhibition (HAI) serum antibody titers were evaluated at each time point using 
1918 VLPs as the test antigen (A).  Sera from adult vaccinated mice (2 weeks post final 
vaccination) and aged vaccinated mice (16 months post final vaccination) were evaluated for 
HAI activity against 2009 pandemic viruses (Cal/07/09 and mex/4108/09) and 1918 VLPs 
(SC/1/1918) (B).  Bars represent geometric mean titer (+95% confidence interval).  A p value of 
less than 0.05 was considered significant. 
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7.5.4 Heterologous antibody responses in aged mice 
 
To evaluate if antibodies elicited by the 1918 VLPs cross-reacted with 2009 pandemic viruses, 
sera from 1918 VLP vaccinated adult (3-4 months; n=13) and aged (20 months; n=14) animals 
were analyzed for heterologous antibody responses.  Sera from adult mice was collected 2 
weeks after the final vaccination, while sera from aged mice was collected 16 months (~64 
weeks) after the final vaccination.  Both adult and aged animals had 2009 pandemic cross-
reactive antibodies and no significant differences between the age groups was detected 
(p>0.05; Figure 34B).  Although the 2009 pandemic HAI titers in the 1918 VLP vaccinated 
animals failed to achieve significance compared to the titer of the mock vaccinated animals, 
100% of adult animals and 50% of the aged animals receiving the 1918 VLP vaccine had 
detectable HAI titers (range of 1:20-1:160 and 1:10-1:320 for adult and aged, respectively), 
while the mock vaccinated animals were all negative (1:10).  Multiple 2009 pandemic viral 
isolates were tested to ensure that the observed cross-reactivity was not unique to a single virus 
and similar titers were found between strains.  Additionally, adult and aged 1918 VLP 
vaccinated animals had equivalent titers to the homologous 1918 test antigen (p>0.05) and 
these titers were significantly increased compared to age-matched mock vaccinated controls 
(p<0.05).  
 
7.5.5 Protection against 2009 pandemic virus challenge 
 
Adult (2 weeks post final vaccination) and aged (16 months post final vaccination) vaccinated 
mice were then challenged intranasally with 1 x 106 PFU of the 2009 pandemic virus 
A/Mexico/4108/2009.  This isolate is not mouse adapted and does not cause a lethal infection in 
adult or aged BALB/c mice, but the dose used resulted in significant weight loss and 
development of clinical disease.  Both adult and aged animals receiving the 1918 VLP were 
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protected from development of clinical sickness and weight loss, while mock vaccinated animals 
became ill and rapidly lost weight (Figure 35A and 35B).  Furthermore, 1918 VLP vaccinated 
animals, regardless of age, were significantly protected from sickness (p<0.05; 4-9 DPI and 3-
13 DPI for adults and aged, respectively) and weight loss (p<0.05; 3-12 DPI and 3-14 DPI for 
adults and aged, respectively) compared to the age-matched mock vaccinated control animals.  
No significant differences were found between adult and aged animals within the 1918 VLP or 
mock vaccine groups.  To evaluate viral burden, lungs were harvested from infected mice at 4 
DPI (n=3/group) and viral replication was determined (Figure 35C).  Adult 1918 VLP vaccinated 
mice had significantly decreased lung viral titers compared to the adult mock vaccinated 
animals.  In contrast, aged 1918 VLP and mock vaccinated mice had equivalent viral titers 
despite the differences observed for disease signs and weight loss. 
   
196 
 
 
Figure 35: Protection from 2009 
pandemic virus challenge.  BALB/c mice 
were vaccinated with 1918 VLPs and 
infected with 2009 pandemic virus 
(A/Mexico/4108/2009) 2 weeks (adult; n=5) 
or 16 months (aged; n=4) after final 
vaccination.  Mice were evaluated daily to 
monitor sickness (A) and weight loss (B).  
Sickness score was determined by 
evaluating activity (0=normal, 1=reduced, 
2=severely reduced) and hunched 
appearance (0=absent, 1=present).  Lung 
virus titers were determined 4 days post 
infection.  Bars represent mean virus titer (+ 
standard deviation).  A p value of less than 
0.05 was considered significant (*p<0.05). 
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7.5.6 Histopathology of infected lungs 
 
To determine if histopathological features after the A/Mexico/4108/2009 challenge could explain 
the dichotomy observed in aged 1918 VLP vaccinated mice protection from disease but 
increased viral titers, lung sections were assessed for histopathological changes, presence of 
influenza and differences in immune response.  On 4 DPI, the lungs of adult 1918 VLP 
vaccinated mice had minimal bronchial and alveolar inflammation compared to adult mock 
vaccinated mice that showed bronchial epithelial intracellular edema and necrosis with 
moderate inflammatory infiltration and areas of intra-alveolar exudate and cellular consolidation 
(Figure 36A and 36B).  Similar to adult 1918 VLP vaccinated mice, aged 1918 VLP vaccinated 
mice showed minor alveolar involvement, however bronchial epithelium had moderate 
intracellular edema with necrotic epithelium sloughing into airway spaces (Figure 36C).  Aged 
mock vaccinated mice showed severe bronchial inflammation and epithelial necrosis, but 
alveolar spaces were less involved than adult mock vaccinated mice (Figure 36D).  
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Figure 36: Histopathology and influenza antigen detection of lungs after 2009 pandemic 
challenge.  BALB/c mice were vaccinated with 1918 VLPs and infected with 2009 pandemic 
virus (A/Mexico/4108/2009) 2 weeks (adult) or 16 months (aged) after final vaccination.  Lungs 
were collected 4 days post infection, formalin fixed and paraffin embedded.  Representative 
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images from hematoxylin and eosin stained sections: adult 1918 VLP vaccinated mice (A), adult 
mock vaccinated mice (B), aged 1918 VLP vaccinated mice (C), and aged mock vaccinated 
mice (D).  Immunohistochemistry for influenza antigen (E-H) and ISH for influenza MP (I-L) was 
performed on sections from paraffin embedded lung tissue at 4 DPI.  Severity of viral antigen or 
influenza ISH foci at 4 DPI was accessed in the bronchi (M and O) and alveolar spaces (N and 
P).  Scoring: 0 = no definitive signal; 1 = occasional focus; 2 = focus in most fields; 3 = more 
than one focus per field. 
 
 To evaluate the location and severity of influenza viral antigen and viral replication, 
immunohistochemical staining using an antibody against influenza A and ISH for influenza A MP 
was scored on 4 DPI lung sections.  Adult 1918 VLP vaccinated animals had occasional 
bronchial epithelium infection and viral replication and even less infection in alveolar spaces 
(Figure 36E, 36I and 36M-P).  This was in contrast to significant bronchial epithelium infection 
and replication observed in adult mock and aged animals, regardless of vaccination (Figure 
36F-H, 36J-L, 36M and 36O).  Alveolar spaces in adult and aged mock animals had pronounced 
influenza antigen and RNA, but aged VLP vaccinated mice showed less alveolar infection than 
mock animals (Figure 36F-H, 36J-L, 36N and 36P). 
To assess differences in immune responses in situ, lung sections from challenged mice 
were scored for presence of macrophages, T cells, neutrophils, IgA secreting cells.  To evaluate 
the antiviral response, lung sections were scored for IFN  transcription.  Macrophage and T cell 
infiltrates were less abundant in adult 1918 VLP vaccinated mice compared to adult mock and 
aged animals, regardless of vaccination (Figure 37A-J).  Similar results were observed with 
neutrophils (data not shown).  Total numbers of IgA positive cells (not influenza specific) were 
higher in aged animals than adult mice, regardless of vaccination status (Figure 37K-O).  
Immunohistochemistry for IgG and IgM was attempted but the level of background staining 
precluded analysis.  Adult 1918 VLP vaccinated mice showed few IFN  RNA foci compared to 
adult and aged mock and aged 1918 VLP vaccinated mice (Figure 37P-T). 
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Figure 37: Analysis of immune response by immunohistochemistry and ISH after 2009 
pandemic challenge.  BALB/c mice were vaccinated with 1918 VLPs and infected with 2009 
pandemic virus (A/Mexico/4108/2009) 2 weeks (adult) or 16 months (aged) after final 
vaccination.  Lungs were collected 4 days post infection, formalin fixed and paraffin embedded.  
Immunohistochemistry for Iba1+ macrophages (B-E), CD3+ T cells (G-J) and IgA+ cells (L-O) 
and ISH for IFN  (Q-T) was performed on sections from paraffin embedded lung tissue.  
Sections were scored for severity of infiltrate: Iba1+ macrophages (A), CD3+ T cells (F), IgA+ 
cells (K) and IFN  foci (P).  Iba1 scoring:  0 = scattered throughout section; 1 = collected around 
bronchi; 2 = forming cuff around bronchi; 3 = severe cuffing of bronchi, extending into alveolar 
spaces.  CD3 scoring:  0 = rare; 1 = scattered throughout section; 2 = abundant throughout 
section; 3 = abundant with collections surrounding bronchi.  IgA scoring:  average of the number 
of positive cells in 25 microscopic fields (40X).  IFN  scoring:  number of foci in section.  
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7.5.7 Post-infection cellular responses 
 
To determine the magnitude of influenza-specific cellular responses post-infection, spleens and 
lungs from vaccinated animals (n=3/group) were harvested 6 DPI and both antibody secreting 
cells (ASC) and IFN-  producing cells were analyzed by ELISpot assay.  Although the vaccines 
were administered via intramuscular injection, anti-1918 HA IgG secreting cells were not 
detected in significant quantity in the spleens of any animals, but 1918 specific ASC were 
detected in the lungs of 1918 VLP vaccinated mice regardless of age (Figure 38A).  Importantly, 
both adult and aged 1918 VLP vaccinated animals had equivalent numbers of lung ASC which 
were significantly increased compared to the age matched controls (p<0.05). 
 Additionally, 1918 VLP vaccine primed influenza-specific IFN-  producing cells were 
analyzed (Figure 38B).  IFN-  production in the spleen was low to undetectable and no 
significant differences were found between any of the groups regardless of stimulating antigen.  
Adult mice receiving the 1918 VLP had significantly more lung IFN-  producing cells responding 
to the immunodominant peptide HA533 compared to adult mock animals (p<0.05).  Aged mice 
vaccinated with 1918 VLPs and stimulated with HA533 peptide had increased numbers of IFN-  
producing cells compared to aged mock animals (p<0.05).  Similar to the ASC numbers, both 
adult and aged 1918 VLP vaccinated animals had equivalent numbers of IFN-  producing cells 
after infection.  Although IFN-  producing cells were detected in the lung using truncated 1918 
HA protein or intact virus as stimulating antigens, no significant differences between groups 
were observed. 
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Figure 38: Post-infection antigen specific cellular immune response.  BALB/c mice were 
vaccinated with 1918 VLPs and infected with 2009 pandemic virus (A/Mexico/4108/2009) 2 
weeks (adult) or 16 months (aged) after final vaccination.  Lungs were collected 6 days post 
infection, single cell suspensions were prepared and the numbers of anti-1918 HA antibody 
secreting cells (A) and influenza-specific IFN-  producing cells (B) were determined by ELISpot 
assay.  Cells were stimulated with 1918 soluble HA (1918 sHA), inactivated virus, and class I 
immunodominant peptide (HA533).  Values represent the mean spots (+ standard deviation) for 
each group. 
 
 
7.5.8 Passive transfer of immune sera 
 
To evaluate the contribution of serum factors to protection, 9 week old recipient animals 
(n=5/group) were administered pooled sera via IP injection from adult (2 weeks post 
vaccination) and aged (16 months post vaccination) 1918 vaccinated animals and aged mock 
animals.  At 24 h after serum transfer, mice were challenged intranasally with the 2009 
pandemic virus A/Mexico/4108/2009 (1 X 106 PFU).  Although this isolate does not cause a 
lethal infection in adult or aged BALB/c mice, the disease course in 9 week old mice is more 
severe and, as such, the young mice are a more sensitive model for evaluating protective 
efficacy (unpublished observations).  Pooled serum from adult and aged 1918 VLP vaccinated 
animals was confirmed to have equivalent levels of anti-1918 antibody titers prior to transfer 
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(total IgG end point dilution of 1:3200 and HAI of 1:80 for each VLP group).  Mice receiving 
either adult or aged 1918 VLP vaccinated serum developed mild clinical illness, while mice 
receiving mock vaccinated serum developed more severe disease (p<0.05; 4-8 DPI) (Figure 
39A).  Interestingly, adult 1918 VLP serum recipients resolved the clinical symptoms more 
rapidly than the aged 1918 VLP serum recipients (p<0.05; 7-8 DPI).  Mice receiving adult 1918 
VLP serum had significantly less weight loss compared to both mock serum recipients (p<0.05; 
4-8 DPI) and aged 1918 VLP serum recipients (p<0.05; 6-8 DPI) (Figure 39B).  Aged 1918 VLP 
serum recipients had equivalent weight loss compared to the mock serum recipients at every 
time point except for 8 DPI.  Although the aged 1918 VLP serum recipient mice developed 
longer-lasting disease and lost more weight than the adult 1918 VLP serum recipients, both 
adult and aged 1918 VLP recipients were completely protected from death while 80% of the 
mock recipients had reached experimental endpoint by 8 DPI (p<0.01; Figure 39C).  
Interestingly, both adult and aged 1918 VLP transferred serum had similar levels of IgG1, IgG2a 
and IgG2b, but only the adult 1918 VLP serum had detectable IgG3 (Figure 39D). 
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Figure 39: Passive transfer protection from 2009 pandemic challenge.  BALB/c mice were 
vaccinated with 1918 VLPs and blood collected 2 weeks (adult) or 16 months (aged) after final 
vaccination.  Serum was pooled for each age group, heat inactivated and transferred via IP 
injection to naïve recipient mice.  1 day after transfer, recipient mice were infected with 2009 
pandemic virus (A/Mexico/4108/2009).  Mice were monitored daily for sickness (A) and weight 
loss (B).  Mice reaching the experimental end point of >20% weight loss were humanely 
euthanized (C).  Sickness score was determined by evaluating activity (0=normal, 1=reduced, 
2=severely reduced), hunched appearance (0=absent, 1=present) and ruffled fur (0=absent, 
1=present).  Prevalence of IgG isotypes in pooled transferred serum was determined via ELISA 
(D).  A p value of less than 0.05 was considered significant (*p<0.05; **p<0.01). 
 
 
* 
* 
** 
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7.6 DISCUSSION 
 
In this study, we evaluated the efficacy of pre-immunity to 1918 derived antigens in protecting 
against 2009 pandemic H1N1 virus in aged mice.  Sequence analysis indicated that the HA 
protein from the 2009 H1N1 pandemic virus is more closely related to the 1918 virus than the 
H1N1 strains that re-emerged in humans in 1977 [316].  Indeed, structural similarities between 
1918 HA and 2009 pandemic HA have been elegantly described and indicate conservation 
within antigenic sites that is not present in contemporary seasonal HA molecules [317]. 
Additionally, neutralizing antibodies derived from human survivors of the 1918 pandemic were 
able to cross-neutralize 2009 pandemic virus, confirming the antigenic predictions [323, 341].  
Although severe seasonal influenza infections usually occur in the very young and older age 
groups, epidemiological evidence has indicated that elderly populations were unusually 
protected from severe infections during the 2009 H1N1 pandemic.  Our group and others have 
found high levels of cross-reactive antibodies in the older populations and it is hypothesized that 
this is due to prior exposure to antigenically similar influenza virus [319, 320, 322].  
Furthermore, there is direct evidence of the protective efficacy in mice with prior exposure to 
1918-like or classical swine H1N1 influenza virus to 2009 pandemic infection [316, 324].  Cross-
protective efficacy of older viruses to 2009 pandemic infection in animal models has provided 
mechanistic evidence for the observed phenomenon of decreased disease severity in the older 
human population, but has not directly evaluated the duration of the cross-reactive immune 
responses.  We sought to confirm and expand these findings to aged animals in order to more 
closely mimic the findings in humans.  Our results indicate that the anti-1918 influenza immunity 
acquired early in life can indeed retain its cross-protective efficacy against a 2009 pandemic 
challenge in later stages of life. 
 Age-associated defects in immune responses generally lead to increased susceptibility 
to infectious disease and decreased responsiveness to vaccines [325].  Furthermore, intrinsic 
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defects within the B cell response directly cause decreased responses to influenza vaccine in 
elderly humans [342].  Although several studies have established a defect in immune responses 
to vaccination in the elderly [342-345], we sought to evaluate the durability and efficacy of 
immune responses initially elicited in young animals.  We found that vaccine responses were 
produced efficiently in adult mice (Figure 33A and 33B) and were robust enough to protect 
against the highly lethal reconstructed 1918 virus challenge (Figure 33C and 33D).  The 
duration of homologous receptor blocking antibody was evaluated and titers elicited as adults 
were maintained throughout the lifespan of the mouse (Figure 34A).  Although the antibody 
titers tended to decrease with age, these differences were not statistically significant (p>0.05).  
Structural analysis and neutralizing antibody binding has indicated cross-reactivity between 
1918 and 2009 pandemic HA proteins and this has been confirmed in adult mice [316, 317, 
323].  Shortly after vaccination, the antibody response is dominated by low-affinity responses 
produced by short-lived plasma cells that may have the benefit of being more cross-reactive due 
to reduced somatic mutation in response to a specific antigen [328].  Prior studies have only 
evaluated antibody responses at 2-4 weeks after antigen exposure and as such the observed 
cross-reactivity may be due to the kinetics of the antibody response and not completely 
indicative of the long-lasting antibody repertoire.  We found that similar to adult mice, aged 
animals maintained equivalent levels of cross-reactive antibody titers (Figure 34B).  These 
results indicate that the cross-reactive antibodies observed in adult animals are long lasting and 
therefore probably produced not only by short-lived plasma cells generated immediately in 
response to vaccination, but rather by long-lived plasma cells (LLPC) that continue to produce 
antibody for an entire lifetime.  An important caveat of this study is that we evaluated a single 
antigen and its role in eliciting cross-protective immunity.  A more realistic scenario is one that 
includes multiple exposures, via infection or vaccination, of antigenically distinct viruses over a 
lifetime.  Although LLPC would be unable to respond to the new antigens, an accumulation of 
diverse LLPC and resulting serum antibodies could lead to even more robust cross-reactivity.  In 
   
207 
 
support of this idea, serologic data from humans suggests that those individuals who have anti-
2009 pandemic cross-reactive antibodies are more likely to be positive for other historic viruses 
[322].  A second, but not mutually exclusive, possibility is that memory B cells (MBC) may 
respond to the new antigens and a cross-reactive epitope(s) could be specifically boosted by 
sequential exposure.  Indeed, the increased numbers of broadly-neutralizing antibody secreting 
cells in response to 2009 pandemic infection in humans supports the notion that the MBC 
specific for a cross-reactive epitope can be activated during heterologous infection [331]. 
 Most human influenza viruses require adaptation to cause disease in mice, except for 
highly pathogenic viruses, including 1918 and H5N1 isolates [346].  The 2009 pandemic virus 
also readily infects mice, although lethality differences have been reported when comparing 
multiple virus isolates [316].  The strain used for challenge infections in these studies 
(A/Mexico/4108/2009) is not lethal to adult mice, but does cause significant morbidity 
(unpublished observations).  Aged mice have an impaired immune response following influenza 
infection and display increased morbidity and delayed innate immune activation [230].  
Interestingly, 2009 pandemic virus infections in older adult (1 year) mice have decreased 
severity compared to young (4 week) mice [347].  We found that naïve aged and adult animals 
had similar morbidity profiles with aged animals displaying prolonged signs of disease (Figure 
35A).  This could be due to a delayed immune response in the aged animals at both the 
initiation and contraction stages leading to prolonged inflammation in the lungs [230].  
Vaccinated animals from both age groups did not develop any signs of morbidity in response to 
the infection even though high levels of virus were recovered from lungs of aged vaccinated 
animals 4 days post-infection (Figure 35C).  Although the differences were not significant 
between the vaccinated groups, the observation was confirmed by immunohistochemistry for 
influenza antigen and in situ hybridization for influenza RNA.  In situ analysis of pathological 
responses and viral replication revealed that adult vaccinated animals were protected from 
infection of both bronchial and alveolar spaces, while aged vaccinated animals were only 
   
208 
 
protected from alveolar infection (Figure 36).  This suggests that alveolar inflammation and/or 
infection has a greater contribution to the development of morbidity than bronchial infection 
which is consistent with post-mortem analysis of fatal human cases [310-312].  One possible 
explanation for why virus was detected in the bronchial epithelium in aged vaccinated animals, 
but not in adult vaccinated animals, is that the initial immune response is delayed in the aged 
cohort [230].  A delay in the kinetics of antigen presentation could allow for additional spread 
within the lung that results in the observed bronchial disease.  Alternatively, the time from 
vaccination could also contribute to the differences in viral replication between adult and aged 
vaccinated mice.  Adult vaccinated mice were challenged only 2 weeks after the final 
vaccination, while aged mice were challenged 16 months after final vaccination.  Because of the 
shorter timeframe, larger numbers of effector cells in adult mice could be available at the time of 
infection and therefore more efficiently control virus replication.  However, it was surprising that 
the aged animals showed greater numbers of IgA-expressing cells than adult mice.  Since this 
was not dependent on vaccination status, it could be a reflection of the lifespan difference 
between mice and the number of pathogen exposures.  Overall in the histopathological analysis 
of the immune response, we observed greater infiltrates of macrophages, T cells, neutrophils 
and IFN  RNA expressing cells in the aged and adult mock mice than the adult 1918 VLP 
vaccinated mice.  This suggests that the intensity of the observed immune response is a 
reflection of the level of viral replication in the lungs.  Aged-vaccinated mice had similar viral 
burden and immune infiltrate compared to unvaccinated mice, but they did not lose weight or 
display any signs of disease.  Therefore, restriction of viral replication to the bronchial spaces in 
aged vaccinated mice likely contributed to the less severe disease than that observed in the 
naïve adult or aged mice.  These findings confirm prior observations that a 1918 influenza 
vaccine protects adult mice from 2009 pandemic influenza challenge and extend this finding to 
aged animals that originally experienced the 1918 antigens early in life; a finding that is 
analogous to humans. 
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 Influenza-specific CD8+ T cells are primarily responsible for the clearance of virus 
infected cells after influenza infection and are detectable after primary infection by day 5 [348].  
One defect that is associated with the aging immune response is the reduction in CD8+ T cell 
function [349].  Our results indicate that IFN-  producing T cells specific to a Class I 
immunodominant peptide are recruited to the site of infection as efficiently in vaccinated aged 
animals as in adult animals (Figure 38).  Consistent with aging-associated T cell defects, a 
reduced, albeit not significant, number of IFN-  producing cells were found in naïve aged 
animals compared to the adult controls.  Interestingly, when inactivated whole virus was used as 
the stimulating antigen, IFN-  producing cells were not significantly detected above background. 
This is likely due to the vaccine containing only HA and NA antigens derived from influenza 
virus and a HIV-Gag core.  In addition to T cell related age defects, B cells are also impaired 
[350, 351].  Vaccinated animals in both age groups had equivalent levels of serum antibody pre-
challenge and similar numbers of antigen-specific antibody secreting cells detectable in the 
lungs 6 days post-infection while unvaccinated animals did not have any detectable antigen-
specific antibody secreting cells (Figure 38).  Interestingly, antigen-specific antibody secreting 
cells were not detectable in any group prior to challenge (data not shown).  The rapid recall of 
both T and B cells in the lungs of vaccinated animals indicates that the adaptive immune 
response that was primed in young animals is maintained late in life, even though the ability to 
respond to new antigens might be impaired.  This observation is consistent with the finding that 
accumulation of memory B cells in aged animals negatively regulates lymphpoeisis of B cells, 
which are required to respond to new antigens [352].  Although the adaptive response to 
vaccines is known to be impaired in aged mice, the immunological memory elicited by 
vaccination as a young adult is maintained and aged animals respond to challenge as efficiently 
as adults. 
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 Serum surveillance of humans has indicated that the elderly population has an increased 
frequency of 2009 pandemic cross-reactive antibodies [319, 320, 322].  To determine if cross-
reactive systemic antibody is sufficient to protect from 2009 pandemic challenge, we passively 
transferred immune serum from both adult and aged mice into naïve recipient mice prior to 
challenge.  Consistent with published results, young mice (<10 weeks of age) are highly 
susceptible to 2009 pandemic challenge and therefore provide a sensitive model for evaluating 
protective efficacy [347].  Serum from vaccinated mice, regardless of age-group, protected mice 
from death while naïve animal serum did not (Figure 39).  Interestingly, adult serum recipients 
lost less weight and had reduced morbidity compared to aged serum recipients.  This was not 
due to differences in administered serum antibody titer as adult and aged serum had equivalent 
levels of both total anti-HA antibody and receptor blocking antibody (data not shown).  
Additionally, the IgG subclass profile indicated that although the adult and aged animals had 
equivalent levels of the dominant isotypes (IgG1, IgG2a and IgG2b), the adult mice had low but 
increased amounts of IgG3 compared to the aged mice (Figure 39D).  IgG3 is a minor fraction of 
antibody to T cell dependent antigens and is the major isotype to T cell independent antigens 
[353].  Additionally, IgG3 is a potent activator of the classical complement pathway, likely due 
the properties of cooperative binding [354, 355].  Enhanced complement fixation mediated by 
the HA-specific IgG3 in adult sera could be a mechanism responsible for the decreased 
morbidity observed in the recipient mice.  It is interesting to speculate that the loss of IgG3 in 
aged mice is due to LLPC being more efficiently generated in the presence of T cell help, 
whereas it is retained in the adult mice because of the shorter kinetics of the vaccine regimen.  
In addition to IgG3 variability, differences in affinity profiles or non-HA antibodies could also 
explain the observed morbidity differences.  Antibodies to the NA protein of 2009 pandemic 
virus are increased in elderly humans [111] and the protective role of anti-NA immunity cannot 
be excluded in this study.  Another possibility for the differences in morbidity is that the antibody 
milieu in the adult serum is more diverse than the aged animals.  Although the anti-HA specific 
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antibody titer is equivalent between the age groups, the LLPC producing the antibody in the 
aged animals are likely less diverse than those cells producing the antibody in the adult animals 
due to the kinetics of the vaccination.  Additionally, the finding that the vaccinated animals did 
not display any signs of morbidity implies a critical protective role for the cellular component of 
the immune response in addition to the cross-reactive receptor blocking antibodies.  Cellular 
immunity in presence of protective antibodies is also more predictive of protection in the context 
of highly pathogenic 1918 influenza virus challenge [356].  Therefore, although serum antibody 
is sufficient to protect from severe disease and death, cellular immune responses in both the T 
and B cell compartments likely contribute to protection from the morbidity associated with 2009 
pandemic infection in both aged and adult mice. 
 Virus-like particles are an intriguing platform for developing new influenza vaccines [150, 
221, 260, 357].  The VLPs are self-assembling and completely non-pathogenic particles similar 
in morphology to intact virions [258].  For the vaccines used in this study, the influenza proteins 
HA and NA were psuedotyped onto the surface of HIV Gag particles.  This strategy has been 
used for multiple applications and takes advantage of the robust budding properties of the Gag 
protein [192, 260].  Lifelong antibody responses are more efficiently produced by virus infection 
than by non-replicating antigens [358].  We found that vaccination with 1918 influenza VLPs 
elicited robust lifelong immunity that was effective at protecting against heterologous 2009 
pandemic virus challenge.  Importantly, the cohort of vaccinated animals allowed to age was not 
vaccinated in the presence of adjuvant indicating that the duration of the elicited immune 
response was not a function of an adjuvant.  Although antibody producing cells were not 
detectable in the bone marrow or spleens of vaccinated animals prior to challenge (data not 
shown), presence of specific antibody in the serum could be due to one of at least two 
possibilities: the cell frequency was below the detection limit of the assay but sufficient to 
maintain serum IgG titer or secreting cells were in a lymphoid compartment that was not 
analyzed.  These studies were performed in mice and only evaluated a single HA antigen, 
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however, the findings reported here indicate VLP-based vaccinations are capable of eliciting 
lifelong immunity as measured by both serum antibody (Figure 34) and cellular recall to infection 
(Figure 38). 
 This is the first evaluation of cross-reactive immunity to 2009 pandemic influenza in an 
aged animal model.  Antigenic similarities between the pandemic influenza strains of 1918 and 
2009 have been demonstrated at the structural level, indicated by human data and confirmed in 
adult animal models [316, 317, 319].  Here, we show animals that experience 1918 influenza 
antigens during adulthood maintain the cross-protective immunity to 2009 pandemic H1N1 
influenza late into life.  The aged animals were not protected from viral replication, but restricted 
the virus to larger airways and did not show signs of alveolar infection, which is the most 
common feature of fatal human disease. The life-long immunity evaluated in these studies was 
established by vaccination with a non-replicating VLP rather than by infection, and included B 
and T cell cross-reactive responses in addition to serum antibody.  The studies reported here 
confirm prior work by others that 1918 influenza can elicit cross-reactive antibody responses to 
2009 pandemic influenza and expands those findings to aged animals, further validating the 
hypothesis that decreased disease severity in the elderly human population observed during the 
2009 H1N1 pandemic may be due to prior exposure to antigenically similar viruses. 
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8.0 SUMMARY AND DISCUSSION 
 
 
 
Pandemic outbreaks of influenza have occurred four times in the past 100 years and were 
responsible for tens of millions of deaths worldwide [60, 71].  The World Health Organization 
(WHO) has identified three criteria for defining the start of a pandemic: 1) the emergence of a 
virus to which the world’s population is mostly naïve, 2) the new virus must be able to replicate 
and cause severe disease in humans and 3) the virus must be efficiently transmitted among 
humans, as evidenced by chains of human to human spread [183].  Highly pathogenic avian 
influenza of the H5N1 subtype has fulfilled two of these criteria: it is a novel subtype and results 
in an approximately 60% fatality rate [55, 185].  Neutralizing antibody to the viral glycoprotein 
hemagglutinin (HA) is the most important aspect of immunity to influenza [359].  Targeting HA 
via vaccination is the traditional method for reducing the impact of influenza-related illness.  
H5N1 diversity complicates pre-pandemic vaccine development because of antigenic 
differences in the HA.  Phylogenetic distance in the HA gene separates H5N1 into 10 distinct 
clades and the majority of human infections are from clades 1 and 2.  Furthermore, diversity 
within clade 2 alone has resulted in the identification of distinct subclades and sub-subclades 
[360].  There is little receptor blocking antibody cross reactivity between clades and subclades 
despite high levels of HA protein identity (>90%).  Developing vaccines that are able to 
overcome the antigenic diversity of H5N1 is a crucial step in pandemic preparedness. 
 The overall objective of this research was to develop a broadly reactive vaccine for 
highly pathogenic H5N1 influenza.  The HA antigen was the primary target for vaccine 
   
214 
 
development because neutralizing antibody is the most important factor in preventing influenza-
related disease.  The first aim of this work was to design and characterize a consensus-based 
H5N1 HA.  The second aim was to evaluate the breadth and intensity of the immune responses 
elicited by the consensus HA designed in aim 1.  The third aim was to determine the protective 
efficacy of the consensus HA vaccine against H5N1 influenza challenges.  This work 
demonstrated for the first time that a consensus-based HA virus-like particle vaccine elicits a 
broad antibody profile.  Additionally, the centralized antigen generation methodology developed 
for increasing vaccine breadth is applicable to both seasonal and pandemic influenza vaccine 
design. 
 The work presented in this dissertation resulted in the development of a consensus-
based HA antigen that was termed computationally optimized broadly reactive antigen 
(COBRA).  The COBRA sequence was unique and has not been isolated from either human or 
environmental infections.  The fully synthetic COBRA protein retained the natural functions of 
HA: receptor binding and cell fusion.  COBRA virus-like particle (VLP) vaccines elicited a broad 
antibody response that had receptor blocking activity against a greater number of virus isolates 
compared to a polyvalent vaccine.  All H5N1 VLP vaccines investigated during the course of this 
work protected animals from severe disease and death.  Consistent with prior reports, protection 
from severe disease and death did not correlate with receptor blocking antibodies to the 
challenge virus.  Protection in the absence of receptor blocking antibodies could be mediated by 
several mechanisms such as non-receptor blocking antibodies, cellular immunity, or anti-
neuraminidase (NA) antibodies.  Antibodies to the HA protein can neutralize virus infectivity 
without blocking receptor binding by inhibiting cell fusion.  For the vaccines tested, neutralizing 
antibodies correlated with receptor blocking antibodies.  Non-neutralizing anti-HA antibodies can 
also mediate protection via complement activation and opsonization of infected cells.  Indeed, 
transferred serum that had non-neutralizing anti-HA antibodies protected recipient animals from 
severe disease and death indicating a potential role for binding antibody in protection.  All 
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vaccines tested also elicited anti-HA cellular recall responses to infection.  However, the major 
targets of the cellular immune response, NP and PB2 [117, 118], are not contained in the VLPs 
tested in this work and it is unknown if the anti-HA cellular response alone would be sufficient 
for protection from severe disease.  Additionally, all of the vaccines contained NA and elicited 
anti-NA antibodies.  It is therefore possible that the NA component in all of the VLP vaccines 
contributes, at least in part, to the observed protection from severe disease.  Although the 
mechanism underlying protection from severe disease and death remains unclear, the COBRA 
vaccine more efficiently limited virus replication compared to a polyvalent vaccine.  The reduced 
viral burden in COBRA vaccinated animals suggests a correlation of increased receptor 
blocking antibody titer with decreased viral replication.   
 Preventing clinical symptoms without reducing viral shedding allows for transmission and 
viral evolution.  Vaccines that prevent clinical illness but permit viral replication and transmission 
can hasten virus escape, and are proposed to have led to the selection of the H5N1 variants 
currently circulating in Asia [77].  For the first time, this work compared a centralized H5N1 
vaccine to both monovalent and polyvalent primary isolate-based H5N1 vaccines.  Even though 
all of the tested vaccines protected animals from severe disease, the reduced viral titers in the 
COBRA vaccinated animals represent a novel finding.  Surprisingly, the COBRA vaccine was 
more effective at reducing viral titers than a comparator vaccine homologous to the challenge 
virus.  One explanation for this observation is that COBRA elicited higher titer receptor blocking 
antibodies to the challenge virus than the primary isolate-derived vaccine.  This is consistent 
with prior reports showing the poor immunogenicity of naturally occurring H5N1 HA [188, 189, 
361].  If a different challenge virus was used and the matched vaccine elicited similar antibody 
titers as COBRA, then the differential control of virus would likely be ameliorated.  This work 
therefore suggests that the synthetic design of COBRA may have altered the structure of the 
protein to make it more immunogenic.  One feature of COBRA that may enhance its relative 
immunogenicity compared to primary isolates is the retention of the polybasic cleavage site in 
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COBRA, but not in the comparator vaccines.  The cleavage site mutations are essential for 
attenuating H5N1 viruses and the primary isolate vaccines used in these studies were 
generated from such mutated viruses.  Removal of the polybasic cleavage site has been 
associated with decreased immunogenicity of live-attenuated vaccines [214], but this is likely 
due to decreased levels of replication.  Retaining the cleavage site could also result in structural 
features that more accurately reflect that which are found in the challenge virus.  Other features 
known to impact immunogenicity, such as glycosylation [235] or a serine at position 223 [202], 
are not different between COBRA and the comparator vaccines (data not shown).  Although the 
mechanism by which COBRA vaccinated animals controlled virus replication more efficiently 
than those receiving matched vaccine remains to be elucidated, the result is a novel and 
interesting finding.  Centralized vaccines developed by other research groups have either failed 
to detect a difference in viral replication [172] or did not compare the centralized antigen to 
primary vaccine candidates [180-182, 254].  Reducing viral burden is a critical aspect in 
evaluating pandemic vaccines because limiting viral replication will directly impact the 
transmissibility of the emerging virus.  This work has established COBRA as a superior vaccine 
compared to prior H5N1 vaccines due to the decreased levels of virus detected in COBRA 
vaccinated animals.  Additionally, the comparison of COBRA to other antigens using the same 
delivery system is critical in demonstrating that COBRA itself results in a broader antibody 
profile and more efficient protection.  VLPs have been shown to broaden antibody responses 
alone [221], but non-COBRA antigens in the context of the VLP did not have as broad of a 
reactivity profile as COBRA.  The studies described in this dissertation have, for the first time, 
compared a centralized antigen to primary isolate-based vaccines using a VLP delivery 
platform.  This work demonstrated COBRA to elicit increased breadth of receptor blocking 
antibodies and more efficiently control viral replication compared to primary isolate-based 
antigens.   
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 COBRA vaccines elicited a broader profile of receptor blocking antibodies than either 
monovalent or polyvalent vaccines.  This difference cannot be explained by total sequence 
identity as all vaccines studied were >93% identical.  HA proteins in general are highly similar 
and total protein identity scores can often obscure the more subtle differences in antigenic 
positions.  For H5N1, a panel of 20 antigenic residues has been identified [197].  Restricting 
analysis of amino acid identity of the vaccine antigens to these 20 antigenic positions is a better 
representation of the diversity between the proteins (Table 10).  Furthermore, structure 
modeling of the HA proteins has indicated that the COBRA protein retains the most common 
structural features at proposed antigenic sites (Figure 40).  An interesting finding in the 
structural models is that surface residues are not the only ones that alter antigenic regions.  
Several of the 20 antigenic residues did not map to the surface of a particular antigenic site, but 
remained variable and antigenically important.  When modeled onto a molecular structure, many 
of these “internal” residues altered the position or orientation of surface antigenic structures.  
These observations suggest that predicting antigenic divergence based on surface antigen 
identity fails to capture all of the possible changes, and that differences outside of accepted 
antigenic sites can still impact antibody binding.  A limitation of the antigenic structure analysis 
is that the models are hypothetical and based on solved structures of similar molecules.  An 
important next step for this work is to determine the structure of the COBRA HA protein.  A 
solved structure would enable more definitive analysis of antigenic regions and could indicate 
which epitopes are contributing to the increased breadth of elicited antibodies.  It is unlikely that 
linear epitopes are responsible for the differences in antibody breadth because peptide ELISAs 
using diverse antisera failed to detect any differences between vaccines (data not shown).  Non-
linear epitopes are the most common structural features at the various antigenic sites and it is 
likely that these conformational epitopes are the critical determinants of antibody breadth.  
Rationally designed vaccine antigens based on epitope structure could represent the future of 
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vaccine design and the work presented in this dissertation indicates that structural features are 
important determinants of vaccine breadth. 
 
Table 10: Sequence Identity 
 
 The COBRA-based HA described in these studies addressed the objective of developing 
a broadly reactive vaccine for H5N1 influenza.  Although COBRA did elicit broadly reactive 
antibodies, the mechanism behind the expanded breadth remains unclear.  At least two 
explanations are plausible: 1) the COBRA antigen contains a unique, single epitope against 
which a broadly neutralizing antibody is elicited, or 2) the COBRA antigen captures a collection 
of epitopes against which multiple antibodies are elicited.  One way to address this lingering 
question is through the development of monoclonal antibodies.  Unique monoclonal antibodies 
could each be evaluated for their receptor-blocking profile and then mapped onto the original 
antigen.  If monoclonal antibody mapping indicates that expanded breadth is due to a single 
epitope, future antigen design could focus on the given epitope and expand its reactive profile.  
Alternatively, if multiple antibodies that each react within a cluster of antigenically related viruses 
are identified, future antigen design could use an individual epitope to specifically address a 
single antigenic family.  For example, a chimeric HA could be designed that captures a clade 
specific neutralizing epitope in each antigenic site.  COBRA methodologies could be applied to 
developing clade-specific antigenic sites and then the different sites engineered into a single 
molecule.  In addition to investigating the underlying mechanism of broad reactivity, COBRA-
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derived monoclonal antibodies would also be useful in the development of therapeutics to be 
used in the event of a pandemic.  Indeed, neutralizing antibodies are effective at ameliorating 
disease from highly pathogenic influenza even when administered after infection [103]. 
 
Figure 40: Structural modeling of antigenic regions.  HA1 structures were predicted using 
3D Jigsaw comparative modeling (http://bmm.cancerresearchuk.org/~3djigsaw/) [362].  
Structures were overlayed and antigenic regions analyzed for changes.  The left panel shows 
the whole HA1 and right panels show close ups of three antigenic regions: A, B and C.  Arrows 
indicate divergent structures. 
 
 Another possible outcome of broad reactivity is more rapidly evolving strains of 
influenza.  COBRA vaccinated animals had decreased viral replication compared to polyvalent 
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vaccinated animals, but the immunity was not sterilizing.  Even the low levels of viral replication 
found in animals receiving COBRA vaccines provide the virus an opportunity to mutate and 
evade the broad antibody response.  This possibility could be evaluated by serially passaging 
influenza virus in the presence of various antisera (or monoclonal antibodies) and monitoring 
the pathogenicity and growth characteristics of the escaped viruses.  The new viruses could 
then be sequenced and evasion mutations in the HA protein identified.  It is possible that viruses 
selected under the pressure of COBRA antisera would more rapidly accumulate antigenic 
variability and result in highly divergent strains.  Alternatively, the functional constraints of the 
HA molecule combined with the broadly reactive COBRA antibodies could fully restrict the virus 
and prevent further divergence.  Either outcome would provide insights into the virologic 
outcomes of broadly reactive immune responses, which are important considerations as broadly 
reactive vaccines are being developed. 
Table 11: Resistance associated residues. 
Region: A (154) A (157) B (140) B (171) C (100) D (228) 
COBRA Q P D N N K 
Clade 0 L S N S S E 
Clade 4 L S N S S T 
Clade 2.1 L P D S N K 
Clade 2.2 Q S D N N K 
Clade 2.3 Q P D N N K 
Clade 7 L P N N S K 
 
Resistant isolates Susceptible isolates 
 
 The COBRA vaccines investigated in this work were focused on the diversity specifically 
within clade 2 of H5N1.  The results of the studies presented here demonstrate that COBRA is 
effective at increasing breadth within clade 2, but is limited when the test antigens are from 
divergent clades.  Furthermore, the COBRA antigen evaluated in these studies included only 
sequences from human isolates and could be failing to capture avian epitopes.  Although clade 
2 is the most widespread and is responsible for the majority of human infections, an ideal H5N1 
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vaccine would not be restricted to any single clade.  The COBRA vaccine failed to elicit 
receptor-blocking antibodies to representative isolates from clades 0 and 4.  Interestingly, the 
resistant viruses shared antigenic residues that were not found in susceptible viruses (Table 
11).  For example, in region A, resistant viruses were divergent from COBRA at two positions 
(154 Q→L and 157 P→S) and although susceptible viruses may have one of the changes, none 
had both (Figure 41A).  Additionally, divergence at two amino acids in region B (140 D→N and 
171 N→S) was associated with resistance (Figure 41B).  None of the divergent residues were 
associated with the specific host from which the isolate was derived: the clade 4 virus is an 
avian isolate and the clade 0 virus is a human isolate.  Due to the antigenic location of the 
divergent amino acids, it is possible that they play key roles in evading receptor blocking 
antibody responses.  Furthermore, the criteria for clade designation only consider total HA 
sequence identity and it is possible that the current classification system fails to efficiently group 
antigenically related viruses.  Because the layered design of COBRA utilized pre-determined 
clades and sub-clades, subtle antigenic differences that drive resistance may fail to cluster 
within any specific clade and would have been lost in the antigen design.  To overcome these 
limitations, new COBRA antigens could be designed using different input sequences or different 
layering techniques.  For example, clade 2 vaccines could be improved by adding avian 
sequences and including additional subclades (2.4, 2.5 and 2.6) that only have avian isolates.  
To expand the vaccine to cover all of H5N1, COBRA technology could again be utilized by 
layering together all of the clades.  Additionally, changing the layering process to ignore total 
HA-based clade designations and instead utilize antigenic residue-based clustering could alter 
the breadth of any new COBRA vaccine.  Altering either the input sequence population used to 
generate the antigen or the layering technique by which the antigen is constructed are both 
predicted to impact the reactivity profile of the new vaccines.  Indeed, phylogenetic analysis of 
newly designed antigens indicates that either inclusion of clade 2 avian sequences or other 
clades results in a sequence that is more central to all of H5N1 (Figure 42).  One possible 
   
222 
 
outcome of making an antigen more central to all clades of H5N1 is the loss of reactivity within 
the more divergent clade 2.  If a single COBRA antigen is unable to expand antibody breadth to 
all clades and subclades of H5N1, a polyvalent approach could be used.  This work and others 
have demonstrated the validity of using polyvalent vaccinations to increase the breadth of H5N1 
vaccines (see Chapter 6 and [161]).  Using COBRA antigens as polyvalent components would 
enable the inclusion of multiple COBRA antigens, each addressing a specific antigenic cluster.  
Avian influenza of the H7 and H9 subtypes have also caused human disease and are additional 
reservoirs from which pandemic influenza could emerge.  COBRA antigens could be developed 
for each subtype, H5, H7 and H9, and then combined for pre-pandemic vaccinations.  Pandemic 
influenza emerges suddenly, and the vast diversity of influenza A viruses renders impossible the 
accurate prediction of the exact strain that will cause the next pandemic.  To overcome this 
challenge facing pandemic preparedness, development of broadly reactive vaccines (e.g. 
COBRA) and strategies (e.g. polyvalency) are critical. 
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Figure 41: Modeling of resistant residues.  HA1 structures representing COBRA (green), 
clade 2.3 (pink; susceptible) and clade 0 (red; resistant) were predicted and overlayed as before 
(Figure 40).  Predicted location of resistance associated residues is indicated by arrows for 
antigenic region A (A) and antigenic region B (B). 
 
 
Figure 42: Phylogenetic analysis of additional H5N1 COBRA genes.   The unrooted 
phylogenetic tree was inferred from HA amino acid sequences derived from 8 to 10 
representative isolates in all clades and subclades and also the COBRA HA using the maximum 
likelihood method.  Clade/subclade clusters were identified and are indicated in the shaded 
ovals.  The stars identify where the COBRA antigens are located relative to the various 
representative isolates.   
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 A limitation of the work presented in this dissertation is that the vaccines were all 
delivered using a virus-like particle (VLP) platform.  VLPs are a promising new generation of 
influenza vaccines [150, 221, 222, 363], but are not approved for human use as influenza 
vaccines.  Importantly, VLPs expand vaccine breadth, regardless of antigen, compared to 
recombinant protein vaccines [221].  The expanded antibody breadth elicited by COBRA VLPs 
was not due to the VLP itself as vaccines containing only a different HA failed to achieve the 
same broad responses.  It remains to be determined if a COBRA antigen can continue to elicit 
broadly reactive antibodies when used in a non-VLP platform.  Because currently licensed 
influenza vaccines are virus-based (either split and inactivated or live-attenuated; see Section 
1.8), the COBRA antigen should be evaluated in these platforms.  Reverse genetics technology 
(see Section 1.10.2) could be used to generate novel viruses expressing the COBRA HA.  
These would be H5N1 viruses that do not circulate in nature and therefore non-wild type internal 
genes (e.g. cold adapted virus) would be required.  The COBRA-virus could then be evaluated 
as a vaccine candidate.  The broadly reactive antibody profile elicited by COBRA is likely due to 
unique antigenic features of the synthetic HA rather than the VLP delivery system.  However, 
the trimeric conformation on the surface of the VLP is probably an important feature of the 
vaccines evaluated in this work and splitting the COBRA-virus could affect the oligomerization.  
Investigating COBRA vaccine antigens in multiple vaccine platforms is an important step 
forward to demonstrate that the broad antibody profile is not an artifact of the VLP.  
Furthermore, the most direct path for licensure of a COBRA-based influenza vaccine is to utilize 
established and standardized influenza production and purification methods.  For COBRA-
based influenza vaccines to have the most significant impact on improving human health, 
changing the vaccine platform from experimental VLPs to licensed methodologies is essential. 
 In addition to directly vaccinating humans, a vaccine utilizing the COBRA antigen 
described in this work could make an impact via use in poultry.  Poultry vaccines can 
successfully limit the spread of H5N1 through farms [77].  Additionally, agricultural vaccines 
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have less rigorous standards to which they must adhere.  VLPs and other experimental delivery 
platforms would be more easily transitioned into animal use than for human use.  Vaccinating 
poultry with COBRA could positively impact the world in at least two different ways.  First, 
decreasing the amount of circulating virus reduces the chances for transmission to humans.  
Sporadic human cases continue to cause severe disease and each transmission event provides 
a new opportunity for the virus to acquire additional mutations and/or gene segments that will 
enable a stable host-switch.  Vaccinating poultry would further reduce the current human 
disease burden as well as decrease the opportunities for avian viruses to evolve to mammalian 
hosts.  Second, large-scale poultry vaccinations would prevent the culling of flocks in response 
to outbreaks.  Eradication of an emerging virus is the optimal strategy of control, and for 
domestic poultry this means destroying infected flocks.  This large scale loss of agricultural 
resources can have devastating impacts on local economies and resulted in the loss of 1.5 
million birds in Hong Kong in late 1997 [364].  The COBRA vaccines described here were 
immunogenic and effective in three animal models: mice, ferrets and non-human primates.  
Although the relative immunogenicity in avian species is unknown, it is reasonable to expect 
that COBRA will retain its immunogenic properties because of the past success with multiple 
animal models. 
 The work presented here focused on developing pre-pandemic vaccines.  Influenza 
pandemics occur sporadically and can result in severe human disease.  Despite the attention 
devoted to pandemic influenza, seasonal epidemics continue to cause human disease and 
result in up to 36,000 deaths each year.  Antigenic diversity in circulating human influenza 
remains a challenge for influenza vaccines and is currently addressed by re-formulating the 
vaccine when an escaped drift variant emerges.  Applying COBRA antigen-design methods to 
seasonal influenza could reduce the frequency of replacing vaccine strains.  A large amount of 
data is available for the antigenic properties of human influenza viruses.  The exact antigen 
design approach would be different for seasonal influenza than H5N1 influenza due to the 
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different evolutionary trajectories.  However, COBRA-based methods could be used to capture 
the most common antigenic features of each subtype.  Antigenic clusters, for instance, have 
been identified and could be utilized for the COBRA-based layering approach [48, 365, 366].  
Applying COBRA methodology to seasonal influenza could provide a more “real world” impact 
on human health than pre-pandemic vaccine development.  Therefore, this dissertation has 
provided the framework within which broadly reactive influenza vaccines, both seasonal and 
pandemic, may be developed. 
 The COBRA vaccines evaluated during the course of these studies demonstrated that a 
broadly reactive influenza vaccine is possible.  Although the antibody reactivity profile was 
broad, the mechanism underlying this phenomenon is unclear.  Future work should be focused 
on elucidating the reasons for increased breadth.  First, determining the structure of the 
molecule should be investigated.  Modeling has indicated a structural basis of breadth, but 
these observations should be confirmed.  Next, monoclonal mapping of the broadly reactive 
profile should be completed.  Information gained from determining the epitope(s) that elicits the 
broad antibody response could then be applied to future COBRA antigens.  Finally, viral escape 
should be driven with COBRA-derived antibodies to investigate the virologic outcomes of 
broadly reactive antibodies.  Together, these studies would be expected to determine the 
mechanism underlying COBRA-mediated antibody breadth.  Additionally, development of novel 
COBRA antigens incorporating additional clades could continue to expand the antibody breadth 
to eventually cover all of H5N1.  It will be important to determine if a single antigen can retain 
reactivity with the diverse clades or if multiple, clade-specific COBRA antigens will need to be 
developed. 
 The work presented here demonstrated that a centralized HA (COBRA) based VLP 
vaccine elicited a broadly reactive antibody response.  The reactivity profile of COBRA receptor 
blocking antibodies was broader than that of a polyvalent comparator.  Importantly, the immune 
responses of all vaccines evaluated protected animals from severe disease and death, but 
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COBRA vaccines more effectively reduced viral replication.  It remains to be elucidated what 
aspect of the vaccine protected animals from severe disease, but for the first time a centralized 
vaccine was shown to reduce virus burden more efficiently than primary isolate-based vaccines.  
Further work is needed to understand the mechanism of increased antibody breadth from the 
COBRA vaccines to improve future iterations of antigen design.  The data presented in this 
dissertation indicate that broadly reactive influenza vaccines are possible, and that COBRA-
based antigens should be developed as both seasonal and pandemic influenza vaccines. 
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